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Norwegian population of patients with substance use disorders. An additional aim was to 
examine the prevalence of treatment needs in the region both in terms of level of care and the 
need for an integrated programme for co-occurring substance use and psychiatric disorders. A 
multicentre study was conducted at 10 Norwegian treatment facilities for substance use 
disorders; this dissertation consists of a pilot study of the translated ASAM Criteria second 
revised software version and three research papers. These papers have been accepted for 
publication in international scholarly peer reviewed journals. The project and some of the 
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conferences.  
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Summary 
 
Summary  
The main purpose of this dissertation was to investigate ASAM Criteria software revised 
version for predictive and convergent validity by assessing patients with a substance use 
disorder to optimal level of care (LOC). The dissertation combines one unpublished pilot 
study and three main papers. The pilot study is based on a satisfaction survey (n=8) and inter-
rater reliability testing of patient videos (n=5) and assessors’ agreement. The validation study 
has a prospective naturalistic double-blind multi-site design and the three papers are based on 
data from a structured baseline interview (n=261) and follow-up interview (n=153) three 
months after treatment initiation. They were recruited from 10 different centres in the mid-
region of Norway. The private and public treatment facilities included in this dissertation 
cover the specialised treatment for substance use disorders in the region, with detoxification 
services, outpatient, inpatient and residential treatment both short and long-term. Opioid 
Maintenance treatment is also included, and can be given in either outpatient or inpatient 
setting depending on patients’ needs. The public clinic follows a biopsychosocial approach for 
understanding and treatment of substance use disorders which includes a variety of services. 
Interventions include, for example, motivational interviewing, individual or group therapy 
sessions, family therapy, cognitive therapy, milieu therapy, social skills training, vocational 
training, physical training and many more. The various services provided in this region clearly 
show the complexity in providing treatment for this disorder, and the need for thorough 
assessment before placing patients at a specific LOC. The services are closely connected to or 
in direct cooperation with the municipalities covering housing and occupational needs. The 
theoretical framework for the dissertation is to apply a biopsychosocial approach to 
understanding, assessment and treatment of patients with a substance use disorder. While this 
is the consensus reached in the field, different approaches still exist. There is a necessity to 
examine the history of the development of the concept of addiction to the substance use 
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disorder definition we see and use today, to understand how the biopsychosocial approach 
emerged as the consensus in the field. The shift from a moral model to medical approach is 
vital to the understanding of the concept of the disorder and treatment of it. In addition, the 
main diagnostic and classification systems that Norway and the ASAM criteria uses when 
classifying substance use disorders will be discussed.  
This study was initiated by the region itself in light of the need for harmonising the regions’ 
assessment practices and investigating the prevalence of service need in the region. Because 
ASAM criteria software version is based on the DSM-IV criteria and follows a 
biopsychosocial approach to substance use disorder, this approach was deemed appropriate. In 
addition it is the only tool that can give automatic treatment recommendations on LOC 
placement based on over 6000 calculations. In need of translation and because it was a revised 
second edition, the criteria underwent validation testing on Norwegian substance use 
disordered population even though validation testing from USA provides support for the use 
of the criteria. ASAM criteria is a computer-assisted structured interview and clinical decision 
support programme that implements validated tools including the Addiction Severity Index 
and measures biopsychosocial conditions to match patients to an optimal LOC. Paper I 
assessed patients seeking help for substance use disorders in order to determine the ASAM 
Criteria’s predictive validity in terms of treatment outcomes among matched and mismatched 
patients. At post-test, patients who had received matched treatment based on the ASAM 
recommendation reported less use of alcohol and cannabis versus undermatched patients. 
Overmatched patients had no better outcomes than matched patients; in some cases no change 
occurred or a more intensive LOC was recommended at post-test. Consistent with prior 
studies, the ASAM Criteria Software Norwegian version demonstrates elements of predictive 
validity for determining intensity of LOC placement using all three prospectively planned 
measures.  
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Paper II examined the discrepancies between ASAM Criteria LOC recommendations and 
Treatment-as-Usual, along with the software’s ability to clinically distinguish between 
patients with different LOC to determine convergent validity. The discrepancies found are in 
line with previous research: the more intensive recommendation by ASAM yielded better 
outcomes three months after for the matched group. The ability of the ASAM Criteria to 
clinically distinguish between the different LOC lends support for the software’s convergent 
validity. This ability to distinguish by severity was taken further in the third paper which also 
examined the programme’s Dual Diagnosis taxonomy, incorporated in the second revised 
version to assess patients’ need for more specialised programmes for co-occurring psychiatric 
disorders. We aimed to study the prevalence of co-occurring disorders programme 
recommendations and ASAM Criteria convergent validity in terms of locating patients with 
co-occurring disorders and discriminating between severities among those who received more 
intense recommendations. The results are in line with previous research with the use of these 
criteria, and the different recommendations show differences in characteristics, severity and 
outcomes. The higher the recommendation, the more psychiatric severity seen among the 
patients recommended for them. Significant differences were seen in both characteristics and 
severity. The results show a high prevalence of dual diagnosis programme recommendations 
in this region and characteristically clinical meaningful differences between the different 
recommendations. The new version of ASAM Criteria Software Dual Diagnosis taxonomy 
convergent validity is supported by the results. The successful translation and software testing 
in Norway should encourage larger studies – preferably across nations and treatment system – 
seeking higher power with larger subsamples across primary drug of choice and 
match/mismatched conditions. 
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1. Introduction 
1.1. Background and main aims 
The present dissertation investigated data to test and validate the second revised ASAM 
Criteria software version and its usefulness in correct placing of patients with a substance use 
disorder to optimal level of care (LOC). The complexity of substance use disorders demands a 
health care system that is up to date both in terms of knowledge of the disorder and optimal 
treatment for these patients. To achieve this, it is vital to conduct more thorough assessments 
to match services to fit the needs of the patients. New reforms in Norway and patients’ rights 
regulated by law enhance the need for harmonising the practice in terms of assessing and 
providing optimal services for these patients. 
The Health authorities in Norway have the responsibility to make sure that the patients are 
given inter-disciplinary specialised treatment (Department of Health, 2004). How patients are 
assessed before they enter specialised substance abuse treatment today varies greatly where 
some assessment centres have vast experience with this kind of work while others do not, and 
the patients’ drug use and life situations can make these assessments difficult. As a result, the 
patients can be given treatment options before a complete assessment of their needs meaning 
the options can be based on a lack of knowledge about the patient’s condition, and in addition 
some centres have little knowledge about all treatment options available to address the 
patient’s needs.  
Given the different approaches for assessing patients with a substance use disorder and 
questions used when assessing patients’ severity on important dimensions, key elements for 
measuring severity may go unnoticed when aspects of their substance use problems are not 
dealt with. In order to secure quality work, harmonising the practice with a standardised 
validated assessment tool for all of the centres in this region is desirable. Introducing a 
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comprehensive assessment tool can give the centres the opportunity to measure patient’s 
needs on important dimensions at earlier stages before they enter treatment, and give the 
treatment centres a better foundation for decisions about treatment placement and individual 
plans for the patient. 
Searching for a standardised assessment tool, the ASAM Criteria (American Society of 
Addiction Medicine Criteria, second revised version) was deemed eligible for studying 
patients in Norway with a substance use disorder.  The instrument was developed from 
ASAM patient placement criteria to match patients to discrete LOC based on their needs 
across six dimensions (Mee-Lee, Shulman, Fishman, Gastfriend, & Griffith, 2001), and was 
translated into Norwegian. The Criteria and its biopsychosocial measurement dimensions 
have been shown both to predict treatment success and to be cost effective (Annis, 1988; 
Alterman et al., 1994; Gastfriend & McLellan, 1997, Hayashida et al., 1989; Sharon et al., 
2003; Magura et al., 2003).  
The validation testing of the ASAM Criteria has undergone substantial research however this 
second revised software version has not undergone such validation testing on multi-sites with 
follow-up measures. With the new version translated into Norwegian, a multi-site validation 
study in the central region of Norway was conducted after a pilot study on the translated 
version. The results in this present dissertation are taken from baseline and second follow-up 
interview from a total of four interviews with recruited patients. 
 
1.1.1. Main aims 
 
Conducting a validation study of ASAM second revised edition in Norway is important for 
many reasons and the main aims of the study were:  
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1. Possibilities of using the revised software version of the ASAM Criteria for 
harmonising the assessment centres’  procedures through pilot testing satisfaction 
among assessors and patients and inter-rater reliability measures of the revised 
version. 
2. Investigate predictive and convergent validity with the second revised Norwegian 
software version for treatment outcomes and baseline severity among the different 
recommendations. 
3. Investigate the prevalence of needs both in terms of LOC needed in the region and the 
need for integrated services for patients with co-occurring substance use disorder and 
psychiatric disorders for future health care planning. 
 
The theoretical background, a biopsychosocial understanding of substance use disorders, has 
shaped the development of the concept of addiction used earlier to the substance use disorder 
concept we use today. The causes, sustainment and treatment of this disorder throughout 
history from a moral view to a more medical understanding are vital to understand how this 
has affected treatment and also assessment of needs.  The shift from patients being understood 
as immoral outlaws to receiving patients’ rights by law in Norway equal to other chronic 
disorders is important for treatment development and outcomes for this group (Department of 
Health, 2004). The introduction will begin with a description of the development of different 
approaches to the biopsychosocial model we use today.  This also entails a description of the 
two classification systems and diagnostic manuals for substance use disorders used in Europe 
and USA, one used by the Norwegian health care system (ICD-10) and the assessments 
centres included in this study,  while the other is incorporated into the ASAM Criteria 
(American Psychiatric Association, 2000; DSM-IV). The introduction also includes a section 
about treatment offered in Norway based on the biopsychosocial approach, and how 
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assessments are executed in this region. The history and development of the ASAM Criteria is 
briefly described together with the inclusion of co-occurring disorders in the revised version 
and prevalence among patients suffering from a substance use disorder. The last section 
discusses why these placement criteria can be useful in Norway and the specific hypotheses 
the three articles have investigated. 
 
1.2. The history of the addiction concept to substance use disorder we use 
today 
Around 1850, society began to see the effects of high alcohol consumption in their working 
class, and the addicts were viewed as immoral criminals that needed to be punished and 
persecuted for their abuse. It was believed that through discipline, they would become more 
moral human beings thus leading to a reduction in use (Hamran, 2005). Alcohol was also seen 
as a poison whereby the availability of this poison led to misuse and addiction. The solution 
was to keep people away from it so the problem would disappear. One of the most important 
tools society uses today is actually to control access to substances. Control over the 
availability of alcohol in our society has been effective for prevention purposes (Hamran, 
2005). 
1.2.1 Disease model  
 
In the beginning of 1900, reports began stating that different drugs could have harmful side 
effects (Goldstein, DesLauries, Burda, & Johnson-Arbor, 2009) and people were still craving 
alcohol despite lack of access (Fekjær, 2004). The moral model shifted to a disease model for 
understanding addiction propagating the idea that people needed treatment and help for their 
addiction problems rather than being punished. More treatment centres were developed, but 
some believers of the moral model forced hard labour on alcoholics as treatment. With the 
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shift in 1930 involving a more medical approach to the concept, more disciplines started to 
look at correlations between use and harmful effects, and develop broader treatment 
alternatives. Families were involved more closely in the treatment of their family members as 
their importance was discovered (Fekjær, 2004). Interdisciplinary treatment became central in 
the field – which continues to be important today. For medical personnel, the medical 
perspective has been predominant while for other disciplines the psychosocial has been more 
important. This can be due to the fact that they have traditionally worked with patients at 
different times and phases of their treatment. Working across disciplines and integrating all of 
these perspectives is now viewed as the most effective approach to the treatment of patients 
with a substance use disorder. 
 
1.2.2. International Classification of Diseases (ICD-10) 
 
ICD-10 (International Classification of Diseases, rev 10) was developed by the World Health 
Organization in 1992 (WHO, 1993). ICD-10 is used widely in Europe today and is the 
diagnostic manual used by the Norwegian health care system to determine substance use 
disorder. Currently, it is classified as a mental and behavioural disorder supporting the view 
of addiction as a learned behavioural disorder. This is the criteria used to assess if the 
individual has a problematic use of substances, or clear dependence to a drug or multiple 
drugs, namely addiction. The diagnostic criteria of addiction as per ICD-10 guidelines are 
listed below: 
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”Recognized by an unfit pattern of drug use which leads to clinical deterioration or 
exhaustion shown in three (or more) of the following factors:” 
1) Tolerance: Increased amount of substances is necessary to obtain the desired effects 
(i.e. development of tolerance symptoms); 
2) Abstinence: Physiological abstinence symptoms when substance use is stopped or 
reduced; 
3) Use of substances in larger amount or over longer periods of time than intended 
4) A persistent urge exists or there are few successful attempts to cut down or control the 
use   
5) Much of the time is spent on activities that are necessary to retrieve, use, and recover 
from the substance abuse 
6) Important social, occupational, or recreational activities are abandoned or reduced 
because of the abuse 
7) The use continues regardless of persistent or accommodating physical and 
psychological problems which most likely are caused by or worsened by their drug use 
 
The diagnostic classification by ICD-10 can be viewed as categorical and does not take into 
account that different abusers have different degrees of severity. Some are not as severely 
inflicted as others, and this is dependent on multiple factors. Different drugs have different 
consequences on the development of physical and psychological dependence, tolerance 
development, and other biological, social, environmental factors.  
 
1.2.3. DSM-IV 
 
The American classification system, operating with the ASAM Criteria, is called DSM-IV 
(American Psychiatric Association, 2000). It separates substance addiction into criteria for 
substance abuse and criteria for dependence. A distinction between abuse and dependence 
was based on the concept of abuse as a mild or early phase; dependence as a more severe 
manifestation.  
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The definition for substance abuse is a pattern leading to significant impairment or distress as 
manifested by one or more of the following four criteria: 
1. Failure to fulfil major role or obligation 
2. Frequent use of substances in situations in which it is physically hazardous (e.g., driving an  
automobile or operating a machine when impaired by substance use) 
3. Frequent legal problems for substance use 
4. Continued use despite having persistent or recurrent social or interpersonal problems 
 
The dependency criteria are similar to the ones in ICD-10. Now, the revised fifth version 
classifies substance dependence as substance use disorder (American Psychiatric Association, 
2013). The term is used in this dissertation as a standard phrasing of the disorder and has also 
been the standard phrase in the submitted articles this dissertation is based on. A single 
diagnosis matches the patients’ symptom experience better while considering their problems 
on a continuum from mild to severe. Each specific substance is addressed as a separate use 
disorder (e.g., alcohol use disorder, opiate use disorder, etc.), but nearly all substances are 
diagnosed based on the same overarching criteria. In this overarching disorder, the criteria 
have not only been combined, but strengthened. Whereas a diagnosis of substance abuse 
previously required only one symptom, mild substance use disorder in DSM-5 requires two to 
three symptoms from a list of 11. Drug craving will be added to the list and problems with 
law enforcement will be removed due to cultural considerations that make the criteria difficult 
to apply internationally. 
As mentioned earlier, the ICD-10 criteria is used in the Norwegian health care system and 
DSM-IV (now updated to include the fifth version in the fall 2013 version) is incorporated in 
the ASAM Criteria software. Services vary in this region’s health care system but have a goal 
to individually adjust treatment offered to fit patients’ needs whenever possible (Referral 
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routines; www.rus-midt.no). Treatments have become broader and more scientifically funded 
than rehabilitation was previously. The shift in approaches to the disorder affecting the 
development of treatment, and the shift towards a biopsychosocial approach to the assessment 
and treatment of patients with substance use disorder means that more patients’ needs are met, 
although all the needed LOC and services are still lacking. However the services are 
becoming increasingly aware of the patients with co-occurring disorders like somatic and 
psychiatric disorders with programmes being created to target these needs together with their 
substance use disorder to achieve success in treatment (Evjen, Øiern, & Kielland, 2003).  
 
1.3. Biopsychosocial approach 
One of the first advocates for this approach within the medical world was George L. Engel 
(Engel, 1977). He challenged the biomedical thinking by showing other significant factors 
affect the disease and its course. He stated that the biomedical approach did not answer the 
scientific and social challenges that medicine and psychiatry were facing and he was referring 
to the effect of treating patients with placebo medicine – showing the influence of 
psychosocial factors on many biological treatments. Study results have shown that medicine 
alone cannot treat patients with substance use disorders, but a combination of medicine and 
psychosocial treatment does have a positive effect on patients (Volpicelli, Pettinati, McLellan 
& O’Brien, 2001). The medication should have been effective by itself if the biology of 
humans was the predominant factor.  Engel’s biggest contribution to the field was challenging 
and broadening clinical views and understanding of the disease by applying a broader medical 
approach to meet patient needs. The weakness of earlier approaches is that they are 
insufficient and not broad enough to give comprehensive and satisfying explanations on their 
own. A combination of ideas from different perspectives can address the limitations of 
individual theories. Substance use disorder in all its complexity is more fully explained and 
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understood from a biopsychosocial view which takes into account several factors in 
understanding of the disorder. 
A biopsychosocial approach to explain addiction considers all factors associated with the 
cause, development and expression of the disorder. In 2004, reforms by the Norwegian 
government sought to give addicted patients’ rights to treatment that are equivalent to other 
chronic medical diseases (Department of Health, Patient right law, 2004). The goal was that 
addiction treatment should evolve into inter-disciplinary specialised services that focus on 
individually-based social, biological and mental health needs. The complexity of addiction 
demands comprehensive assessment (Gastfriend & McLellan, 1997; Ravndal, Vaglum, 
Lauritzen, 2005); without it, there is a risk of treating the wrong problems or failing to 
provide services that meet patients’ needs. There is also a consensus in the field regarding the 
complex interaction between biological, psychological, and social factors that contribute to 
the development and maintenance of substance use disorder. This is shown by the 
composition of their personnel group, which is interdisciplinary, i.e. doctors, nurses, 
psychologist, social workers who together address multiple needs of the patients. Services 
offered include medical therapy, behavioural therapy, individual and group therapy, 
performed in an outpatient setting or inpatient setting. Moreover, there is interdisciplinary 
assessment teams examining the areas of a patient tied to a substance use disorder. And the 
underlying approach that providers follow is biopsychosocial for understanding, assessing and 
treating this disorder although not always in such a systematic order like the ASAM Criteria. 
A widely held belief, the complex interaction of biological, psychological and social factors 
affects the development and sustains substance use disorders and therefore the assessment and 
treatment should adopt this approach.  
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1.3.1 Biological factors 
 
The effect of our genes in substance use disorder is still unclear (Buckland, 2008). Genes 
linked to vulnerability for developing alcoholism that are connected to neural pathways in the 
reward system, behaviour control, and resistance to stress have been discovered (Ducci & 
Goldman, 2008).  In their article, the authors state that genes account for more than 50% of 
the explained variance in vulnerability to develop alcoholism in twin studies thus supporting a 
high inheritance factor. But it is hard to locate specific genes when one is dealing with 
complex diseases like substance use disorders, although the biological influence is clear. And 
to fully understand the disorder, one needs to examine the interaction of genes and the 
environment.  The environment and stimuli associated with the substance or its use can 
provoke a conditioned response and activate craving and symptoms of abstinence. The 
disassociation between drug incentives which make you want it, together with the good 
experience it gives, are linked to a hypersensitive reward system due to intake over time 
(Leshner & Kobb, 1999). Sensitivity arises from the direct effect of the drug and associated 
stimuli not directly related to the drug. This leads to more use, and the abusing behaviour is 
coupled with poor decision making and impaired ability to judge one’s behaviour. This lack 
of control is tied to changes in the brain. Long term use damages the nucleus accumbens 
which uses dopamine to regulate and induce euphoria. A substance stimulates dopamine 
release or enhances its activity, and long term use can deplete the nucleus accumbens’ ability 
to regulate euphoria. When the intake of substances stops, withdrawal symptoms emerge 
recognised by the opposite of euphoria, which is dysphoria. This chronic relapsing disorder 
has been found to create maladaptive drug associated memories, and thus also a learned 
disorder (Milton & Everett, 2012).   
Withdrawal symptoms vary, but some common markers exist (The Norwegian Medical 
Association, 2006). These abstinence symptoms refer to the physiological or psychological 
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craving symptoms like shivering, fever, restlessness, and a strong urge to use substances. 
Irregular activity in the nucleus accumbens is associated with withdrawal symptoms and can 
lead to use of substances to avoid the unpleasantness (Lehmann & Jensen, 2004). The 
chemical effect leads to a desire for more when it leaves the body, and common for all 
substances is that symptoms are a sign of imbalance in the body indicating psychical 
dependency.  In addition to psychological dependency, this contributes to and sustains intake 
and behaviour. Psychological dependency is the sensation of a strong desire or urge to take 
substances and controlling behaviour related to intake (WHO, 1993). 
 
1.3.2. Psychological factors 
 
Personality traits and mental disorders can influence substance use disorders greatly. Traits 
such as excitement seeking and risk taking can increase attractiveness of substances (Cami & 
Farre, 2003). Disorders such as schizophrenia, bipolar disorder, depression, and ADHD are 
associated with greater risk for developing substance use disorder – but causality is difficult to 
determine. Was it the psychological disorder that caused the substance use disorder or was it 
the latter that caused the mental disorder? Both can be affected and what we can determine is 
that prevalence of co-occurring psychological disorders among substance use disorders is high 
both in Norwegian studies and international ones (Bakken, Landheim & Vaglum, 2005; Cole 
& Sacks, 2008; Helseth, Samet, Johnsen, Bramness & Waal, 2013; Melberg, Lauritzen & 
Ravndal, 2003; Ravndal et al., 2005; Schulte, Meier, Stirling & Berry, 2008). This 
comorbidity makes it harder to treat and can have a negative effect on outcomes like high 
attrition, low treatment attendance, and worse outcome (Angarita, Reif, Pirard, Lee, Sharon, 
& Gastfriend, 2007; Hides, Dawe, Young, & Kavanagh, 2007; Magura et al., 2003; Schulte, 
Meier, Stirling & Berry, 2010).  
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1.3.3. Social factors 
 
Even if an individual through genetic inheritance and social factors can be at risk for 
developing substance use disorders, they do not have to develop this disorder; however this 
vulnerability creates a greater risk if they are brought up in a hostile environment with 
conflicts, bad parent/child relations, substance use, and physiological or psychological abuse. 
Among adult alcoholics, a majority reported being victims of child abuse and/or sexual abuse 
(Stewart, 1996). Likewise children from very good and stable homes can also develop 
substance use disorders. Clark, Lesnick, and Hegedus (1992) found that youths with alcohol, 
substance abuse or dependency had  6 to 12 times higher probability of being a victim of 
physical abuse and 18 to 21 times greater chance of being subjected to sexual abuse than 
others without this disorder. The use might inhibit anxiety and depression they experience, 
and over time they identify themselves with other users with similar issues. The new 
environment sustains the use and gives the involved a sense of identity which often is not in 
accordance with the rest of society. And their social network is often scarce and little 
supportive when they decide to enter treatment. This loneliness can make it more difficult to 
remain drug free after treatment (Persson & Stallvik, 2007). In Persson and Stallvik’s study, 
patients reported that it can be challenging to approach family and old friends; their sense of 
not belonging and not being worthy is high among these patients. They often also lack work 
obligations, school, or leisure activities to keep them occupied. When obtaining drugs, taking 
them, and recreating after intake has been the main activity for such a long time it can be quite 
challenging to fill this void with health promoting activities. Many report having social 
anxiety as a consequence of not being part of society for a long time further complicating 
matters. Patients also reported that when they feel bored or experience loneliness, cravings 
increase and the further down the spiral they go, the harder it is to re-enter society. 
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The biopsychosocial model incorporates leading theories in the field and gives a framework 
for understanding why some develop this disorder, and why it sustains despite all the negative 
consequences. The uniqueness and needs an individual possesses are taken into consideration 
with such an approach to substance abuse and dependency as a disorder. Biological, 
psychological and social factors contribute to or inhibit the possibilities to come into contact 
with substances and develop addiction through genes, physical or psychological disorders, 
family relations, and other environmental factors.  
 
1.4. Treatment in Norway 
A biopsychosocial approach has implications for the LOC provided in our health care system. 
Previously, the LOC in Norway were categorised by how long it takes for the patients to 
undergo treatment (i.e. detoxification, normally taking less than two weeks, was defined as 
level one, whereas outpatient treatment was defined as level two, inpatient less than six 
months as level three, and inpatient treatment over six months as level four). Now the field in 
Norway has shifted and we see a division of LOC based on intensity and resources that the 
clinics can provide.  Intensity accounts for personnel resources, therapy offered and medical 
treatment provided. A greater focus on co-occurring disorders those patients might have 
demands psychiatric and medical programmes to meet patients’ needs (Evjen et al., 2003). 
The division of levels are now more in line with the division in ASAM Criteria (Mee-Lee et 
al., 2001), and new levels have also been developed in this region which were unavailable 
when this study began recruiting centres. Intensive outpatient services also called day 
treatment providers were not available, but is currently a developing LOC in this region.  
Individuals with this disorder often enter treatment late therefore the disorder has had time to 
develop and cause major consequences for the individual’s physical status, psychological 
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health and work obligations, housing and social networks. Phases of treatment are usually 
based on the patients’ initial understanding of their problems with substances based on 
Prochaska and DiClementes’ (1992) phases of change theory. They might feel pressured by 
their environment to enter treatment, but might not have the desire to be treated themselves. 
They can also be detected and referred to treatment by social workers helping them with 
financial and housing issues. Referrals must include a thorough description of the problem, 
history, other co-occurring disorders, individual plans and suggestions, or treatment 
preferences of the patients. 
 
1.5 Assessment of substance use disorder in the middle region of Norway 
The middle region of  Norway had 10 assessment centres where a thorough assessment of 
patients’ needs are taken with some using unstructured interviews and others structured 
instruments to measure severity like the Addiction Severity Index (ASI; McLellan, Luborsky, 
Woody & O’Brien, 1980). Testing ASAM Criteria as a possible tool for harmonising 
practices to improve assessment and placement is one of this dissertation’s major aims. The 
complexity of addiction creates a need for a comprehensive assessment of needs (Gastfriend 
& McLellan, 1997; Ravndal et al., 2005); without it, there is a risk of treating the wrong 
problems or failing to provide services that meet patients’ needs. Defining substance use 
disorders as a biopsychosocial disorder both in etiology and expression demands that the 
assessment and treatment employ this approach (Gastfriend & Mee-Lee, 2003). The 
assessment process must consider the influence of a substance use disorder on the patient’s 
physical health, psychological health and social conditions, along with the notion that 
substances have a clear effect on the brain especially long term use, and all of this must be 
considered during the assessment and intake process. By interviewing the patients thoroughly, 
it becomes easier to observe how they answer the structured questions, how they respond to 
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them, and if there are severe cognitive deficiencies that need further assessment to fully 
understand the patients’ needs.   
 
1.6. History of assessment and ASAM Criteria 
The Patient Placement Criteria (PPC) published by the ASAM represents the most common 
protocol for assigning patients to treatment in the USA since its original publication in 1991 
(Hoffman, Halikas, Mee-Lee, & Weedman, 1991). By 2001 it had undergone considerable 
research and added sub-levels of care and a focus on co-occurring disorders in the second 
revised version, ASAM PPC-2R (Mee-Lee et al., 2001).  
The ASAM Criteria Software, endorsed by a national professional society, is a structured and 
comprehensive assessment designed to recommend the optimal LOC. The ASAM Criteria, 
used by a majority of US states (Mee-Lee et al., 2001), has undergone several studies 
supporting its usage and the principle of these criteria multidimensional needs assessment in 
treatment planning (Annis, 1988; Hayashida et al., 1989; Alterman et al., 1994; Mechanic, 
Schlesinger & McAlpine, 1995; Gastfriend & McLellan, 1997; Hser, Polinsky, Maglione & 
Anglin, 1999; McLellan et al,. 1997; Gastfriend, Lu & Sharon, 2000). It is a structured 
interview that implements validated tools like the ASI (McLellan et al., 1992) to assess 
patients’ needs, with clinical decision support software, quantitatively calculating all of the 
ASAM Criteria adult admission decision rules. Studies in the USA found high inter-rater 
reliability (Baker & Gastfriend, 2003), good face validity (CSAT, 1995), and predictive 
validity (Angarita et al., 2007; Magura et al., 2003; Sharon et al., 2003; Staines, Kosanke, 
Magura, Bali, Foote, & Deluca, 2003; Turner, Turner, Reif, Gutowski, & Gastfriend, 1999). 
Convergent validity has also been reported, e.g., patients with different LOC 
recommendations were distinct on ASI Subscale Composite Scores (ASI CS) such as ASI 
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Medical and Psychological and on alcohol withdrawal measures, with progressively more 
severe scores as the LOC intensity escalates (Sharon et al., 2003). 
The criteria and the dimensions on which patients are measured have been shown both to 
predict treatment success and to be cost effective (Annis, 1988; Altermann et al., 1994; 
Gastfriend & McLellan, 1997; Hayashida et al., 1989). Studies of patients mismatched by the 
ASAM Criteria have shown that they are less likely to show up for treatment and have worse 
treatment outcomes than matched patients who had better 90-day outcomes (patients were 38 
% more likely to enter continued treatment after detox, and less likely to return to detox 
within 90 days; Angarita et al., 2007; Magura et al., 2003; Staines et al., 2003). Staines et al. 
(2003) also compared the degree of agreement for the ASAM Criteria Software versus 
counsellors’ assessment under treatment-as-usual (TAU) conditions. In this study, clinical 
staff had training and computer-guided interview assistance along the ASAM dimensional 
assessment process, however, the actual ASAM Software algorithm score was kept blind to 
staff and patients. Surprisingly, staff disagreed with the computer scored LOC 
recommendations in 58% of the 248 cases, and the ASAM Software recommended a more 
intense initial LOC than the TAU protocol in 81% of the discrepant cases. The patients who 
were assigned to treatments that were matched by the computer had better 90-day outcomes, 
even after TAU clinicians received ASAM Criteria training and used computer-assisted 
interviewing (but without the algorithm) (ASAM Criteria; Mee-Lee et al., 2001). These 
results indicate that the software has both convergent ability in terms of discriminating by 
severity measures (Sharon et al., 2003) and predictive validity with better LOC placement and 
assessment of patients’ needs with the use of the structured interview that ASAM Criteria has 
over TAU. 
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1.7. Co-occurring disorders among patients with a substance use disorder 
Several studies including patients with both a substance use disorder and a co-occurring 
psychiatric disorder show high prevalence  in both Norwegian and international studies 
(Bakken et al., 2005; Cole & Sacks, 2008; Helseth et al., 2013; Melberg, Lauritzen, & 
Ravndal, 2003; Ravndal, Vaglum, & Lauritzen, 2005; Schulte et al., 2008). While numbers 
vary by study, national studies have found prevalence within 32 to 65% (Bakken et al., 2005), 
while international studies have found lower but increasing numbers (20% in Grant et al., 
2004; 46% in Schulte et al., 2008). Patients categorized in this group have poorer prognosis, 
legal difficulties and unemployment (Dausey & Desai, 2003), and higher prevalence of 
suicide attempts (Bakken & Vaglum, 2007; Darke, Ross, Lynskey, & Teesson, 2004). These 
considerations need to be taken into account when assessing and treating these patients. By 
not recognising co-occurring problems early, clients’ needs might not be met, which in turn 
can lead to unfavorable outcomes like high drop-out rates, no-show for treatment, and less 
beneficial outcomes from treatment (Angarita et al., 2007; Hides et al., 2007; Magura et al., 
2003; Schulte et al., 2010). Results from studies on integrated treatment seem to indicate that 
it is more effective than sequential services for this group of patients (Brunette, Mueser, & 
Drake, 2004). 
Patients with a high severity of co-occurring problems matched to high service-intensity 
programmes have better treatment outcomes than patients with high co-occurring severity 
treated in low-intensity programmes, showing that matching by intensity has improved 
outcomes (Chen, Barnett, Sempel, & Timko, 2006). The most recent fall 2013 ASAM Criteria 
book changed the term Dual Diagnosis to co-occurring mental disorder.  
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1.8. Revised version assessed needs and LOC including Dual Diagnosis 
programme recommendations 
In the revised version, Mee-Lee and colleagues (2001) introduced taxonomy of addiction 
treatment programmes based on their Dual Diagnosis capability. The categories are defined as 
Addiction Only Services, Dual Diagnosis Capable and Dual Diagnosis Enhanced. Based upon 
the fact that a majority of patients with a substance use disorder also have a co-occurring 
psychiatric disorder, it has been proposed that all addiction treatment should at least be Dual 
Diagnosis capable (Minkoff, Zweben, Rosenthal, & Ries, 2003). Thus, the addiction treatment 
programmes should be able to handle patients with co-occurring disorders which are stable in 
symptoms and severity. McGovern, Xie, Acquilano, Segal, and Drake (2007) studied the 
ASAM taxonomy for dual diagnosis categories and found that one-fourth of the programmes 
classified themselves as Addiction Only Services only, two-thirds (65%) of the programmes 
reported being in the Dual Diagnosis Capable category, and a few (10%) programmes 
classified themselves as Dual Diagnosis Enhanced programmes. Results support the 
taxonomy of ASAM classification system by showing that Dual Diagnosis Enhanced 
programmes report treating patients with significantly greater psychiatric severity than Dual 
Diagnosis Capable and Addiction Only Services. However more research is needed regarding 
the use of ASAM taxonomy to test its validity for making clinical distinctions between the 
different recommendations. 
 
1.9. Why patient placement criteria in Norway? 
The human mind rarely follows formal criteria to form judgments and conduct decision 
making, and we are slow to adopt new treatments despite research and clinical evidence of 
safety and superiority (Hogarth, 1987; Volpicelli, Alterman, Havashida, & O’Brien, 1992). If 
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decision rules for the use of the Norwegian version of the ASAM Criteria software specify 
optimal placements, and patients are assigned to treatments that yield the best outcomes, at 
the least intensive LOC for their needs to be met safely, it can have great benefits for the 
patients’ healing and rehabilitation process and the utilisation of available resources. Over-
matching, i.e. referral to a more intensive LOC, would then be recognised as more restrictive 
and/or more costly than needed.  Under-matching, i.e. referral to a less-than-recommended 
LOC, may then lead to poor engagement, poor retention, poor clinical outcome, and low cost-
effectiveness.  Also the greater need for a standardised tool for assessing patients will be 
beneficial for both clinical and research purposes and further development of health care 
services for this patient group. 
Using such a standardised software based tool will also simplify the process of collecting 
patient data, reviewing it, and analysing it by having a software based programme that 
provides transferable raw data for the recommendation and severity report on each patient. 
This is useful both clinically and for research purposes. 
 
1.10. Specific hypotheses tested in this dissertation 
It is important to replicate previous studies conducted with the first edition of the ASAM 
Criteria using the Second Edition, Revised version, as well as on a different national sample 
with different languages and treatment systems, to further investigate abilities to both match 
and discriminate between patients’ symptom severity and needs. This dissertation also 
includes a pilot study conducted prior to the validation study that was not published due to a 
small sample of assessors and patients. However it is included in the dissertation to show the 
translation process and satisfaction and inter-rater reliability among assessors and patients. 
This is information deemed important for clinicians and health care systems thinking of 
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adopting these Criteria in their own system. In addition to answering one of the dissertation’s 
main aims, possibilities and usage of the ASAM Criteria for harmonising the assessment 
centres practice in the region are considered. After the pilot study was complete, the 
validation study started and data was gathered for the three main articles this dissertation 
combines. 
The first article this dissertation includes tested the ASAM Criteria Software, Second Edition, 
Revised version in Norwegian for predictive validity among the Norwegian substance use 
disorder treatment-seeking population. At baseline and follow-up, we examined drop-out 
from assigned treatment before the three month follow-up interview, frequency of use of 
alcohol or other medical or illegal substances in the last 30 days, severity measures on the ASI 
Composite Subscale Scores (ASI CSs), and whether initially matched vs. mismatched patients 
would subsequently require a lower or higher LOC at follow-up, according to the ASAM 
Criteria recommendation.  
The second article further extends the work of the first one by exploring two hypotheses: first, 
the new ASAM Criteria LOC recommendations should show convergent validity with the 
most commonly used addiction severity measure, the ASI CSs, and second, the ASAM LOC 
recommendations should show predictive validity, in terms of discrepancies between patients 
assigned according to ASAM vs. TAU placement. Replicating and extending the findings by 
Staines et al. (2003), which used the ASAM PPC-1 (Patient Placement Criteria) version, we 
sought to study the newer ASAM Criteria software version, to investigate whether the more 
restrictive ASAM placements are justified by better treatment outcomes. Finally, whereas that 
was a single-site study, the articles in this dissertation use multiple sites which allow for 
greater inclusion of patients, LOC, treatment variation, and generalisability.  
The third article further extends the work of the two previous ones by exploring the 
convergent validity for Dual Diagnosis programmes. The aim of this study is to investigate 
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the prevalence of Dual Diagnosis Programme recommendation among treatment seeking 
patients with a substance use disorder, and investigate what characterises those that get 
Addiction Only Services, Dual Diagnosis Capable or Dual Diagnosis Enhanced 
recommendation by the ASAM Criteria software. Also treatment outcomes at three months 
after treatment initiation among those with and without Dual Diagnosis programme 
recommendation were assessed on the variables; show for treatment assigned and treatment 
retention.  These outcome measures together with the discrimination of severity in the low vs. 
high treatment recommendations are used to test ASAM Criteria software version for 
convergent validity. We also studied changes in the ASI CSs to see how the patients’ severity 
changed in the already existing treatment system without specific Dual Diagnosis 
programmes to offer.
2. Method 
2.1. Pilot study of the Norwegian translated version 
 
Since this study was in preparation for a large multi-site validation study, assessors from 
several clinics were recruited. Ten clinics from the central region of Norway covering three 
counties agreed to participate and provide personnel to be trained as ASAM assessors. 
Patients were recruited from the same clinics. Both outpatient and inpatient clinics with a 
variety of services were included. The final sample consisted of eight out of 20 assessors; 
chosen based on practical reasons, they were the first to complete the course and complete 
their training videos, to check their satisfaction with the ASAM Criteria and its feasibility. No 
significant differences were found between the assessors or patients’ on descriptive variables 
between those chosen to participate in this pilot-study and those who were left out. 
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2.1.1. ASAM Assessors 
 
The final sample in this study included eight assessors with satisfaction data, and six assessors 
with complete ASI composite scores from 5 training video interviews. The assessors consisted 
of six females and two males with a mean age of 42 (30-55). The assessors had a minimum of 
15 years of school (M=16, SD=1.51) and maximum of 19 years, and a minimum (max) of 3.5 
(19) years with experience as a clinician in the drug addiction field (M=9.13, SD=6.08).  
 
2.1.2. Pilot Patients  
 
The target videos consisted of 10 patients, and five of these videos were completed by all of 
the assessors to quality check the software and inter-rater reliability (three men and two 
females). Ages ranged from 27 to 49 years (M= 36.4, SD = 9.26). The main drug of choice 
was opiates (two men and one female), sedatives/sleeping pills (one female), stimulants (one 
man). In addition, they all had co-occurring problems with other drugs like sedatives, alcohol, 
stimulants and cannabis, and four patients reported co-occurring anxiety and depression 
diagnoses. One patient also reported PTSD together with ADHD and two patients reported 
personality disorders. Four out of five patients had previously been in contact with addiction 
treatment facilities for their substance use disorder. Number of treatment contacts with 
different addiction treatments facilities ranged from zero to three (M; SD = 1.8; 1.30), but 
counting only stays for detoxification this number ranges from zero to five (M; SD = 2.2; 
1.92). LOC determined by clinicians in this sample was: two inpatient placements, two 
outpatient opiate maintenance treatment, and one with a combination of inpatient and opiate 
maintenance treatment. For marital status, three patients reported being single, and two had 
co-living arrangements with their partners. 
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2.1.3. Procedure Pilot study 
 
The translation of the software was a major task in this project, and the importance of high 
quality and cross cultural adaptation of the translation of instruments to ensure that concepts 
stay in line with the original design of the instrument is crucial (Gjersing, Caplehorn, & 
Clausen, 2010). We chose to do a full scale translation and correction of the ASAM Criteria 
before it could be used in a validation study to ensure that we would be using the instrument 
for the purpose for which it was designed, namely assessing the severity and needs and 
recommending patients for optimal treatment services. We also designed a comprehensive 
training programme to ensure that assessors would be sufficiently trained to execute the 
interviews properly. The original instrument was translated from the original English into 
Norwegian based on recommendations from previous studies (Hoffmann et al., 1991; 
Weedman, 1987). Two individuals produced the initial translations independently. The 
translators were native Norwegian speakers with good fluency in the original language and 
the translated versions were synthesised into a single version by a third independent 
translator. Thereafter, the synthesised translation was reviewed by an expert committee, 
comprising methodologists, health professionals, language professionals and the translators. 
The expert committee assessed whether a word or phrase reflected the same meaning in both 
the original and adapted versions, and if they were in line with previously translated 
instruments in Norway which the ASAM Criteria software edition included, such as the 
Europ-ASI (Lauritzen & Ravndal, 2004). The ASI questions were identical to the already 
existing Europ-ASI and with other items, changes were made to reach consensus. These 
assessments ensured that items were translated correctly and would be relevant in the new 
setting. The instrument underwent several changes based on these assessments, and also 
during interview testing, changes were made to the language. Based on these changes, we 
produced a Norwegian version of the complete ASAM Criteria questions and answers set, and 
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could move forward with testing the instruments’ feasibility and validity for the Norwegian 
drug addicted population. After the certification courses where all the ASAM elements and 
software were introduced and tested, they rated 10 training videos to complete the course and 
qualify for a certification diploma. During this time, they also received individual supervision, 
group supervision, and a 1-day course to review and discuss the levels described in ASAM 
Criteria and evaluate their experience with the assessments. After their first and last video, 
they were asked to fill out a 34-item questionnaire specially designed for this pilot study. 
 
2.1.4. Training video  
 
In order to create target videos for the training and assessment of the assessors across the 
treatment programmes in the region, the Principal Investigator conducted the ASAM Criteria 
computerised interview with 10 inpatient and outpatient patients. The 10 target videos 
consisted of a full side view of the patient and audio of both the interviewer and the patient. 
Duration of administration was automatically recorded during the interviews by the software 
programme and was compared to previously reported administration times. 
 
2.1.5. Satisfaction Questionnaire 
 
During the course, all assessors were asked which elements were important for their 
satisfaction with the instrument, and key issues that were mentioned by all included that the 
software should be broad enough to cover all aspects of the patient, easy and time efficient to 
execute, and that the computer should not interfere with the clinical assessment setting and 
diminish personal contact with the patient. A set of 34 questions was created to measure the 
ASAM-assessors’ satisfaction with different aspects of the ASAM Criteria software edition. 
The assessors were asked to rate their satisfaction on a five-point Likert scale, with open 
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questions for comments on the different parts of the assessment tool and its usability. They 
were told to grade how satisfied/unsatisfied they were or how much they agreed/disagreed 
with the questions. In addition, we added a question regarding use of this assessment 
interview on all patients they assess, with a yes/no/unsure response category (question item 
2), and question 4 if the use of the computerised ASAM Criteria software was a risk to the 
personal contact experience with the patient.  They were given the questionnaire on two 
separate occasions, once after their first training assessment interview and again after their 
last training interview. With regard to their comments, the items in the satisfaction 
questionnaire also included questions regarding computer use, knowledge enhancement from 
the assessment, and if they wanted to add, change, or remove any of the questions. 
 
2.1.6. Satisfaction among patients 
 
Patients’ experiences with the structured interview were collected using open-ended questions 
at the end of the interview: How was your experience with this form of interviewing 
compared to how you were assessed when you entered treatment? And are you confident that 
I have asked all the questions I need to know about your needs and make a placement 
decision? 
 
2.1.7. Statistical analysis 
 
Duration of administration was automatically recorded for each section of the assessment and 
descriptive statistics were calculated. Satisfaction with the ASAM Criteria software was 
evaluated by examining whether there were any changes in the individual satisfaction 
questionnaire items after the first and last training video interviews. For inter-rater reliability 
(IRR) testing, counsellors were asked to rate 10 videos, of which five complete training 
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videos were used for the IRR calculation with the intra class correction method (ICC). The 
assessors were evaluated based on how well they agreed on the ASI-composite scores on the 
five videos. For complete surveys, we had technical issues with the software causing loss of 
data on the PPC dimensions, and this affected the determination of LOC. These pilot findings 
were sent back to the programmers and repaired before the execution of the larger validation 
study on the ASAM Criteria software. As this was fixed after the pilot study, we could not 
measure Inter-rater reliability for LOC recommendations. 
 
2.2. Validation study  
2.2.1 Sampling and procedure 
 
The sample comprises treatment seeking patients with a substance use disorder from the mid-
region of Norway. In addition to a baseline interview and follow-up after three months, 
patients were also asked to do two more interviews six and 12 months after treatment 
initiation. This study includes data from baseline and three month follow-up interview. There 
was also a pilot study conducted prior to the full scale validation study which is included as a 
separate section.  
 
This prospective double-blind, multi-site, naturalistic study was conducted at 10 different 
assessment and treatment clinics from the region, sampled across three counties. Both 
outpatient and inpatient clinics with a variety of services were recruited. During February 
2010 and July 2012, patients at the treatment clinics were approached by ASAM assessors. 
These clinics consisted of six inpatient and four outpatient facilities. Specialised treatment for 
patients with a substance use disorder was differentiated into four LOC in Norway when the 
study started, with detoxification at the lowest level and inpatient treatment over six months 
as the highest LOC offered (Norwegian Ministry of Health, 2009). Division was based upon 
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length descriptions, not intensity. However this changed during the study period and became 
similar to the division of LOC that we see in the ASAM Criteria with more focus on 
coordination of services (Mee-Lee et al., 2001; Norwegian Ministry of Health, 2009). The 
levels in Norway are now divided like this: 
1. Outpatient treatment  
2. Intensified outpatient/day-treatment 
3. Inpatient/residential treatment 
 
The intensity and amount of services are taken into consideration in the division of LOC. 
Detoxification and opiate maintenance therapy can be offered at any level, together with 
somatic and psychiatric services that patients might need. Patients from day treatment were 
not included in the validation study as there were no centres providing this LOC when we 
started recruiting.  
 
2.2.1. Sample 
 
All the necessary applications were distributed and approved before patients were recruited. 
The study was approved by the Regional Committees for Medical Health Research Ethics 
(REK) and the Norwegian Social Science Data Services. The assessors at each centre 
informed the patients about the study and all recruited patients provided informed consent. 
Eligible patients had to be 18 years of age, speak and understand the Norwegian language, 
and be stable with regard to intoxication with alcohol and/or drugs, and/or psychiatric 
symptoms. Stable meant that they either had to be cognitively cleared from their last 
substance use, or had taken prescribed or tolerable doses such that they could function in an 
interview setting. Eligible patients did not have to be abstinent. They agreed to accept TAU 
recommended placement, and they were all clinically diagnosed with substance dependence 
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or abuse according to the International Classification Diagnostic, version 10 (WHO, 1993) 
Criteria for this diagnosis which is the preferred diagnostic classification system in Norway. 
There were 310 patients approached in this study and 290 agreed to participate (94% response 
rate).  
The sample in this study is comparable to other similar studies in Norway (Landheim, 
Bakken, & Vaglum, 2003; Melberg et al., 2003; Nordfjærn, Hole, & Rundmo, 2010). The 
latest study from the same region is also similar in terms of higher reports on unemployment, 
mood disorders and anxiety compared to the two first ones, and consequently the 
representativeness of this current study with Norwegian substance use disorder patients was 
considered satisfactory.  The final clinical sample consisted of 261 patients, 66% male, ages 
18–61.  A majority was never married (79%), 36 % were living alone, and 46 % with family, 
partner or friends.  Nine percent (9%) of the total sample lived with children. Over 18% 
reported no stable living arrangement in the last three years.  A mean of almost 11 years (SD= 
±1.87) of education was reported and the longest occupied job had a mean of almost 5 years 
(SD= ±2.13). Almost half of the sample (49%) were unemployed and only 13% had income 
from employment in the last 30 days. There was a mean average on nearly four legal 
convictions in the sample.  
On clinical measures, the majority of the sample reported stimulants as main drug of choice 
(32%), followed by 24% with alcohol, 17% with opiates, and 12% with sedatives. Also 42.5% 
reported using two or more substances per day so they could be classified as poly-drug users. 
Treatment history in substance abuse treatment revealed an average of one stay (SD= ±5.27) 
in alcohol treatment prior to this and two stays in drug treatment (SD= ±4.63), however this 
variable was skewed with some patients having over 70 and 60 stays in alcohol and drug 
treatment.  When removing those outliers, we see that mean prior stays in alcohol treatment 
dropped from one to 0.57 (SD= ±1.66), and drug treatment with a mean of 1.80 (SD= ±2.92). 
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Psychiatric diagnosis was reported by ASAM assessors and analysed group wise separating 
those in need for Addiction Only Services or Dual Diagnosis Capable or Dual Diagnosis 
Enhanced programmes. Common psychiatric diagnosis reported by patients in all three groups 
were anxiety (49% (n = 47), 67% (28) and 57% (70), depression (51% (49), 45% (19) and 
51% (63)), and borderline or other personality disorders (28% (27), 31% (13) and 38% (47). 
Less common in Addiction Only Services, but more frequently reported by patients with Dual 
Diagnosis Capable and Dual Diagnosis Enhanced recommendation were bipolar disorder (5 % 
(5)vs. 14% (6) and 11% (13), psychosis (2% (2) vs. 10% (4) and 17% (21), PTSD (5% (5) vs. 
26% (11) and 18% (22) and eating disorders (3% (3) vs. 7% (3) and 10% (12). On PTSD and 
Psychosis, there were significantly more reports from the Dual Diagnosis groups compared to 
Addiction Only Services. In the Addiction Only Services group, 49% (47) of the patients 
reported having an active psychiatric diagnosis vs. 62% (Dual Diagnosis Capable, n= 26; 
Dual Diagnosis Enhanced, n= 76) in both the Dual Diagnosis groups but the difference was 
not significant.  
Over 65% (62) in the Addiction Only Services group had never been in psychiatric inpatient 
treatment before, and 35% (34) has never been in psychiatric outpatient care. However in the 
Dual Diagnosis Capable group, 52% (22) had never been in psychiatric inpatient treatment 
before and 43% had never been in psychiatric outpatient care. And in the Dual Diagnosis 
Enhanced group, 47% (58) had never entered psychiatric inpatient care and only 24% (30) 
had never undergone psychiatric outpatient care.  
2.2.2. Procedure 
 
All patients received a TAU assessment, i.e., routine intake interview at assessment centres by 
personnel who had not been introduced to the ASAM Criteria. Afterwards, patients received 
the ASAM Criteria Software interview at baseline with trained ASAM assessors who did not 
participate in the centres’/clinics’ TAU assessment or placement during the study period. 
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During the ASAM interview, patients were interviewed during the same 30-day time period 
as during their TAU interview, i.e., at intake. Matching was defined by the congruence of the 
clinically-derived TAU recommendation relative to the ASAM recommendation (the putative 
gold standard). If they agreed, the patient was categorised as belonging to the matched group. 
If the TAU assignment was higher, the patients were categorised as overmatched and if lower 
than the software recommendation, the patient was defined as undermatched.  
 
2.2.3. Double blind design 
 
Because the recommendation by the software is created in a separate report file, we were able 
to lock this function so that the recommendation would be kept blind to both assessors and 
patients. If they tried to view the report, a message appeared informing the user that the 
ASAM recommendation was concealed for research purposes. Patients and ASAM-assessors 
were kept blind to the ASAM algorithm-based LOC recommendation at both baseline and 
follow-up, and the patients were naturalistically referred to the TAU-recommended LOC. 
Interviews took place in routine offices and patients were contacted by the ASAM assessors 
(not necessarily the same one) again after three months for follow-up interviews. Figure 1 
shows a Flow Chart of the recruitment and follow-up process. 
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Figure 1: Participant recruitment and follow-up rates  
Available for Follow-Up Reassessment  
(N=153) 
Three months after treatment initiation 
Missing at Follow-Up (n=108) 
 
x Life situation: (n=7) 
x Active psychosis: (n= 3) 
x No contact: (n=98) 
Follow-Up Sample Matched (n=86) 
 
Follow-Up Sample Overmatched 
(n=44) 
 
Final baseline sample (n=261) 
 
Naturalistic double blind prospective design 
Matched/mismatched conditions by ASAM recommendation 
LOC Placement by TAU assessment 
 
Matched (n=150) 
ASAM Criteria LOC: 
x LI Outpatient (n=6) 
x LIII Inpatient (n=144) 
TAU LOC placement:  
x LI Outpatient (n=6) 
x LIII Inpatient (n=144) 
Follow-Up Sample Undermatched 
(n=23) 
Overmatched (n=60) 
ASAM Criteria LOC: 
x No treatment 
recommendation (n=41) 
x LI Outpatient (n=4) 
x LII Intensive Outpatient 
(n=15) 
TAU LOC placement:  
x LI Outpatient (n=1) 
x LIII Inpatient(n=59) 
 
Excluded (n=29) 
x Intoxicated or psychiatric instabilities: 
(n=25) 
x Never returned for completion: (n= 4) 
 
Assessed for eligibility (n= 290) 
Undermatched (n=51) 
ASAM Criteria LOC: 
x LII Intensive Outpatient 
(n=11) 
x LIII Inpatient (n=40) 
TAU LOC placement:  
x LI Outpatient (n=51) 
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2.3. Measurement instruments 
2.3.1. Case Report Form 
 
For all patients included in the study, a journal was created in which ASAM assessors 
registered the patient’s LOC recommended by TAU and whether the patient remained in 
treatment at follow-up interview. Additional information like drug screening/episodes, 
interview process, or other vital information was also registered in the journal. 
 
2.3.2. ASAM Criteria Software Interview 
 
The ASAM Criteria is used by a majority of US states (Mee-Lee et al., 2001) and has 
undergone nine studies with 3641 patients. Inter-rater reliability with the first edition software 
was 0.77 (ICC) (Baker & Gastfriend, 2003). Results from our pilot study are similar in regard 
to inter-rater reliability on the ASI composite scores. The current Second Edition, Revised 
tool (PPC-2R) assesses prior treatment, substance use duration, frequency and recency, 
severity of addiction, substance use disorder diagnosis, withdrawal symptoms, relapse 
potential, personality characteristics and psychiatric symptoms, cognitive function, motivation 
for treatment and environmental factors. It includes previously validated tools including (in 
the Norwegian version) the European version of the ASI (Hodgins & El-Guebaly, 1992; 
Leonhard, Mulvey, Gastfriend, & Shwartz, 2000; Lauritzen & Ravndal, 2004), the Hamilton 
Depression Scale (Hamilton, 1960), the Clinical Institute Withdrawal Assessment for Alcohol 
(CIWA-AR) (Sullivan, Sykora, Schneiderman, Naranjo, & Sellers, 1989), and the The 
Clinical Institute Narcotic Assessment (CINA) Scale for Withdrawal Symptoms (Peachey & 
Lei, 1988; Mee-Lee et al., 2001). With approximately 6,000 calculations, the software 
constructs an algorithm-based recommendation, a 3-5 page report describing the patient’s 
needs within the different dimensions, and a final LOC recommendation. The diagnostic 
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terminology used in this software version was consistent with the DSM-IV (American 
Psychiatric Association DSM, Fourth Edition, 2000; the ASAM Criteria Fall 2013 version 
incorporates DSM-5).  
 
The ASAM Criteria is a highly intricate (350 page) hierarchical decision tree in which 
the decision rules are organised along six clinical dimensions of assessment:  
1. Intoxication and withdrawal 
2. Biomedical complications and conditions 
3. Emotional/behavioural complications and conditions 
4. Treatment readiness 
5. Potential for continued use or relapse 
6. Environmental conditions. 
 
These are matched to 6 general LOC: 
x 0.5 Early Intervention: contains services for individuals who are at risk of developing 
substance-related problems or for those for whom there is not yet sufficient 
information to document a substance use disorder. 
x I. Outpatient Treatment: organized, non-residential services, which may be delivered 
in a wide variety of settings. Addiction or mental health treatment personnel provide 
professional evaluation, treatment and recovery service. Such services are provided in 
regularly scheduled sessions and follow a defined set of policies and procedures or 
medical protocols.  
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x II. Intensive Outpatient Treatment, e.g., partial hospitalization: organized outpatient 
service that delivers treatment services during the day, before or after work or school, 
in the evening or on weekends. Such programs provide essential education and 
treatment components while allowing patients to apply their newly acquired skills 
within "real world" environments. Programs have the capacity to arrange for medical 
and psychiatric consultation, psychopharmacological consultation, medication 
management, and 24-hour crisis services.  
x III. Residential/Inpatient Treatment: services staffed by designated addiction treatment 
and mental health personnel who provide a planned regimen of care in a 24-hour 
live-in setting. They are housed in, or affiliated with, permanent facilities where 
patients can reside safely. They are staffed 24 hours a day. Mutual and self-help group 
meetings generally are available on-site. Level III encompasses four types of programs 
and defining characteristic of all Level III programs is that they serve individuals who 
need safe and stable living environments in order to develop their recovery skills. 
x IV. Medically Managed Intensive Inpatient Services, e.g., hospital care: provide a 
planned regimen of 24-hour medically directed evaluation, care and treatment of 
mental and substance-related disorders in an acute care inpatient setting. They are 
staffed by designated addiction-credentialed physicians, including psychiatrists, as 
well as other mental health and addiction credentialed clinicians.  
x OMT. Opioid Maintenance Treatment: medical maintenance therapy like methadone 
or buprenorphine for opiate use disorders, which can be delivered within any level of 
care if the criteria’s for an opiate use disorder is met. 
Within these levels of care, there exist detailed sub levels for more specific program criteria, 
and there is also specific program recommendation given for co-occurring disorders. 
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A thorough description of all the LOC mentioned above can be found in Mee-Lee and 
colleagues’ book (2001). The descriptions contain guidelines for what a LOC should contain 
in the form of personnel, therapies, support systems, and documentation.  Three types of 
programs within the recommended LOC reflect their ability to address co-occurring substance 
related and mental disorders. These are Addiction Only Services, Dual Diagnosis Capable and 
Dual Diagnosis Enhanced. 
 
Addiction Only Services deals with patients with none or minor psychiatric disabilities that 
are not perceived to be interfering with treatment for their substance use disorder. 
 
Dual Diagnosis Capable programs mainly focus on treatment of substance related disorders, 
but also treat patients who have relatively stable diagnostic or sub-diagnostic co-occurring 
mental health problem related to an emotional, behavioural or cognitive disorder. 
 
Dual Diagnosis Enhanced is designed to treat patients who have more unstable or disabling 
co-occurring mental disorders in addition to their substance related disorders. All staff must 
be cross-trained in both disorders. High staff ratio with a main focus on the patients’ dual 
diagnosis instability and integrated dual diagnosis staff, services and content are found in this 
programme specification. 
 
2.3.3. Psychiatric diagnosis 
 
Analyses in article III uses data where the patients were asked directly if they have an active 
psychiatric diagnosis and ASAM assessors are asked to report any active psychiatric 
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diagnosis the patients might have after interviewing them on symptom severity and history of 
psychological problems. These are used as outcome variables along with ASI CSs to 
determine severity and characteristic differences within the different LOC recommendations. 
 
2.3.4 The European ASI (Europ-ASI)  
 
The ASI was developed to evaluate the severity of addiction-related problems in terms of 
lifetime perspectives as well as recent use (past 30 days) on the following dimensions: 
medical status, employment and support status, drug and alcohol use, legal status, family and 
social relationships and psychiatric status (McLellan et al., 1980; McLellan et al., 1992). The 
ASI in the Norwegian ASAM Software is a European version; its reliability and validity is 
well documented (Hodgins & El-Guebaly, 1992; Leonard et al., 2000; Lauritzen & Ravndal, 
2004). ASI CSs is calculated using a subset of items from each of the seven domains. For 
example, The Psychiatric CSs screens for a range of problems including depression, anxiety, 
violent behaviour, hallucinations, and suicide-related episodes in the past 30 days. 
Additionally, clients provide information on prescribed medications for any 
psychological/emotional problems. For more detailed information of the composite scores, the 
manual is available online (www.Triweb.tresearch.org/CompositeManual; McGahan, Giffith, 
Parente & McLellan, 1986).  
 
2.4 Norwegian LOC included in the study  
In this study, only Outpatient (ASAM Level I) and Inpatient/Residential Care (Level III) were 
available and included as TAU options. Personnel on both LOC are interdisciplinary trained, 
often with additional formal education in substance use disorders and psychiatric co-occurring 
disorders. The LOC have access to and collaborate with community social workers to secure 
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housing arrangement, and to assist patients in attending more intense treatment if needed by 
referral or closely coordinated services such as acute medical or psychiatric care units. The 
LOC provide help or assistance with vocational training, and there is a focus on family and 
friend relationships to enhance patients’ social support. All clinics apply a biopsychosocial 
approach to the understanding and treatment of substance use disorders. This means that all 
these aspects, biological conditions and complications, social and psychological conditions 
and complications should be taken into consideration when assessing and recommending 
treatment services to fit the needs of the patient. 
In the outpatient setting, patients receive individual therapy at least once a week, but the 
majority also have more than one session, e.g., with counsellor, psychologist, psychiatric or 
medical services. Both group therapy and vocational training are provided at this level if 
needed. Opiate maintenance treatment and other medical services are also provided. Length of 
treatment is based on patients’ progression but often involves a minimum of 10-12 sessions. 
In the inpatient setting, treatment is offered for three months to 1.5 years depending on the 
patient’s needs. Some programmes have more experience with severe alcohol dependence, 
others with drug dependence, but they address all substances as well as other needs. The 
therapies offered vary, but common services include a set weekly treatment plan that patients 
follow over time which includes individual sessions, group sessions, exercise, leisure 
activities, legal assistance, housing assistance and vocational training/school.  
 
2.5 Statistical power and group size  
 
The effects of the PPC assessment are measured as a function of clinical difference in 
outcome between matched and mismatched treatments. A meaningful difference in outcome 
in favour of optimal matching should be at least 25%, as indicated by a 25% decrease in 
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reported drug/alcohol use. Furthermore, we accept a probability of Type I error of 5% with 
80% power, requiring 95 patients in each condition. The 95 patient requirement was not met 
for the matched and mismatched groups at three month follow-up (n=85, n=68, respectively). 
2.6 Statistical analysis 
Violation testing was performed for outliers, normality and linearity before analyses were 
conducted. In the first article, descriptive statistics were carried out to investigate sample 
characteristics on both demographic and clinical variables. Baseline and follow-up outcome 
measures in this study included: a) dropout, b) frequency of drug use last 30 days reported at 
intake, c) the seven ASI CS scores, and d) whether patients were assessed and recommended 
by the ASAM Criteria software to the same, higher or lower LOC at follow-up compared to 
their baseline LOC recommendation by ASAM. A lower or unchanged follow-up LOC would 
be considered a positive outcome. A higher LOC at follow-up is seen as a worsening of 
symptoms and less progression requiring additional services.  
To assess the primary outcome event that should be predicted by ASAM LOC under-
matching (vs. matching), i.e., drop-out from baseline to follow-up, an independent t-test for 
continuous variables and Chi-square for categorical ones was used to analyse drop-out and 
potential baseline differences between patients who dropped out from the study versus (vs) 
patients who remained in treatment. In the event of meaningful baseline differences between 
the baseline and follow-up samples, an intent-to-treat analysis might be in order; therefore 
paired sample t-tests were used to detect significant changes for the three groups separately on 
the frequency of use and ASI CSs, from baseline to follow-up. GLM univariate analysis of 
variance was used to analyse differences for matched vs. undermatched, and matched vs. 
overmatched groups, applying the patients’ baseline measures as covariates. The baseline 
covariates included the ASI CSs and frequency of use. Estimates of effect sizes (Cohen’s d 
and Cramer’s V) were also included in paper I. These were calculated to examine the strength 
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of group differences. A d value around .10-.20 is usually interpreted as a small difference, 
.40-.50 as a medium difference and a value around .70 or above reflects a strong difference 
(Cohen, 1992).  
In Article II, the analysis of level of agreement/disagreement between LOC assignment from 
TAU and ASAM algorithm based recommendation, utilised a Crosstab with Pearson Chi-
square analysis. Determination of convergent validity used the baseline ASI CSs differences 
between the three LOC, followed by a planned contrast test to determine the significance of 
clinical differences between pairs of LOC. Determination of the predictive validity of 
matching vs. mismatching employed a paired sample t-test on the ASI CSs mean changes 
from baseline to follow-up. This second report separates the analyses by LOC and explores 
discrepant cases in terms of both match/mismatch condition and LOC assignment.  
And finally in article III to show the prevalence of the different treatment recommendations 
by the ASAM software, we used percentage distributions. Univariate ANOVA and Chi-square 
tests were used to analyse baseline group differences for the different recommendations on 
demographical and clinical characteristics. We analysed group differences across the three 
recommendations on the following outcome variables: demographic and clinical status and 
history (psychiatric diagnosis, treatment history, no-show for assigned treatment and suicide 
attempts) at baseline. When a significant difference was found, we applied a Scheffe post-hoc 
analysis to determine which of the groups differed. Retention at follow-up was also analysed 
to see if they differed on this variable. Paired sample t-test was used to study changes in the 
ASI CSs from baseline to follow-up. A planned contrast test was conducted using GLM 
univariate analysis between the low to high intensity ASAM recommendations to determine if 
patients with more intense recommendations were significantly more severe.  Analyses from 
all the articles were performed with the statistical analysis package PAWS, version 18. 
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3. Results 
3.1. Pilot study 
The primary purpose of this pilot study was to conduct a quality check of the Norwegian 
translation of the ASAM Criteria second revised software version by measuring: duration of 
administration, satisfaction and inter-rater reliability among the assessors and patients who 
had completed the training course and training videos.  
 
Pilot study figure 1: Administration Time for the ASAM PPC-2R 
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3.1.1. Duration of Administration 
 
The durations of administration registered for each section during the interview are shown in 
Pilot study figure 1. Drug and alcohol section together with the psychological one is the most 
time consuming parts of the interview with a mean of 59 and 39 minutes. No patients refused 
to undergo the interview or terminated prematurely. Patients had no problems completing the 
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interview in one session, and only two patients needed two sessions to complete the interview 
due to other appointments. 
 
3.1.2. Satisfaction among Assessors on the 34-item Satisfaction Questionnaire 
(N=8) 
 
Pilot table 1 shows descriptive statistics of means for each question item, and difference in 
means before and after completion of training with the videos. The first 5 pairs in Table 1 
show the assessors’ satisfaction with ASAM software edition and the last 8 pairs shows their 
satisfaction with the instruments’ different sections. The satisfaction items mean change from 
the first to the second session ranged between -0.101 to 0.445, showing a higher satisfaction 
on the second session for items 3, 5, 6, 7, 8, 15; no changes on items 1,9,10,12, 13, and 
decrease in satisfaction on items 11 and 14.  
Also two other questions were assessed in addition to these pairs (Item 2 and 4). Question 2 
asked if they would use the software assessment on all of their patients and they reported the 
same at both test points. Two people answered yes, 2 reported no, and 4 were unsure if they 
could use it on all patients. This indicates that they did not see this as an assessment option for 
all referred patients, which makes sense in a clinically diverse patient group.  
Question 4 asked if the experience of personal contact during the interview session changed 
after the training period. After their first interviews, there was only one assessor who reported 
that the assessment interview gave room for personal contact, and after the completion of 
training there were five assessors reporting personal contact. Five assessors answered “both” 
after the first video and only one reported “both” at follow-up, meaning that the experience of 
personal contact shifted towards a more positive experience after more training. There was 
also a change from zero to two “unsure” answers at follow-up.  
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When asked if the use of ASAM Criteria gave the assessors enhanced knowledge (Question 
1), no one reported being dissatisfied, and six of eight assessors reported being satisfied to 
very satisfied, indicating that they felt enhancement in knowledge when using ASAM Criteria 
to assess patients.  
For the question on how satisfied they were with the interview they just executed (Question 
3), six assessors reported being satisfied, and two assessors answered the category “neutral” 
that is in the middle of the 5-point Likert scale (satisfied with some parts, unsatisfied with 
others),  revealing good satisfaction when conducting an interview with this instrument.  
When asked to rate their satisfaction with the ASAM Criteria versus how they assess as usual 
(Question 5), five assessors reported being satisfied with the ASAM Criteria compared to 
how they would usually assess patients. This indicates greater satisfaction with the use of 
ASAM Criteria than assessment as usual. The use of a computer was reported to be 
satisfactory for five of the assessors (Question 6), and the rest answered that they were 
“neutral”. Overall satisfaction with the ASAM Criteria show that seven assessors report being 
satisfied (Question 7), and one reported being neutral.   
The ASAM Criteria is structured into eight sections with multiple questions in each. 
Assessors were asked about their satisfaction regarding each specific section: general 
information, work/vocational activity, family/social network, drug history, medical health, 
legal issues, psychical health, and an overall “completion” section rating the patients’ needs, 
and availability of and access to those services. Results for each of these sections all had a 
mean above 3.5 indicating a high degree of satisfaction among the assessors on all sections.  
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Table 1: Mean scores in the pilot study on Satisfaction among assessors with the ASAM 
PPC-2R before and after training 
 
Questions/items First 
session 
 
Second session 
 
 
Mean change after 
completion of 
training 
*Item 1: Did the assessment with 
the use of ASAM Criteria enhance 
your knowledge about the patient? 
3.78 3.78 0.0 
**Item 3: How would you rate 
your overall satisfaction with 
ASAM Criteria? 
3.22 3.67 0.45 
Item 5: How satisfied/unsatisfied 
are you with ASAM compared to 
assessment as usual? 
3.33 3.56 0.22 
Item 6: How satisfied/unsatisfied 
are you with using a computer 
during the interview? 
3.44 3.56 0.12 
Item 7: How satisfied/unsatisfied 
are you with the entire interview 
session as a whole? 
3.56 3.78 0.22 
Item 8: How satisfied/unsatisfied 
are you with the Completion 
section in ASAM? 
3.33 3.56 0.23 
Item 9: How satisfied/unsatisfied 
are you with the Work section? 
4.0 4.0 0 
Item 10: How satisfied/unsatisfied 
are you with the Psychological 
section 
3.67 3.67 0 
Item 11: How satisfied/unsatisfied 
are you with the Family section? 
4.0 3.89 -0.11 
Item 12: How satisfied/unsatisfied 
are you with the Drug section? 
3.89 3.89 0 
Item 13: How satisfied/unsatisfied 
are you with the Legal section? 
4.11 4.11 0 
Item 14: How satisfied/unsatisfied 
are you with the Medical section? 
3.78 3.67 -0.11 
Item 15: How satisfied/unsatisfied 
are you with the General section? 
3.89 4.0 0.11 
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3.1.3 Satisfaction among patients 
 
All patients were asked after the interview session how they experienced the interview and 
they all were positive towards the interview. Only one out of 10 patients reported too many 
questions. Those nine other patients who did not find it too excessive found the structure to be 
very good when it came to retrieving information about their needs and expressing them. The 
broadness gave them a sense of security that the assessors had gone through all the important 
dimensions with respect to their needs, and security that they had given the information 
necessary for the assessors to place them in the right LOC. All patients reported being secure 
that they had been given the necessary questions to place them in optimal treatment and none 
had additional questions that they believed were important for assessing their needs.  
Pilot table 2 shows the ICC for ASI composite scores on all 5 test videos. Using the 
composite scores of the ASI as means for establishing inter-rater reliability, it was possible to 
demonstrate perfect or near perfect agreement across all assessors.  
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Table 2: Inter-rater reliability measures on ASI and ASAM Criteria dimensions across 6 
assessors on 5 patient videos in the pilot study. 
 
 
ASI Composite Subscale scores  CI (95 %) ICC (*SIGN.) 
    
 Medical Lower bound .951 .992*** 
  Upper bound 1.00  
 Employment Lower bound .831 .954*** 
  Upper bound .997  
 Alcohol Lower bound .955 .992*** 
  Upper bound 1.0  
 Drug Lower bound .797 .944*** 
  Upper bound .996  
 Legal Lower bound 1.0 1.0*** 
  Upper bound 1.0  
 Family Lower bound .883 .987*** 
  Upper bound 1.0  
 Psychiatric Lower bound .935 .988*** 
  Upper bound 1.0  
*p<.05   **p<.01  ***p<.001   CI=Confidence Interval. 
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3.2. Paper I: Matching Patients with a Substance Use Disorder to Optimal 
Level of care with the ASAM Criteria Software 
 
The aim of this article was to investigate the ability of the second revised ASAM Criteria 
Software to predict outcomes among patients with a substance use disorder after three months 
in treatment. A total of 261 (171 males) patients completed the baseline interview.  Of the 
total sample, 57% (n=150) were matched according to the ASAM Criteria recommendation, 
almost 20% (n=51) were undermatched and 23% (n=60) were overmatched. Over 40% of the 
total study sample did not show for the follow-up interview, and dropout was indeed greater 
in the undermatched patients. A total of 55% (n=28) of the undermatched group left treatment 
before three month follow-up interview versus 38% (n=57) in the matched group and 30% 
(n=18) in the overmatched group. At post-test, patients who had received matched treatment 
reported less use of alcohol and cannabis vs. undermatched patients. On the ASI CSs, the 
matched group had a significant reduction in six out of seven severity composite scores (all 
but ASI Employment) versus two (ASI Drug and ASI Family) out of  seven in the 
undermatched, and three (ASI Alcohol, ASI Drug and ASI Legal) out of seven within the 
overmatched group. Percent of patients per group ready to step-down to lower LOC was: 46% 
under-matched, 61% matched, and 17% over-matched, favoring the matched condition. 
Controlling for baseline measures on frequency of use and the 7 ASI CSs in a GLM univariate 
analysis, the matched group had significantly lower follow-up severity than the overmatched 
group on ASI CSs Family scores.  
Overmatched patients did not have better outcomes than matched patients; in some cases no 
change occurred or a more intensive LOC was recommended at post-test. Consistent with 
prior studies, the ASAM Criteria Software Norwegian version demonstrates elements of 
predictive validity in determining intensity of LOC placement using all three prospectively 
planned measures.  
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3.3. Paper II:  Predictive and Convergent Validity of the ASAM Criteria 
Software in Norway 
This second report further extends the work in article I by exploring two hypotheses: first, that 
the new ASAM Criteria LOC recommendations should show convergent validity with the 
most commonly used addiction severity measure, the ASI, and second, that the ASAM 
recommendations should show predictive validity, in terms of discrepancies between patients 
assigned according to ASAM vs. TAU. The greatest discrepancy between TAU and ASAM 
was with LII Intensive Outpatient Care. This was caused by the unavailability of LII at the 
time in this region. In contrast, with the availability in Norway for LIII, this Inpatient category 
yielded agreement in 78% of the cases. The ASAM Software recommended a more intensive 
LOC than TAU in 20% of cases. Of the 261 patients, there were 41 who did not receive a 
LOC recommendation (i.e., data showed sub-clinical severity or were insufficient). These 
patients were excluded and the final sample size for the analyses was n= 220. Results revealed 
significant differences for the LOC placement by TAU vs. ASAM recommendations.  The 
group that was ASAM-recommended to receive the most intensive LOC, LIII 
Inpatient/Residential, had a consistent pattern of higher observed mean baseline scores than 
the outpatient group (LI+LII) on all seven ASI CSs. Comparing the groups, significantly 
higher severity means were found in the most intensive LOC on ASI Psychological CSs and 
ASI Drug CSs. The ability of the ASAM Criteria to clinically distinguish between the 
different LOC lends support for the software’s convergent validity. 
The differential outcomes for the matched versus mismatched groups demonstrates predictive 
validity for the ASAM Criteria Software. The undermatched group had worse outcomes than 
the matched group for all undermatched conditions, which favors’ the ASAM Criteria 
recommendation. The overmatched group did not appear to benefit from more intensive 
placement by TAU, thus also favouring the ASAM Criteria recommendation. 
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3.4. Paper III:  Convergent validity of the ASAM Criteria in Co-occurring 
Disorders. 
 
The aim for the third article was to look at the prevalence of Dual Diagnosis programme 
recommendations, and investigate what characterises those patients with Addiction Only 
Services, Dual Diagnosis Capable or Dual Diagnosis Enhanced recommendation from the 
ASAM Criteria software. Finally treatment outcome three months after treatment initiation 
was investigated among those with and without Dual Diagnosis recommendation on the 
following variables: show for treatment assigned, treatment retention, and change in severity 
in the ASI CSs.  The sample contained 96 (37%) patients who received Addiction Only 
Services programme recommendation along with 42 (16%) patients recommended for Dual 
Diagnosis Capable programme and 123 (47%) patients recommended for Dual Diagnosis 
Enhanced programme. Studying group differences showed significantly lower age and fewer 
years of work experience in the Dual Diagnosis Enhanced group compared to Dual Diagnosis 
Capable and Addiction Only Services groups. We see an overall higher percent with Bipolar 
disorder, Psychosis, Borderline or other personality disorders, PTSD, and eating disorders in 
both the Dual Diagnosis groups compared to Addiction Only Services group, but only PTSD 
and Psychosis is significantly different. A higher percentage of suicide attempts were found in 
the Dual Diagnosis Capable (45%) and Dual Diagnosis Enhanced (44%) groups compared to 
Addiction Only Services group (31%), but these differences were not significant. Both the 
Addiction Only Services (five out of seven ASI CSs) and Dual Diagnosis Enhanced (six out 
of seven ASI CSs) group had reduced severity at follow-up, but when controlling for baseline 
measures no group differences were found. The higher the recommendation, the more 
psychiatric severity we see among the patients recommended for them. This implies that the 
ASAM Criteria has the ability to discriminate on psychiatric severity and thus support 
convergent validity for the criteria on co-occurring disorders.  
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4. Discussion 
4.1. Pilot study 
 
This pilot study left us with an instrument and a network of skilled assessors which could be 
used to test the validity of the PPC on the Norwegian population. It yielded a quality-checked 
training programme, and tested satisfaction and inter-rater reliability which may be useful in 
the future to secure skilled assessors across the country of Norway.  
4.1.1. Inter-rater reliability 
 
Inter-rater reliability among the assessors showed near perfect agreement on the ASI CSs on 
this revised edition with Norwegian language. This is very similar to the findings found by 
Baker and Gastfriend (2003) for the PPC-1 Assessment Software, indicating that the 
computer-assisted structured interview is an effective system for delivering and recording ASI 
scores. Also, this finding indicates that even with counsellors whose focus is clinical care; a 
quality research assessment can be obtained with the help of the instrument.  
The process of establishing inter-rater reliability for LOC assignment was not possible in this 
pilot study, but has previously been conducted with success in Baker and Gastfriend’s study. 
In the future, our team will test inter-rater reliability on the LOC assignment with the new and 
quality checked version of the ASAM Criteria second revised software version (Norwegian). 
Given the results from previous studies (Baker & Gastfriend, 2003; Magura et al., 2003) these 
results further support the use of this structured software interview in a clinical setting by 
skilled assessors for optimal placement of patients with a substance use disorder.  
Administration time for the comprehensive psychosocial assessments averaged 2.5 hours in 
line with previous studies with trained interviewers (Magura et al., 2003). This finding does 
not take into account the longer-term learning curve which can be expected to yield further 
time efficiencies in the future, as was found with the PPC-1 (Turner et al., 1999). In that 
Discussion 
 
61 
 
software interview, initial duration of administration fell by 15% on average after 20 patient 
administrations. Patients in our pilot and validation study had few or no problems finishing 
the interview in one session, and only a few needed two sessions to complete the interview 
due to other appointments.  There are questions in the ASAM Criteria software version that 
can be removed in the future to reduce the number of questions asked, some questions which 
are asked more than once. Separating between panic attack and anxiety attack in the USA is 
important since there are different medications used to treat it, but in Norway we do not and 
we might be better off with one question instead of the current 16. Another way would be to 
provide the assessors with definitions of the two states and check the appropriate box.  
Possible changes like the one suggested will have an impact on administration time, but it will 
also depend on the severity of the patient. The more issues and needs a patient has, the more 
questions need to be answered and thus the interview takes longer to execute.   
Both patients and assessors have reported satisfaction with the length and depth of this 
structured interview. Assessors reported greater knowledge about their patients’ needs, and 
patients reported being more reflective about their own needs. Showing acceptable 
administration times, high satisfaction among clinicians and high inter-rater reliability for ASI 
CSs assessment, the Norwegian ASAM Criteria Software second revised version and the 
Norwegian Software Training Programme appear to provide more than adequate feasibility 
and reliability to justify its broader implementation in a regional, multi-site, real-world 
treatment system and possibilities for harmonising practice among assessment centres. This 
pilot study produced an instrument and a network of skilled assessors which were further used 
to test the validity of the revised ASAM Criteria software edition for patients in the mid-
region of Norway. 
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These are findings from a very small pilot-study, so the results should be discussed with 
caution. A larger satisfaction and inter-rater reliability testing on multiple variables, including 
LOC, with several assessors and patients would be interesting to conduct if a widespread 
distribution of the assessment tool is planned for the future.  
 
4.2. Validation study 
The core aim of the present dissertation was to examine the ASAM Criteria second revised 
version predictive and convergent validity in terms of matching patients with a substance use 
disorder to optimal LOC and provide the assessment centers a possible tool for harmonising 
the region’s practice. The specific aims were investigated and discussed in three different 
empirical papers. The first paper focused on the predictive validity of the ASAM Criteria on 
matching patients to optimal LOC and investigated differences in outcomes among those 
matched to the right LOC to the ones mismatched to a lower or higher level than needed. The 
outcome variables included retention, frequency of use, severity on the ASI CSs, and 
recommended LOC at follow-up. The findings demonstrate elements of validity for the 
Norwegian translated software version of the ASAM Criteria and are in line with previous 
studies (Sharon et al., 2003; Magura et al., 2003). The discrepancies between the ASAM 
Criteria recommendations and TAU placement were investigated further in the second paper 
with a greater focus on the outcomes among match and mismatched patients on different LOC 
along with the Criteria’s convergent validity in terms of discriminating between those with 
low/high severity and less/more intense LOC needs. In the third and last paper, the ASAM 
Criteria was investigated for convergent validity in terms of discrimination among those in 
need for Dual Diagnosis Programmes and characteristic differences in severity between the 
different recommendations. Together these three papers present the specific aims for this 
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project to answer the main aim: to validate the second revised Norwegian translated ASAM 
Criteria software edition.  
The predictive validity in article one and two was tested by comparing outcomes from the 
matched patient group with the mismatched groups and results favoured the matched group in 
all four categories measured at follow-up: retention, reductions in substance use, ASI CSs, 
and LOC recommendations.  
A significantly higher portion of the under-matched patients dropped out of the assigned 
treatment, and the matched group had a significant reduction in days of stimulant use 
compared to the overmatched group, supporting the hypothesis that mismatching is not 
beneficial for the patients. Matched patients had better three months outcome than both the 
mismatched groups and the software discriminate, thus showing support for convergent 
validity between those with low vs. high severity in the recommendations. This indicates that 
the Norwegian translated revised ASAM Criteria software version is a valid tool to assess and 
recommend optimal LOC for patients with a substance use disorder. The findings from the 
articles also suggest better recommendation by the ASAM Criteria software than TAU, 
justified with better results among the matched versus mismatched patients. A better 
recommendation and placement can contribute to an improved utilisation of the region’s 
treatment offers and also fulfil patients’ needs in a more satisfactory way for better treatment 
outcomes by better placements.  
Results from the third paper revealed a high proportion Dual Diagnosis programme 
recommendations from the ASAM Criteria software in this region. The group differences that 
were found support the convergent validity of the ASAM taxonomy for co-occurring 
disorders and the software’s ability to identify patients in need for integrated programme 
services. The successful outcomes in the Dual Diagnosis Enhanced group, nevertheless, 
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suggest that these patients can have as good outcomes as those with less intense needs, as long 
as their needs receive appropriate care at the right intensity.  
4.3. Assessed to optimal LOC 
4.3.1. Frequency of use from Baseline to Follow-up 
 
Alcohol consumption was significantly reduced for the matched and overmatched group, in 
line with a previous validation study of the ASAM Criteria (Magura et al., 2003). The 
overmatched group was no better than the matched group at follow-up, and actually had less 
improvement on the ASI CSs than the matched group. Thus, it appears unwise to overuse 
available resources when one only gets the same, less improvement, or a worsening of 
severity scores, than a matched LOC achieves.  
Sedative/hypnotic use was the only category that increased among the matched group and 
significantly decreased among the undermatched group. This might possibly be due to 
primary care patients becoming newly managed by addiction treatment centers, which in 
Norway tend to provide medically managed care with sedatives to optimize patients’ 
programme retention, e.g., through enhancing sleep, or reducing severe anxiety/anxiety 
attacks. To explore this hypothesis, prescription adherence was surveyed: in the matched 
patient group almost 70% took prescriptions as intended vs. 25% of the under-matched group. 
The common use of sedative in treatment clinics our study follows international clinical 
guideline recommendations (not exceeding two weeks) and appropriate doses are used. Were 
the use of it is problematic and patients do not compliant to the description the treatment plan 
is revised accordingly. Primary doctors are advised to stop prescribing sedatives when their 
patients enter treatment for a substance use disorder, and this can be the reason we see a drop 
in the use among under-matched patients. This discrepancy might also be caused by the fact 
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that under-matched patients may have lacked optimal services and therefore show a lack of 
compliance.  
Cannabis reduction was also significant for matched patients, and reduction in use of two or 
more substances per day also shows a trend favouring the matched group. This was not the 
case for the mismatched patients. It should be noted that analysis of these specific substance 
use changes offers substantially less statistical power because not all patients used each of the 
analysed substances.  
 
4.3.2. Changes in ASI CS severity scores 
 
Greater statistical power should be anticipated from the ASI subscale analysis, because all 
patients provided data and the variables are continuous at fairly high resolution, although it 
would be preferable to have mismatched samples that are equal in size to the matched sample. 
The statistical power set to detect differences was 95 in each group and we did not reach that 
level of inclusion in all three groups. The ASI paired sample t-tests favoured matching vs. 
both under-matching and overmatching, with significant improvements among the matched 
group on six out of the seven ASI CSs. Under-matched patients showed improvement in two 
and the overmatched group improved on three subscales, but it is worth noting that the under-
matched group significantly reduced ASI Drug severity scores and ASI Family score. This 
indicates that treatment has had an effect, although it was less intense than recommended, but 
not to the same extent for the under-matched patients as seen for the matched condition.   
The ASI Employment dimension, however, was unchanged for all groups. This might be 
explained by the fact that the first three months of treatment focus on addressing medical, 
psychiatric and behavioural improvement before employment issues; follow-up interviewers 
noted that patients seemed concerned with employment only as they became healthier 
throughout the treatment process. The results are similar to the study by Turner et al., 2003, 
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which also found this variable to fail in differencing between the groups. No studies have 
followed the patients with a second interview with the use of the computerized edition like 
ours. Therefore it is difficult for direct comparisons.  
 
4.3.3. Changes in LOC recommendations 
 
Patients’ LOC recommendations at follow-up were changed in a positive direction for 61% of 
the matched group and 46% in the under-matched group. It however changed in a negative 
direction for the overmatched group, in which only 17% were recommended for a lower 
intensity LOC at follow-up than at baseline. None in the matched group were recommended 
for a more intense LOC at follow-up, but in the overmatched group, over 35% of patients (out 
of 46) were recommended for a higher LOC than baseline recommendations. These results are 
interesting compared to previous research, which also found worse outcomes among 
overmatched patients in the form of more “no shows” for the next step in treatment (Angarita 
et al., 2007). If overmatching yields no better treatment outcome than matched patients, and 
also can result in worsening of outcomes, there is considerable clinical risk in patient 
assessment – not just in giving less treatment than patients need, but also in giving too much.  
 
4.4. Predictive and convergent validity of ASAM Criteria second revised 
version 
The second paper of this dissertation examined convergent validity for the ASAM Criteria 
Software and further detailed its predictive validity in terms of three-month follow-up 
outcomes for patients whose placements were matched according to the ASAM Criteria vs. 
those whose TAU placements consisted of lower or higher intensity than ASAM 
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recommended. The sample consisted of 150 patients matched to the recommended LOC based 
on the ASAM Software algorithm, 51 under-matched and 60 overmatched patients.  
The greatest discrepancy between TAU and ASAM was with LII Intensive Outpatient Care 
(LII). This was caused by the unavailability of LII at the time in this region. In contrast, with 
the availability in this region of Norway for LIII Inpatient/residential treatment (LIII), this 
category yielded agreement in 78% of the cases. The ASAM Software recommended a more 
intensive LOC than TAU in 20% of the cases. These results are also similar to previous 
research (Staines et al., 2003) and the overall study provided a sufficient sample size of 
mismatched cases to yield meaningful results.  
 
4.4.1. Convergent validity 
 
Mean severity scores in patients who were ASAM-recommended to the more intensive LIII 
were higher on all ASI CS scores, and significantly so on ASI Drug and Psychological scores, 
vs. patients recommended to less intense LOC. This is in line with a previous study on the 
ASAM Criteria’s convergent validity (Sharon et al., 2003). Patients with more severe 
substance abuse, less social support, or co-occurring psychological disorders benefit more 
from inpatient vs. outpatient treatment (Bartak et al., 2011; Magura et al., 2003) justifying a 
LIII recommendation. Opposite findings were found however, in cocaine users matched to LII 
day-treatment vs. those overmatched to LIII treatment , although that study used only a partial 
implementation of the ASAM Criteria, First Edition (McKay & McLellan, 1992), which may 
have limited the effectiveness of its algorithm. With the present study’s use of the newer 
ASAM Criteria, second revised edition and the comprehensive computerised implementation, 
the more severe means on seven out of seven dimensions, and significant change on ASI Drug 
and ASI Psychological CS scores demonstrate consistency in the ASAM Criteria Software’s 
ability to make clinical distinctions. Furthermore, it makes clinical sense that the ASI 
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Psychological and ASI Drug CS scores might both reach significant baseline differences 
between the LOC, based on their association in prior literature (Lehman, Myers, Thompson, 
& Corty, 1993). Specifically, the impact of psychological problem loading on related 
dimensions, including family and social supports (Kashner, Rader, Rodell, Beck, Rodell & 
Muller, 1991), and their relationships with legal problems (American Psychiatric Association, 
2000) are also evidenced by the higher severity ASI Legal CS mean score.  
 
4.4.2. Outcomes at Follow-Up for the different match/mismatch LOC conditions 
 
The under-matched group has worse outcomes than the matched group, which favors the 
ASAM Criteria recommendation. Under-matching may be based on patients’ own preferences 
for outpatient treatment, due to work or family responsibilities, or practical issues such as 
geography or convenience. Such reasons, however, warrant more educational and 
motivational effort on the part of assessment clinicians, since the data indicate that patients 
would enjoy better outcomes if they can accept the ASAM recommended placements. 
Alternatively, under-matching may occur due to lack of access to certain LOC, as was the 
case with many LII recommendations – and in this case, the ASAM Software serves as a 
needs assessment tool for LOC, precisely revealing the quantitative shortage of treatment slots 
in a geographic region. Given the adverse outcomes of such mismatching, public entities 
would be wise to respond by improving access to care, as is now the case with provision of 
LII in this region of Norway. The overmatched group did not appear to benefit from more 
intensive placement by TAU, thus also favouring the ASAM Criteria recommendation. 
Although overmatched patients in LIII (a controlled environment) might be expected to 
benefit from elimination of access to substances and presumably fewer craving triggers, this is 
less effective and more costly – both in terms of unnecessary restrictiveness for the patient, 
and inefficient service provision for the treatment system. Overall, these results shed light on 
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the crucial need for thorough assessments before matching patients’ needs to appropriate 
services.  
4.5. Characteristics and prevalence of Dual Diagnosis programme 
recommendations 
To investigate the need for integrated services among treatment seeking patients with a 
substance use disorder and ASAM taxonomy for Dual Diagnosis programmes, we analysed 
prevalence and characteristic differences between patients who received Dual Diagnosis 
programme recommendations and those who do not in a third paper. We found that a total of 
37% of the patients received Addiction Only Services recommendation, 16% Dual Diagnosis 
Capable, and 47% were recommended for Dual Diagnosis Enhanced programmes. This 
showed a high prevalence, and compared with prior research showing 32% to 65% patients 
with co-occurring disorders (Bakken et al., 2005); the number of Dual Diagnosis programmes 
recommendation by ASAM seems to be justified. 
  
4.5.1. Characteristic differences between the three groups 
 
Baseline characteristics reveal a significantly lower age and work experience among Dual 
Diagnosis Enhanced recommended patients compared to Addiction Only Services and Dual 
Diagnosis Capable group. More patients in both Dual Diagnosis groups report having a 
confirmed psychiatric diagnosis, but the differences between the groups are not significant. 
The history of significantly more psychiatric treatments in the Dual Diagnosis Capable and 
Dual Diagnosis Enhanced group compared to Addiction Only Services group indicates a 
higher psychological severity, maybe even chronicity within these groups, which in turn can 
be viewed in favour of ASAM Criteria. We expected a greater severity in those groups if the 
taxonomy of ASAM Criteria is correctly designed and can discriminate between patients. This 
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notion further strengthens with clinicians reporting higher percentage of patients with 
moderate to severe psychiatric disorders in the Dual Diagnosis groups, significantly higher 
reports for PTSD and psychosis.  
 
4.5.2. Show rate and retention 
 
No differences were found on showing up for assigned treatment, like previous research has 
found when studying patients with a substance use disorder and a co-occurring psychiatric 
disorder (Angarita et al., 2007). To secure transitions from one LOC to another, there has 
been a greater coordination between the clinics in this region, and patients are given 
information about the treatment before they enter to reduce anxiety and stress during 
transitions. This might explain the greater show rate for treatment we see for all three groups 
in our region compared to a previous study. For retention, a higher percentage in the Dual 
Diagnosis Enhanced recommended group dropped-out of treatment within the first three 
months (45% drop out compared to 33% and 34% in the other groups), but the difference 
between the groups was not significant. 
 
4.5.3. Suicide attempt and outcome differences at three month Follow-Up 
 
Higher proportion of suicide attempts have been seen among patients with co-occurring 
disorders in prior research (Bakken & Vaglum, 2007; Darke et al., 2004), and also in our 
study we see the highest reported attempts in the Dual Diagnosis Capable and Dual Diagnosis 
Enhanced group. However no significant differences were found and there are even fewer 
differences between the groups on thoughts about suicide and tangible plans. One possibility 
is that ASAM Criteria considers responses on additional questions regarding imminent danger 
for the patients, by themselves or others, to recommend a suitable LOC for the patients.  
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There are significantly more reductions three months after treatment initiation in severity 
among the Addiction Only Services and Dual Diagnosis Enhanced group on the ASI CSs than 
for the Dual Diagnosis Capable group.  The results might be explained by the fact that the 
Dual Diagnosis Capable group included older patients and more females than the other two 
groups. This group also has a higher percentage reporting alcohol as main drug of choice, 
which could affect the treatment outcome. Older patients might be more engaged in their 
treatment planning and decisions, but might also have more chronic disorders, more cognitive 
deficits from alcohol abuse and thus are more resistant to treatment. Or they are in such a 
stable state that their severity gets underestimated both by themselves and the assessment 
personnel placing them. Issues regarding self-report measures on psychiatric symptoms from 
patients have been brought up, and Cole and Sacks (2008) found that patients are more likely 
to underestimate their psychiatric suffering thus creating a lower prevalence than in reality. 
This can lead to less attention and treatment for co-occurring psychiatric disorders among this 
group and might explain the lack of significant reduction on all dimensions except for 
Alcohol and Drug ASI CSs.  
Both in the Dual Diagnosis Capable and Dual Diagnosis Enhanced, higher portions of patients 
were sent by TAU to inpatient treatment services, and although not significantly different, 
there are less inpatient placements among the Addiction Only Services group. This can be 
attributed to the more intense services needed by patients with co-occurring disorders, and 
thus support ASAM Criteria ability to place individuals with more severe needs to more 
intense services. There are similar results among the Addiction Only Services and Dual 
Diagnosis Enhanced group on the ASI CS severity scores: both significantly reduced severity 
scores on a majority of the dimensions and had an increase on the ASI Employment score. 
The improvements in both groups suggest that the services provided in this region have the 
capability to deal with more acute and severe co-occurring disorders, and given the right 
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intensity of services both groups have successful treatment outcomes. This is in line with prior 
research that shows better outcomes with the right intensity and integration of services to treat 
both disorders (Brunette et al., 2004; Magura et al., 2003; Sharon et al., 2003). The higher 
mean severity at baseline seen in the Dual Diagnosis Capable and Dual Diagnosis Enhanced 
compared to Addiction Only Services group shows support for ASAM ability to discriminate 
between LOC. On ASI composite score Legal, Family and Psychological; Dual Diagnosis 
Enhanced is significantly more severe than both Dual Diagnosis Capable and Addiction Only 
Services. This is in line with previous research in the field with similar results (Sharon et al., 
2003).  
4.6. Study Limitations and Strengths 
 
First, dropout, which is common in studies including patients with a substance use disorder 
and may be greater in real world clinical samples, is an outcome that validates the ASAM 
matching hypothesis in this study, but also appears to have impacted our statistical power. 
Given the trends we see for stimulants and sedatives in the first paper, larger samples at 
reassessment might have yielded greater statistical power, particularly with the GLM analysis. 
Prior studies reporting rates with only 60% of the “easiest to locate” subsample of an enrolled 
population have been found to provide valuable information and only to be minimally 
different when compared to complete samples, and study attrition may also be unpredictable 
from patient characteristics (Hanstein, Downey, Rosengren, & Donovan, 2000). It is 
important to know that our study offered no incentives in the form of money or other benefits 
to induce patients to complete their follow-up interviews, although compensation might have 
increased the follow-up rate. However, this can be viewed as strength of our study as patients 
participated without compensation. Although future research should strive for higher follow-
up rate by recruiting significant others and employ other outreach efforts, as Lauritzen, 
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Ravndal, and Larsson (2012) did. Their study had high rates (over 90% at first interview) at 
all time-points with a Norwegian drug population. 
Second, the lack of randomization might have biased against the results, as the matched group 
at baseline showed a tendency to be younger and had higher ASI CS Employment, Drug, legal 
and Psych scores than the mismatched conditions. Also the use of paired t-test does not allow 
for covariate adjustment, it only allows us to say that correct LOC placement appears to have 
had an effect in reducing severity on several dimension in the matched group.  There can also 
be other demographic variables causing the effect we see, together with differences in how 
well the clinics used in this study follow the Criteria described by ASAM.  These differences 
might have reduced the extent to which matching could demonstrate a clinical outcome 
advantage over mismatching. The naturalistic design might also have caused the lack of 
significant reduced severity on multiple variables in the Dual Diagnosis Capable group that 
we saw from the third article, caused by a small group size and different gender distribution 
compared to the two other groups studied. However, the use of such a design made it possible 
to investigate the naturalistic prevalence of treatment needs among patients with co-occurring 
substance use disorder and psychological disorders in the treatment seeking population in this 
region. Nevertheless, the outcome findings are substantially in line with previous validation 
studies on the ASAM Criteria, and the naturalistic design can also be viewed as beneficial as 
it reflects the naturally-occurring treatment-seeking population in this region. 
Third, a relevant methodological problem is that differences between the ASAM Software-
obtained treatment recommendation and clinically derived LOC can be a result of the 
numbers of categories available and how experienced the TAU centers was. If the clinicians 
had the full continuum of four LOC available in the community as the ASAM Criteria 
recommend, then discrepancies could have been different from those seen here.  Also how 
experienced the clinics are with assessing the patients will affect their recommendation. A 
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solution to this could have been to categories them from their experience, but since no golden 
standard exited and a harmonization of practice was the goal, this was left untouched. Also 
the lack of control over important clinical issues like; execution of treatment therapy, the 
effect of clinical relations the patient has on treatment attendance and outcomes, and if the 
LOC are fully categorized and functioning like described by the ASAM Criteria might have 
affected the results. In order to be a fully functioning LOC based on the ASAM Criteria 
means that setting, therapies, personnel groups, and documentation need to be following the 
description made by the criteria to fully be capable to handle the patient’s needs. Otherwise it 
does not follow the criteria set for a successful treatment outcome for the patients. 
Fourth, The ASI is the most widely-used severity assessment in addiction (McLellan et al., 
1992), and the reliability and validity of the European ASI and its Composite Subscale score 
method are well documented (Lauritzen & Ravndal, 2004). In the measurement of convergent 
validity, the ASI CSs were used, and some of these questions are used in the ASAM 
computerised algorithm. The ASI questions obtain approximately 50% of the data needed for 
the ASAM Criteria Software algorithm; however, the two instruments have very different 
scoring logics: the ASI’s is actuarial whereas the ASAM Criteria’s is hierarchical. Therefore, 
these two approaches have similar, reliable data acquisition, but different scoring – making 
them relevant and valuable for comparison but non-overlapping. The ASI CSs should 
therefore be different across patients who are recommended by the ASAM Criteria for 
different levels of care. Thus, while worthy of mention, the danger of overlap is minimal.  
Fifth, since we lack categorisation of the LOC included in this study with regards to their 
Dual Diagnosis capability we do not have the ability to conclude if the results are a direct 
result of co-occurring needs being met, but we suspect this might be the case since the Dual 
Diagnosis Enhanced group improved as well as the Addiction Only Services group. The high 
number of patients in need for intense services in this study can be due to the fact that 
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symptoms are higher when entering treatment. But patients have also been found to 
underestimate their psychological problems when entering treatment, influenced by their more 
optimistic view after treatment has been assigned with treatment expectancies (Rokkan & 
Brandtsberg-Dahl, 2003). This can lend support for a true picture of the prevalence of needs 
for integrated services in this region.  
4.7. Future research and clinical implications 
Given the lack of harmonised assessment services and treatment services available in Norway 
and many other countries, this software offers a valuable clinical assessment instrument which 
can enhance knowledge of the patient and coordination of services to suit both patients’ 
clinical and recovery support needs. The ASAM Criteria Software also appears to be worthy 
of implementation in research trials nationally and internationally. Pilot study among 
assessors and patients reveal high satisfaction with the use of this tool in the assessment 
process, and the results from the validation study now conducted in this Norwegian region are 
in line with previous research and favours the use of ASAM Criteria to enhance the 
assessment process, placement decision, enhance the utilisation of the region’s existing LOC 
and optimal treatment outcomes for the patients. In addition the software can be used to 
measure the patients’ progression during treatment to adjust services based on changed needs 
and clinical status. The successful translation and software testing in Norway should 
encourage larger studies – preferably across nations and treatment systems seeking higher 
power with larger subsamples across primary drug of choice and match/mismatched 
conditions. Future studies should investigate this further with larger samples, aim for a full 
categorisation of included LOC with Dual Diagnosis Capability, and test the capacity of the 
programmes that do exist and the patients’ outcomes from these programmes. 
The findings in these papers need to be further investigated including the full continuum of 
ASAM LOC, because this study lacked LII Intensive outpatient treatment and included only a 
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small sample in LI Outpatient category. LOC should also be confirmed as actually delivering 
the services specified by the ASAM Criteria – and a certification procedure has been 
published to aid this task (McGovern et al., 2007). Finally, future studies should enroll larger 
samples, use follow-up procedures with multiple contact persons, and compensate research 
attendance to reduce data loss and aid retention.     
 
4.8. Conclusions 
This study had three main aims:  
1. To apply the  revised software version of the ASAM Criteria for harmonising the 
assessment centers` procedures through testing satisfaction and feasibility among 
assessors and patients along with inter-rater reliability measures of the revised version. 
2. To investigate predictive and convergent validity with the second revised Norwegian 
software version for treatment outcomes and baseline severity among the different 
recommendations. 
3. To investigate service and therapist`s demand in terms of LOC needed in the region 
and the need for integrated services for patients with co-occurring substance use 
disorder and psychiatric disorders for future health care planning. 
 
Conclusions: 
1. The studies indicated high satisfaction among assessors and patients and inter-rater 
reliability was high supporting a valid collection of patient data to execute the 
validation study. 
2. Despite the limitations with high drop-out rate, unequal group sizes and lack of 
treatment levels of care; the ASAM Criteria’s show predictive validity by revealing 
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results favouring the matched group and characteristic differences. The progressively 
more severe composite scores both in terms of LOC intensity and programs 
recommendations for co-occurring disorders support the validity of the ASAM 
Criteria as a useful tool.   
3. There is need of more intensive outpatient treatment services in this region and high 
prevalence of Dual Diagnosis Programme recommendations indicating a need for 
more intense psychiatric services for these patients.  
 
While taking the limitations of the study into consideration, the strength of the study and 
findings offer important insights into the assessment and use of the ASAM Criteria Second 
Edition, Revised software version which incorporates ASAM Criteria taxonomy. Both in the 
assessment process and for treatment planning purposes, this appears to be a promising tool 
worth using in a clinical setting, and for future research purposes.  
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Abstract 
Great variation in patient assessment across Norwegian addiction programs necessitated a 
solution for harmonization. The American Society of Addiction Medicine (ASAM) Criteria 
Software is a computer-assisted structured interview and clinical decision support program. 
Using validated tools including the Addiction Severity Index (ASI), it measures 
biopsychosocial conditions to match patients to an optimal level of care (LOC). METHODS: 
This prospective, multi-site, assessed eligible patients with substance use disorders seeking 
treatment in the mid-region of Norway at intake (n=261) and three months after (n=153) with 
naturalistic LOC placement on: 1) retention, 2) severity on 7 ASI composite subscale scores 
and 3) readiness for step-down care. RESULTS: Retention differed significantly across 
groups and was lowest with under-matching vs. matching/over-matching (45% vs. 62% vs. 
70%, p=.024). Matched patients reported less month-3 use of alcohol (p<.05) and cannabis 
(p<.05) vs. no significant reductions with under-matching, and ASI Composite Scores fell  
with matching on six of seven scales, 2/7 with under-matching and 3/7 with over-matching. 
Percent of patients per group ready to step-down to lower LOC was: 46% under-matched, 
61% matched, 17% over-matched. CONCLUSIONS: Although more research is needed. The 
ASAM Criteria Software Norwegian version demonstrates predictive validity in determining 
placement using all three prospectively planned measures. 
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Introduction 
 
 
The complexity of addiction demands comprehensive assessment; without it, there is a risk of 
treating the wrong problems or failing to provide services that meet patients’ needs 
(Gastfriend & McLellan, 1997; Ravndal, Vaglum, Lauritzen, 2005) . Studies show that mis-
matching patients yields worse follow-through to next stage of treatment, more use of 
substances at follow-up and excessive resources use (Magura et al., 2003; Sharon et al., 2003; 
Angarita, et al., 2007).  
 
The Patient Placement Criteria (PPC) published by the American Society of Addiction 
Medicine (ASAM) is a widely endorsed addiction treatment protocol in the USA since 1991 
(Hoffman et al., 1991). By 2001 the criteria had undergone considerable research and added 
sub-levels of care and a focus on co-occurring disorders in the second revised version, ASAM 
PPC-2R (Mee-Lee et al., 2001). A biopsychosocial approach is applied to understand 
substance use disorder and factors associated with the cause, development and expression of 
the disorder. The Criteria and its biopsychosocial measurement dimensions have been shown 
both to predict treatment success and to be cost effective (Annis, 1988; Alterman et al., 1994; 
Gastfriend & McLellan, 1997, Hayashida et al., 1989). Government reforms initiated in 2004 
gave the Norwegian Health Enterprises responsibility for assuring that patients receive 
specialized addiction treatment (Department of Health, 2004); however, in the absence of any 
harmonized practice for assessment the system needed a standardized validated tool across all 
centres.  
 
The ASAM Criteria Software is a structured and comprehensive assessment designed to 
recommend the optimal level of care (LOC) (Mee-Lee et al., 2001). It is a structured 
interview that implements validated tools (ASI, McLellan, 1992) to guide clinicians in 
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assessing patients’ needs, with clinical decision support software, quantitatively calculating 
all of the ASAM Criteria adult admission decision rules. Studies in the USA have found high 
inter-rater reliability (Baker & Gastfriend, 2003), good face validity (CSAT, 1995), 
convergent validity (Staines et al., 2003; Turner, et al., 2003; Stallvik & Nordahl, 2003), and 
predictive validity (Sharon, et al., 2003; Magura et al., 2003; Angarita, et al., 2007). 
 
Why Placement Criteria? 
The human mind rarely follows formal criteria to form judgment and conduct decision 
making, and we are slow to adopt new treatments despite research and clinical evidence of 
safety and superiority [Hogarth, 1987; Volpicelli et al., 1992]. The ASAM hypothesis holds 
that patients can be assigned to treatments that yield the best outcomes in the least restrictive 
and costly settings, for the shortest durations necessary. Over-matching, i.e. referral to more 
intense LOC, would be overly restrictive and/or costly. Under-matching, i.e. referral to a less 
than recommended LOC would yield poor engagement, poor retention, poor clinical outcome 
and increased healthcare utilization. Valid computer-assisted criteria would establish a 
common assessment language, help clinicians assess patients objectively and 
comprehensively, and establish a science-based model for determining needs for admission, 
continued stay, transfer, and discharge across all SUD treatment settings.  
It is important to evolve further from studies previously conducted with the first edition of the 
ASAM Criteria with the Second Edition, Revised version, and also on a different national 
sample with different languages and treatment systems, to investigate its abilities to both 
match and discriminate between patients’ needs. Most of the studies have tested the earlier 
version of the Criteria, and they include few outcome measures (frequency of use, show-rate, 
and readmissions) and few follow-up studies have been executed. One study has found that 
mismatched patients with co-occurring disorders had greater no-show rate than matched 
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(Angarita et al.2007). We tested this hypothesis and also looked at retention the first 3 months 
of treatment.  In addition we found no published studies on the ASI composite subscale scores 
in terms of predictive validity with the use of ASAM Criteria. Since the ASI it is one of the 
main feeders to the instrument, it would be interesting to study in term of predictive validity. 
Previous studies have used them to test the criteria for convergent validity with results 
supporting the Criteria ability to discriminate among the patients with different LOC 
recommendations (Staines et al., 2003; Turner et al., 2003).In addition a previous study found 
less use of alcohol at post-test (2003Magura et al., 2003) and more readmission among those 
match and mismatched to the criteria and found more readmission among the mismatch 
(Sharon et al., 2003). In our study we investigated the amount of match vs mismatched 
patients who received a lower level of LOC at follow-up instead of readmissions since we did 
a follow-up. A lower LOC would mean a positive progression from treatment and that the 
patients’ needs are met. Based upon the research found and taking it a step further the 
following questions are tested in this study: a) drop-out from assigned treatment before 3 
month follow-up interview; b) clinical improvement, in terms of both frequency of substance 
use in the last 30 days and the 7 Addiction Severity Index Composite Subscale Scores (ASI 
CSs), and c) step-down status, i.e., whether initially matched vs. mis-matched patients would 
subsequently be ready for a lower LOC at follow-up, according to the ASAM Criteria 
recommendation. If the ASAM Criteria shows predictive validity the matched patients should 
be a) show less drop-out from treatment; b) show more clinical improvements in terms of less 
use and lower severity on the ASI CSs at follow-up, and c) show readiness for a lower LOC  
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Method 
Sample 
This double-blind, multi-site, naturalistic study was conducted at 10 different outpatient and 
inpatient assessment and treatment centres from rural and urban areas of central Norway. 
Patients were 18 years of age, spoke Norwegian fluently, and were stable with regard to 
intoxication with alcohol and/or drugs (cognitively cleared from their last substance use, or 
had taken prescribed or tolerable doses such that they could function in an interview setting), 
and/or psychiatric symptoms. Patients agreed to accept Treatment as Usual (TAU) 
recommended placement, and were diagnosed with substance dependence or abuse according 
to the International Classification Diagnostic, version 10 (ICD-10). All patients provided 
informed consent which was approved along with the study protocol by the Regional 
Committees for Medical Health Research Ethics.  
 
We did not have data on all those referred to treatment in the recruitment period. However the 
sample characteristics were in line with previous studies in this region (Nordfjærn, Hole & 
Rundmo, 2010). Of a total of 310 patients asked, there were only 20 who did not want to 
participate. Since so few respondent declined we did not check for any differences in 
characteristics between those who joined versus those who did not. Patients who joined the 
study received a TAU assessment, i.e., routine intake interviews at routine assessment centers 
by personnel who had not been introduced to the ASAM Criteria. Afterwards, patients 
received the ASAM Criteria Software interview at baseline with trained ASAM software 
assessors who did not participate in the centres’ TAU assessment or placement during the 
study period. Patients were contacted by an ASAM assessor (not necessarily the same one as 
at baseline  again after three months for follow-up interviews. During the baseline TAU and 
ASAM interviews, patients were asked about the identical 30-day pre-intake period. Patients 
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and ASAM-assessors were kept blind as to the ASAM algorithm-based LOC recommendation 
at both baseline and follow-up, and the patients were naturalistically referred to the TAU-
recommended LOC. 
 
Matching was defined as congruence between the clinically-derived TAU recommendation 
and the ASAM recommendation (the putative gold standard). The patient was defined as 
mismatched if the TAU assignment was lower than the ASAM recommendation (i.e., under-
matched) or higher (over-matched). Drop-out was defined on patients who dropped out of 
their assigned treatment within the first three months of treatment and before treatment 
completion. 
 
Measures 
The original instrument was translated from the original English into Norwegian based on 
recommendations from previous studies (Hoffmann et al., 1991; Weedman, 1987; Gjersing, 
Caplehorn, & Clausen, 2010), and we did a full scale translation were all items were back-
translated and both clinical expertise and language consultants were included in the process. 
 
The ASAM Criteria, used by a majority of US states (Mee-Lee et al., 2001), has undergone 
several studies supporting its usage and the principle of these criteria multidimensional needs 
assessment in treatment planning (Annis, 1988; Hayashida et al., 1989; Alterman et al., 1994; 
Mechanic, Schlesinger & McAlpine, 1995; Gastfriend & McLellan, 1997; Hser, Polinsky, 
Maglione & Anglin, 1999; McLellan et al,. 1997; Gastfriend, Lu & Sharon, 2000). Inter-rater 
reliability with the first edition software was 0.77 (Intra-class correlation coefficient)(Baker & 
Gastfriend, 2003). The current Second Edition, Revised tool (PPC-2R) includes previously 
validated tools including (in the Norwegian version) the European version of the Addiction 
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Severity Index (Lauritzen & Ravndal, 2004; Hodgins & El-Guebaly, 1992; Leonhard et al., 
2000), the Clinical Institute Withdrawal Assessment for Alcohol (CIWA-AR) (Sullivan et al, 
1989), and the The Clinical Institute Narcotic Assessment (CINA) Scale for Withdrawal 
Symptoms (Peachey & Lei, 1988; Mee-Lee et al., 2001). With approximately 6,000 distinct 
calculations, the software constructs an algorithm-based recommendation, a 3-5 page report 
describing the patient’s needs in the different dimensions, and a final LOC recommendation. 
The diagnostic terminology used in this software version was consistent with the DSM-IV 
(American Psychiatric Associations Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition, 2000; the fall 2013 version incorporates DSM-5). 
 
The ASAM Criteria is a highly intricate (350 page) hierarchical decision tree in which the 
decision rules are organized along six clinical dimensions of assessment:  
1. Intoxication and withdrawal 
2. Biomedical complications and conditions 
3. Emotional/behavioural complications and conditions 
4. Treatment readiness 
5. Potential for continued use or relapse 
6. Environmental conditions. 
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These are matched to 6 general LOC: 
x 0.5 Early Intervention: contains services for individuals who are at risk of developing 
substance-related problems or for those for whom there is not yet sufficient 
information to document a substance use disorder. 
x I. Outpatient Treatment: organized, non-residential services, which may be delivered 
in a wide variety of settings. Addiction or mental health treatment personnel provide 
professional evaluation, treatment and recovery service. Such services are provided in 
regularly scheduled sessions and follow a defined set of policies and procedures or 
medical protocols.  
x II. Intensive Outpatient Treatment, e.g., partial hospitalization: organized outpatient 
service that delivers treatment services during the day, before or after work or school, 
in the evening or on weekends. Such programs provide essential education and 
treatment components while allowing patients to apply their newly acquired skills 
within "real world" environments. Programs have the capacity to arrange for medical 
and psychiatric consultation, psychopharmacological consultation, medication 
management, and 24-hour crisis services.  
x III. Residential/Inpatient Treatment: services staffed by designated addiction treatment 
and mental health personnel who provide a planned regimen of care in a 24-hour 
live-in setting. They are housed in, or affiliated with, permanent facilities where 
patients can reside safely. They are staffed 24 hours a day. Mutual and self-help group 
meetings generally are available on-site. Level III encompasses four types of programs 
and defining characteristic of all Level III programs is that they serve individuals who 
need safe and stable living environments in order to develop their recovery skills 
Article I: Predictive validity 
 
98 
 
x IV. Medically Managed Intensive Inpatient Services, e.g., hospital care: provide a 
planned regimen of 24-hour medically directed evaluation, care and treatment of 
mental and substance-related disorders in an acute care inpatient setting. They are 
staffed by designated addiction-credentialed physicians, including psychiatrists, as 
well as other mental health- and addiction-credentialed clinicians.  
x OMT. Opioid Maintenance Treatment: medical maintenance therapy like methadone 
or buprenorphine for opiate use disorders, which can be delivered within any level of 
care if the criteria’s for an opiate use disorder is met. 
Within these levels of care, there exist detailed sub levels for more specific program criteria, 
and there is also specific program recommendation given for co-occurring disorders which 
has shown convergent validity (Stallvik & Nordahl, 2014). 
 
Norwegian LOC included in the study  
In this study, only Outpatient (ASAM Level I) and Residential Care (Level III) were available 
and included as TAU options. Personnel on both LOC are interdisciplinary trained, often with 
additional formal education in substance use disorders and psychiatric co-occurring disorders. 
The LOC apply a biopsychosocial approach, referring to more intensive medical or 
psychiatric treatment if needed, collaborating with community social workers to secure 
housing, assisting with vocational training and addressing patients’ social support needs. 
Outpatients receive weekly individual therapy, usually more than one weekly group and 
individual session, with counsellor, psychologist, psychiatric, and medical services and 
vocational training, if needed. Opiate maintenance treatment and other medical services are 
also provided. Treatment length, based on patients’ progression, often exceeds 10-12 sessions. 
Inpatient treatment is offered for 3 to 18 months, depending on patient need. Programs vary in 
experience with alcohol vs. drug dependence, but all address all substances as well as other 
Article I: Predictive validity 
 
99 
 
needs. Common services include a set weekly treatment plan that includes individual and 
group sessions, exercise, leisure activities, legal assistance, housing assistance and vocational 
training/school.  
 
Statistical analysis 
Baseline and follow-up outcome measures in this study included: a) dropout; b) clinical 
improvement, i.e., frequency of drug use last 30 days reported at intake and the 7 ASI CS 
scores at baseline; and c) step-down status, i.e., whether patients were assessed and 
recommended by the ASAM Criteria software to a lower (vs. same or higher) LOC at follow-
up compared to their baseline LOC recommendation by ASAM. Step-down to a lower follow-
up LOC would be considered a positive outcome. To assess the primary outcome event that 
should be predicted by ASAM LOC under-matching (vs. matching), i.e., drop-out from 
baseline to follow-up, an independent t-test for continuous variables and Chi-square for 
categorical ones was used to analyse drop-out and potential baseline differences between the 
groups that dropped out vs. remained in treatment. In the event of meaningful baseline 
differences between the baseline and follow-up samples, an intent-to-treat analysis might be 
compromised; therefore paired sample t-tests were used to detect significant change from 
baseline to follow-up for the 3 groups separately on frequency of use and the 7 ASI composite 
subscale scores (Medical, Employment, Alcohol, Drug, Legal, Family and Psychological). . 
GLM Univariate analysis of variance was next used to analyse differences for matched vs. 
under-matched, and matched vs. over-matched groups. The patients’ baseline severity 
measures on the 7 ASI CSs and frequency of use last 30-days were used as covariates 
(Independent variables) and their follow-up scores on the 7 ASI CSs and frequency of use last 
30-days were the dependent variables in the analysis. Analyses were performed with the 
statistical analysis package PAWS18. 
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RESULTS 
The final clinical sample consisted of 261 patients, 66% male, ages 18–61. Figure 1 shows a 
Flow Chart of the recruitment and follow-up process. Table 1 shows demographics for the 
baseline and follow-up samples for all 3 groups.  
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Figure 1: Participant recruitment and follow-up rates  
Available for Follow-Up Reassessment  
(N=153) 
Three months after treatment initiation 
Missing at Follow-Up (n=108) 
 
x Life situation: (n=7) 
x Active psychosis: (n= 3) 
x No contact: (n=98) 
Follow-Up Sample Matched (n=86) 
 
Follow-Up Sample Overmatched 
(n=44) 
Final baseline sample (n=261) 
Naturalistic double blind prospective design 
Matched/mismatched conditions by ASAM recommendation 
LOC Placement by TAU assessment 
 
Matched (n=150) 
ASAM Criteria LOC: 
x LI Outpatient (n=6) 
x LIII Inpatient (n=144) 
TAU LOC placement:  
x LI Outpatient (n=6) 
x LIII Inpatient (n=144) 
Follow-Up Sample Undermatched 
(n=23) 
Overmatched (n=60) 
ASAM Criteria LOC: 
x No treatment 
recommendation (n=41) 
x LI Outpatient (n=4) 
x LII Intensive Outpatient 
(n=15) 
TAU LOC placement:  
x LI Outpatient (n=1) 
x LIII Inpatient(n=59) 
 
Excluded (n=29) 
x Intoxicated or psychiatric instabilities: 
(n=25) 
x Never returned for completion: (n= 4) 
 
Assessed for eligibility (n= 290) 
Undermatched (n=51) 
ASAM Criteria LOC: 
x LII Intensive Outpatient 
(n=11) 
x LIII Inpatient (n=40) 
TAU LOC placement:  
x LI Outpatient (n=51) 
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Table 1: Baseline and follow-up demographics for matched, under-matched and over-
matched groups 
 Baseline 
                                                 Mis-match 
Follow-Up 
                                                 Mis-match 
 
 
 
Characteristic 
Total  
 
n=261 
M(±SD) 
Match 
 
n=150 
M(±SD) 
Under- 
match 
n=51 
M(±SD) 
Over- 
match 
n=60 
M(±SD) 
Total 
 
n=153 
M(±SD) 
Match 
 
n=86 
M(±SD) 
Under-
match 
n=23 
M(±SD) 
Over- 
match 
n=44 
M(±SD) 
Age (years)  
 
32.08 
(±10.63) 
30.80 
(±10.17) 
33.98 
(±10.38) 
33.76 
(±11.69) 
32.52 
(±10.56) 
31.00 
(±10.27) 
35.35 
(±8.92) 
34.07 
(±11.69) 
Gender (%(n)): 
Males  66 (171) 64 (96) 65 (33) 70 (42) 64 (98) 64 (55) 56 (13) 68 (30) 
Females  34   (90) 36 (54) 35 (18) 30 (18) 36 (55) 36 (31) 44 (10) 32 (14) 
Marital Status (%(n)): 
Never married  79    (206) 82  (123) 70   (36) 79   (47) 78   (120) 84 (72) 52. (13) 80 (35) 
Married   8   (20) 6    (9) 12    (6) 8.  (5) 8      (12) 6   (5) 13.      (4) 7   (3) 
Divorced/separated  13 (35) 12 (18) 18    (9) 13 (8) 14    (21) 10 (9) 35      (6) 14 (6) 
Years lived at last 
address 
 4.76, 
(±6.19) 
 4.06, 
(±5.60) 
6.11 
(±7.17) 
4.06 
(±5.60) 
5.22, 
(±5.69) 
4.49, 
(±5.51) 
4.82 
(±4.14) 
6.76 
(±6.90) 
Living arrangement last 3 years (%(n)): 
With family, partner, 
or friends  
46(120) 47(71) 55    (28) 48 (29) 43    (66) 49 (42) 48   (11) 30 (13) 
Alone  36(93) 35    (53) 35    (18) 35 (21) 41    (62) 34 (29) 48   (11) 50     (22) 
No stable living 
arrangement  
18(48) 17    (26) 10.00 (5) 17 (10) 16    (25) 17 (15) 4    (1) 20  (9) 
Education 
(years complete) 
10.62 
(±1.87) 
10.60 
(±1.68) 
10.76 
(±2.32) 
10.53 
(±1.98) 
10.60 
(±1.87) 
 10.68 
(±1.15) 
10.18 
(±2.54) 
10.65 
(±1.96) 
Work (years  
occupation) 
4.69 
(±2.13) 
5.67 
(±7.32) 
6.95 
(±6.46) 
7.56 
(±9.20) 
7.10, 
(±7.98) 
6.04,  
(±7.04) 
8.22 
(±7.15) 
8.22 
(±9.61) 
Work-status (last 3 years, %(n)) 
Full time  21  (56) 21  (32) 22  (11) 22   (13) 22 (33) 17 (15) 26     (6) 27 (12) 
Part-time 9   (24) 7    (11) 12   (6) 12    (7) 8    (12) 6   (5) 4       (1) 14  (6) 
Student 3  (8) 2     (3) 4    (2) 5     (3) 3   (4) 2   (2) 0 5   (2) 
Retired/disability  19  (49) 19   (29) 25  (13) 12    (7) 19 (29) 21 (18) 30     (7) 9     (4)  
Unemployed  49 (127) 52    (78) 37  (19) 50   (30) 49 (75) 53 (46) 39     (9) 45 (20) 
Income source (last 30 days, %(n)):  
Employment  13 (33) 11 (16) 18 (9) 13 (8) 9 (14) 7 (6) 13 (3) 11 (5) 
Unemployed/public 
assistance  
51(132) 56 (84) 35 (18) 50    (30) 45 (69) 51 (44) 26 (6) 43 (19) 
Retirement/ 
disability  
36.01(92) 32.90 (47) 33 (26) 32.25 (19) 36.00 (59) 32.9 (30) 52.17 (11) 50  (18) 
Legal convictions 3.74, 
(±4.05) 
3.65 
(±4.02) 
2.42 
(±2.43) 
5.14 
(±4.86) 
2.74 
(±2.62) 
3.07 
(±2.99) 
2.20 
(±2.68) 
2.10 
(±1.20) 
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Baseline differences between matched and mis-matched conditions 
Independent t-tests at baseline revealed a trend towards a significant lower age 
(t=.1.915(199), p=.057, d=0.31). No other demographic differences were found between the 
match and mismatched conditions. None of the groups differed significantly on baseline 
frequency of use in the last 30 days. The matched group had a significantly higher baseline 
severity than the under-matched on the ASI Legal CSs (t= -2.396(199), p=.018, d=0.41) and 
ASI Employment CSs (Levene’s test indicated unequal variances F= 13.47, p<.001; t = -
2.054(67.49), p=.044, d=0.37), and the over-matched group was significantly less severe than 
the matched group on the ASI Drug (t= -4.962(208), p<.001, d=0.79) and Psychological CSs 
(Levene’s test indicated unequal variances F= 6.941, p=.009; t= -4.962(140.126), p<.001, 
d=0.77).  
 
Study drop-outs  
Over 40% of the total study sample did not show for the follow-up interview, and dropout was 
indeed greater in the under-matched patients. The overall proportions of matched vs. mis-
matched groups were similar between baseline and follow-up (57%:43% and 56%:44%), 
however at follow-up, a Chi Square analysis showed significant differences between the 
conditions (Ȥ²=7.472 (2), p= .024, Cramer’s V=.169). The effect size for this finding is 
considered small (Cohen, 1988).  A total of 55 % (n=28) of the under-matched group left 
treatment before the 3 month follow-up interview vs. 38 % (n=57) in the matched group and 
30 % (n=18) in the over-matched group. The final follow-up sample was 23 under-matched, 
86 matched, and 44 overmatched. 
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As a result of this differential dropout pattern, it was important to examine differences 
between the baseline and follow-up samples. No differences were found for the demographic 
variables in Table 1. No differences were found on frequency of use of different substances or 
the 7 ASI Composite Subscale scores at baseline within the three conditions.  
 
Clinical status at baseline and follow-up 
In Table 2 clinical status on frequency of use is displayed with ASI CSs for all groups at 
baseline (Table 2a) and follow-up (Table 2b). Table 2a also displays mean years of use.  
 
Table 2a: Baseline Clinical status on duration of use, frequency of use last 30 days and 
ASI Composite Scores for matched, under-matched and over-matched groups 
 
 BASELINE 
Characteristic 
Total 
n=261 
M (±SD) 
n 
Match 
n=150 
M (±SD) 
n 
Under-match 
n=51 
M (±SD) 
 
n 
Over-match 
n=60 
M (±SD) 
 
Mean years used 
Mean days used (during last month) 
     Alcohol    15.18 (±9.62) 
12.75 (±10.70) 81 
14.69 (±9.38) 
13.85 (±11.06) 37 
15.78 (±9.75) 
11.65 (±10.16) 26 
16.05 (±10.18) 
10.76 (±10.24) 
     Opiates      6.07 (±5.40) 
  19.93 (±11.65) 46 
   6.05 (±5.34) 
19.70(±11.92) 14 
   6.15 (±5.78) 
21.07 (±11.54) 7 
   6.09 (±5.49) 
22.57 (±11.13) 
     Sedatives/ 
     Hypnotics 
7.84 (±6.53) 
18.18 (±11.98) 77 
7.91 (±6.34) 
18.90 (±11.93) 25 
 6.18  (±5.70) 
17.32 (±12.31) 20 
9.12 (±7.55) 
17.05 (±12.15) 
     Stimulants  
 
8.84 (±6.57) 
14.58 (±10.12) 50 
 8.66 (±6.38) 
13.60 (±9.92) 15 
7.18 (±6.72) 
16.73 (±10.77) 15 
9.76 (±6.04) 
15.67 (±10.40) 
     Cannabis  10.79  (±7.24) 
18.43 (±10.80) 
58  11.45 (±7.47) 
18.55 (±10.62) 
20 9.88 (±6.17) 
18.33 (±11.32) 
18 9.87 (±7.26) 
18.12 (±11.43) 
     Two or more 
substances per day 
 9.11  (±6.15) 
16.22  (±9.49) 73 
 3.73 (±3.72) 
16.70 (±9.80) 21 
 7.57 (±6.24) 
16.48 (±9.82) 17 
9.66 (±6.38) 
13.62 (±7.48) 
 
ASI Subscale Composite Score 
     Medical .24 (±.29) 150 .28 (±.31) 51 .20 (±.26) 60 .21 (±.27) 
     Employment  .86 (±.22) 150 .88 (±.20) 51 .79 (±.28) 60 .87 (±.21) 
     Alcohol .09 (±.14) 150 .09 (±.14) 51 .12 (±.16) 60 .06 (±.12) 
     Drug  .21 (±.12) 150 .24 (±.12) 51 .21 (±.12) 60 .16 (±.10) 
     Legal  .10 (±.17) 150 .12 (±.18) 51 .05 (±.14) 60 .08 (±.15) 
     Family .20 (±.18) 150 .21 (±.18) 51 .20 (±.20) 60 .16 (±.17) 
     Psychological .26 (±.17) 150 .29 (±.17) 51 .28 (±.18) 60 .17 (±.14) 
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Table 2b: Clinical status at follow-up on the ASI Composite Scores and frequency of use 
last 30 days for matched, under-matched, and over-matched 
 
 FOLLOW-UP 
Characteristic 
Total 
n=153 
M (±SD) 
n 
Match    
n=86 
M (±SD) 
n 
Under-match 
n=23 
M (±SD) 
n 
Over-match 
n=44 
M (±SD) 
Mean days used (reported last 30 days at intake) 
     Alcohol 7.06 (±8.40) 22 7.73 (±8.72) 15 8.57 (±10.11) 14 4.29 (±5.85) 
     Opiates 19.04 (±12.75) 17 19.59 (±12.32) 6 20.83(±14.29) 4 14.00(±14.72) 
     Sedatives/ 
     Hypnotics 16.21 (±12.95) 35 19.03 (±12.80) 8 5.25 (±6.50) 9 15.40(±13.38) 
     Stimulants  9.65 (±11.89) 14 5.14 (±7.92) 4 14.50(±13.23) 5 18.40(±15.88) 
Cannabis 8.19 (±9.38) 14 6.86 (±8.70) 9 14.25(±10.70) 4 2.20 (±.84) 
     2 substances per day 9.19 (±10.80) 17 8.63 (±10.93) 10 12.20(±10.96) 9 7.67(±11.39) 
ASI Subscale Composite Score 
     Medical  .18 (±.24) 86 .16 (±.21) 23 .20 (±.27) 44 .18 (±.27) 
     Employment  .89 (±.19) 86 .91 (±.17) 23 .84 (±.24) 44 .89 (±.19) 
     Alcohol .04 (±.10) 86 .04 (±.12) 23 .06 (±.10) 44 .02 (±.08) 
     Drug  .12 (±.08) 86 .12 (±.07) 23 .15 (±.11) 44 .09 (±.06) 
     Legal  .06 (±.14) 86 .08 (±.15) 23 .01 (±.04) 44 .06 (±.13) 
     Family .12 (±.16) 86 .11 (±.14) 23 .11 (±.19) 44 .15 (±.17) 
     Psychological .20 (±.15) 86 .22 (±.15) 23 .22 (±.18) 44 .14 (±.13) 
 
 
 
For 32% of the total sample, stimulants were the main drug of choice, followed by 24% with 
alcohol, 17% with opiates, and 12% with sedatives. A total of 82.4 % (n= 215) have at some 
point been poly-substance users; used 2 or more substances per day in their lifetime, and 111 
(42.5%) report poly-substance use the last 30 days.   
 
Changes in Frequency of Substance Use from baseline to follow-up 
A paired sample t-test was performed on frequency of use during the last 30 days and on ASI 
CSs between baseline and follow-up (Table 3).  
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Table 3: Paired sample t-test on the outcome measures for all three groups, and GLM 
Univariate analysis of variance between matched and mis-matched groups with baseline 
measures as covariates  
 
 
 
 
 
Match 
t, p 
( n=86) 
 
 
Under-match 
t, p 
(n=23) 
 
 
Over-match 
t, p 
(n=44) 
Match vs. under-match: 
F, p, (Cohen’s d) 
 
Match vs. over-match: 
F, p,  (Cohen’s d) 
 
 
Mean days used last month              
     Alcohol  
2.39, .03* 
 
1.56, .13 
 
2.34, .04* 
.78, .38                 (-0.08) 
.00, .96                  (0.46) 
     Opiates -.08, .94 -.11, .92 1.00, .50 .83, .38                 (-0.09) 
1.12, .32                (0.41)  
     Sedatives/hypnotics 1.23, .23 1.79, .13 1.58, .18 3.04, .09                (1.36) 
.13, .72                  (0.28) 
     Stimulants  
 
2.34, .05 1.23, .31 -.74, .51 .96, .35 (-0.86) 
6.15, .04*             (-1.06) 
     Cannabis  2.66, .03* .49, .64 1.83, .21 1.62, .22              (-0.76) 
.78, .40                (0.75)  
     Two or more substances per day 1.90, .10 .12, .91 1.59, .25 2.53, .14              (-0.33) 
.23, .65                 (0.09) 
 
ASI Subscale Composite  Score     
     Medical 4.25, .00‡ 1.04, .31 .35, .73 1.08, .30                (-0.08) 
1.73, .19                (-0.08) 
     Employment  -1.64, .11 -.60, .55 
 
-.40, .69 1.55, .22                (0.29) 
1.32, .25                (0.16) 
     Alcohol 3.10, .00‡ .99, .34 2.48, .02† .82, .37                 (-0.18) 
.08, .78                  (0.21) 
     Drug  8.97, .00‡ 4.46, .00‡ 4.24, .00‡ 2.55, .113              (0.32) 
3.58, .06                (0.43) 
     Legal  2.99, .00‡ 1.4, .17 2.19, .03* 2.231, .14               (0.63) 
.27, .60                   (0.22) 
     Family 5.26, .00‡ 2.39, .03* 1.83, .07 .01, .93                  (-0.06) 
4.29, .04*             (-1.17) 
     Psychological 3.66, .00‡ 1.6, .13 1.77, .08 .166, .68                     (0) 
2.05, .154                (0.57) 
*p<0.05; †p<0.01; ‡p<0.001 
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On frequency of days used at follow-up, the matched group had significantly reduced their 
use of alcohol by 6 days/month compared to baseline, reduced cannabis use by 11 
days/month, and showed statistical trends towards reduction in stimulant use by 8 days/month 
and reduction in use of 2 or more substances per day. No such significant reductions were 
seen for the under-matched group. The over-matched group had significant reduction on 
alcohol frequency, by 7 days/month.  
After controlling for frequency of use last 30 days baseline measures in a GLM Univariate 
analysis, the matched group had significantly lower use of stimulants at follow-up than the 
over-matched group and the effect size is considered strong (F=6.15, p=.04, d= - 1.06). 
Changes in Mean ASI CS scores from baseline to follow-up 
On the ASI CSs, the matched group had a significant reduction in 6 out of 7 scores (all but 
ASI Employment) vs. 2 (ASI Drug and ASI Family) out of 7 scores for the under-matched, 
and 3 (ASI Alcohol, ASI Drug and ASI Legal) out of 7 for the over-matched group. The 
Employment dimension was unchanged for all groups.  
After controlling for the 7 baseline ASI CSs  in a GLM Univariate analysis, the matched 
group had significantly lower follow-up severity than the over-matched group on the ASI 
Family score and the effect size is considered strong (F=4.29, p=.04, d= - 1.17). No other 
significant differences were found.  
 
Changes in ASAM LOC recommendation from baseline to follow-up 
Of the 86 matched patients who showed for the follow-up interview, 61% were now 
recommended to step down to a lower LOC at follow-up, and 39% were recommended to the 
same LOC. Of the 23 under-matched patients, 46% were ready to step down to lower LOC at 
follow-up; 50% were recommended to the same LOC and 1 was recommended for higher 
LOC. Of the 44 patients over-matched at baseline, 17% were recommended for a lower LOC 
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at follow-up; 48% were recommended for same and 35% for higher LOC. A Chi Square 
analysis showed significant differences and a moderate effect size between the conditions 
(Fisher`s Exact test=47.027, p<.001, Cramer’s V=.41). 
 
Discussion 
The aim of this study was to validate the ASM Criteria by investigating these three 
hypotheses: a) matched patients should show less drop-out from treatment than mismatched; 
b) matched patients should show more clinical improvements in terms of less use and lower 
severity on the ASI CSs at follow-up and c) matched patients should show readiness for a 
lower LOC at follow-up. Results on this three favoured the matched group in all outcomes 
measured: retention, clinical severity on use and ASI Composite Subscale scores, and 
readiness for step down to lower LOC.  
Significantly more under-matched patients dropped out shown by a moderate effect size, 55% 
vs. 38% in the matched group, supporting the first hypotheses that match patients show less 
drop-out from treatment. Stimulants, the most common drug of abuse in this region 
(Nordfjærn et al., 2010), showed a significant reduction in days of use for the matched vs. 
over-matched group, supporting the hypothesis that over-matching is not beneficial, but 
matching might be.  
There are few studies testing predictive validity on the ASAM Criteria; ours separates from 
the other studies by testing the revised software edition, on multiple cites instead of only one 
site, and with several more outcome variables like the ASI CSs which previously has not been 
tested for predictive validity. This makes it difficult for direct comparison with results from 
other studies showing results favoring the tools convergent validity. However we used the 
frequency of use of different substances and found similar results to a prior study which 
reported less use of alcohol among the matched patients (Magura, et al., 2003). 
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Alcohol use in our study showed a significant reduction in the matched and over-matched 
group. The over-matched group had no better results than the matched group at follow-up, 
and had less improvement on the ASI CSs than the matched group.  
Sedative/hypnotic use is the only category that increased in the matched group while 
significantly decreasing in the under-matched group. This might be due to primary care 
patients becoming newly managed by addiction treatment centers, which in Norway tend to 
provide medically managed care with sedatives to optimize patients’ program retention, e.g., 
by enhancing sleep, or reducing severe anxiety/anxiety attacks. In the matched patient group 
almost 70% took prescriptions as intended vs. 25% of the under-matched group. The common 
use of sedative in treatment clinics our study follows international clinical guideline 
recommendations (not exceeding two weeks) and appropriate doses are used. Were the use of 
it is problematic and patients do not compliant to the description the treatment plan is revised 
accordingly. Primary doctors are advised to stop prescribing sedatives when their patients 
enter treatment for a substance use disorder, and this can be the reason we see a drop in the 
use among under-matched patients. This discrepancy might be caused by the fact that under-
matched patients may have lacked optimal services or dropped out of the treatment. 
Cannabis reduction was also significant for matched patients, and reduction in use of 2 or 
more substances per day shows a trend favoring matching. This was not the case for the mis-
matched patients. It should be noted that analysis of these specific substance use changes 
offers substantially less statistical power because not all patients used each of the analyzed 
substances.  
The ASI paired sample t-tests favored matching vs. both under-matching and over-matching, 
with significant improvements among the matched group on 6 out of the 7 ASI Subscales. 
Under-matched patients showed improvement in only 2 and the over-matched group 
improved on 3 subscales, but is worth noting that the under-matched group significantly 
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reduced ASI Drug severity scores and ASI Family score. Treatment has an effect, but not as 
successfully with under-matching as with matching.   
The ASI Employment dimension, however, was unchanged for all groups, suggesting that the 
first 3 months of treatment focus on addressing medical, psychiatric and behavioral 
improvement before employment. The results are similar to the study by Turner et al., 2003, 
which also found this variable to fail in differencing between the groups. No studies have 
followed the patients with a second interview with the use of the computerized edition like 
ours. Therefore it is difficult for direct comparisons.  
 
Patients were recommended for step-down to lower LOC at follow-up in 61% of the matched 
group vs. 46 % in the under-matched and 17 % in the over-matched group. None in the 
matched group were recommended for a more intense LOC at follow-up, but in the over-
matched group, over 35% of patients (out of 46) were recommended for a higher LOC than at 
baseline. The difference between groups was significant and effect size considered moderate. 
These results are also interesting compared to previous research, which found  more “no 
shows” among over-matched patients for the next step in treatment (Angarita et al., 2007). If 
over-matching yields no better treatment outcome than matching, and is also associated with 
worsening outcomes, there may be considerable clinical risk in patient assessment – not just 
from giving less treatment than patients need, but also from giving too much.  
 
Study Limitations 
Dropout, which is common in SUD trials and may be greater in real world clinical samples 
such as this, is an outcome that validates the ASAM matching hypothesis in this study, but 
also appears to have impacted our statistical power. Given the trends we see for stimulants 
and sedatives, larger samples at reassessment might have yielded greater statistical power, 
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particularly with the GLM analysis. Prior studies reporting rates with only 60 % of the 
“easiest to locate” subsample of an enrolled population have been found to provide valuable 
information and only to be minimally different when compared to complete samples, and 
study attrition may also be unpredictable from patient characteristics (Hanstein et al., 2000). 
The present study offered no financial or other retention incentives. Future research should 
incorporate significant others and other outreach efforts that have yielded high retention rates 
(Lauritzen et al., 2012). 
 The lack of randomization might have biased against the results, as the matched group at 
baseline showed a tendency to be younger and had higher ASI CS Employment, Drug, legal 
and Psych scores than the mismatched conditions. Also the use of paired t-test does not allow 
for covariate adjustment, it only allows us to say that correct LOC placement appears to have 
had an effect in reducing severity on several dimension in the matched group.  There can also 
be other demographic variables causing the effect we see, together with differences in how 
well the clinics used in this study follow the ASAM Criteria.  These differences might have 
reduced the extent to which matching could demonstrate a clinical outcome advantage over 
mis-matching; nevertheless, the outcome findings are substantially in line with previous 
validation studies on the ASAM Criteria.  
To address patients’ individual needs, it is important that programs offer treatments meeting 
the intensity and service specifications of the ASAM Criteria. A useful taxonomy has been 
described by McGovern et al. (2007). 
 
Conclusion 
Despite these limitations, these findings offer important insights into the assessment and use 
of the ASAM Criteria PPC-2r software. Both in the assessment process and for treatment 
planning purposes, this appears to be a useful tool. Given the lack of harmonized assessment 
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services and treatment services available in Norway and many other countries, it offers a 
valuable clinical assessment which can enhance knowledge of the patient and coordination of 
services to suit both patients’ clinical and recovery support needs. The results are based on 
real-world patients in routine treatment, and are in line with previous validation studies. Our 
results favour the matched group on retention, drug use and addiction severity, and readiness 
for a lower LOC placement at 3 months. The fact that such research has been successfully 
replicated across different national samples, languages and treatment systems should 
encourage further exploration of this tool as a potential international standard for SUD 
patients. 
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ABSTRACT 
 
The ASAM Criteria Software from the American Society of Addiction Medicine is a new 
computer-assisted structured interview and clinical decision support program that implements 
validated tools such as the Addiction Severity Index (ASI), and measures biopsychosocial 
conditions to match patients to an optimal level of care (LOC). The study methods involved a 
prospective, double-blind, multi-site, naturalistic study of substance use disordered treatment 
seekers. We analyzed: 1) discrepancies in ASAM Criteria LOC recommendations vs. 
Treatment-as-Usual (TAU), 2) the software’s ability to clinically distinguish between patients 
with different LOC (convergent validity) and 3) predictive validity. Results indicated that the 
discrepancies in TAU LOC recommendations vs. the Software were in line with previous 
research. Baseline comparisons using ASI Composite Subscale scores (CSs) showed better 
agreement with the ASAM LOC recommendations vs. TAU. Finally, the ASAM 
recommendations were associated with better outcomes three months later for the matched vs. 
mis-matched groups. These results confirmed the Software’s convergent validity as well as 
predictive validity. These outcomes are promising and suggest that programs should avoid 
both under- and over-matching patients. Future, both national and international studies, 
should include the full complement of LOC specified in the ASAM Criteria, properly 
characterized, with larger samples.  
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INTRODUCTION 
Addiction is a biopsychosocial disorder both in etiology and expression, and therefore patient 
assessment needs to employ this multi-dimensional approach in order to recommend optimal 
treatment (Gastfriend & Mee-Lee, 2003). To prioritize treatment assignment along a 
continuum of different levels of care (LOC), each involving different staffing, services, 
intensity and restrictiveness, requires a thorough assessment of patients’ individual needs. In 
2007, treatment in Norway shifted toward defining LOC in terms of intensity and more 
specific time frames, consistent with the Patient Placement Criteria (PPC) of the American 
Society of Addiction Medicine (ASAM) (Mee-Lee, Shulman, Fishman, Gastfriend & Griffith, 
2001). The ASAM Criteria is a set of professionally developed guidelines for matching 
Substance Use Disordered (SUD) patients to optimal LOC to produce the best treatment 
outcome (Hoffman, Halikas, Mee-Lee & Weedman, 1991). Validation studies of the ASAM 
Criteria have created a computerized algorithm that led to a web-based user-friendly, clinical 
decision support software which performs as many as 6000 calculations based on information 
on the patients’ needs and history to recommend an optimal LOC (Sharon et al., 2003). The 
ASAM Software implements previously validated tools such as the Addiction Severity Index 
(ASI, McLellan, 1992) in a computer-guided interview.  
 
The ASAM Criteria 
The ASAM Criteria’s six dimensions have shown to predict treatment success and to be cost 
effective at the same time (Alterman et al., 1994; Gastfriend & McLellan, 1997; Hayashida et 
al., 1989). Studies demonstrate that patients who are mis-matched in TAU assessments 
compared to what the ASAM Criteria would recommend are less likely to show up for 
assigned treatment and have worse treatment outcomes than matched patients (Staines, 
Kosanke, Magura, Bali, Foote & Deluca, 2003; Magura et al., 2003; Angarita, Reif, Pirard, 
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Lee, Sharon & Gastfriend, 2007). Several studies conducted in the USA found the ASAM 
Criteria Software to have high inter-rater reliability (Baker & Gastfriend, 2003), face validity 
(CSAT, 1995), and  predictive validity (Sharon et al, 2003; Turner, Turner, Reif, Gutowski & 
Gastfriend, 1999; Staines et al., 2003; Magura et al., 2003). Convergent validity has also been 
reported, e.g., patients with different LOC recommendations were found to be distinct on ASI 
CSs such as the ASI Medical and Psychological subscales and on alcohol withdrawal 
measures, with progressively more severe scores as the LOC intensity escalated (Sharon et al., 
2003). 
 
ASAM vs. TAU recommendation 
Staines et al. (2003) compared the degree of agreement for the ASAM Criteria Software vs. 
counsellors’ assessment under TAU conditions. In this study of the first edition ASAM 
Criteria (PPC-1), clinical staff had training and computer-guided interview assistance along 
the ASAM dimensional assessment process, however, the actual ASAM Software algorithm 
LOC recommendation was kept blind to staff and patients. Surprisingly, staff disagreed with 
the computer scored LOC recommendations in 58% of the 248 cases, and the ASAM 
Software recommended a more intense initial LOC than the TAU protocol in 81% of those 
discrepant cases. The patients who were assigned to treatments that were matched by the 
computer had better 90-day outcomes (patients were 38 % more likely to enter continued 
treatment after detox, and less likely to return to detox within 90 days), even after TAU 
clinicians received ASAM Criteria training and used computer-assisted interviewing (but 
without the algorithm) (ASAM PPC-2R; Mee-Lee et al., 2001).  
 
New software was developed to implement the ASAM PPC Second Edition, Revised (PPC-
2R), with new levels, sublevels, and detailed decision rules. This version was implemented in 
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a new validation study, conducted in Norway. Initial results from this study showed that 
matched patients had better outcomes than mis-matched patients at three-month follow-up 
(Stallvik, Gastfriend & Nordahl, 2014). This second report further extends that work by 
examining ASAM vs. TAU discrepancies and exploring two hypotheses: first, that the new 
ASAM Criteria LOC recommendations should show convergent validity with the most 
commonly used addiction severity measure, the ASI, and second, that the ASAM LOC 
recommendations should show predictive validity in the differential outcomes between 
patients assigned according to ASAM vs. TAU. Replicating and extending the findings of the 
Staines et al. (2003) study, which used the PPC-1 version, we sought to study the newer PPC-
2R version software, to investigate whether the more restrictive ASAM placements are 
justified by better treatment outcome. Finally, whereas that was a single-site study, the 
Norwegian government-sponsored system made feasible a multi-site study. 
 
METHODS  
 
Sample 
As previously reported, 261 treatment-seeking SUD adults were recruited between February 
2010 and July 2012 [Stallvik, et al., 2014]. Of these 66% were male, and the mean age was 32 
years (18-61). Over 79% were unmarried, 46% lived with family, friends or partner, and 53% 
received unemployment or public assistance. Sample characteristics are in line with previous 
studies conducted in this region (Nordfjærn, Hole & Rundmo, 2010). Baseline (BL) 
demographic characteristics were tested across the three cohorts with different naturalistic 
ASAM LOC recommendations, which showed no significant differences in age, gender, and 
years of education or income source. All patients had substance dependent or abuse disorders 
meeting International Classification Diagnostic, version 10 (ICD-10) Criteria. Comparing the 
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BL versus Follow-up (F/U) samples no significant differences was found in the matched or 
mismatched conditions.  
 
Procedure 
All patients provided informed consent which was approved along with the study protocol by 
the Regional Committees for Medical Health Research Ethics (REK). Interviews took place in 
routine clinical offices, and patients were interviewed by trained ASAM Software assessors at 
BL and again after three months with an F/U interview which again used the ASAM 
Software, although not necessarily with the same assessor as at BL. The patients had to be 
18 years of age, had to speak and understand the Norwegian language, and be stable with 
regard to intoxication with alcohol and/or drugs, and/or psychiatric symptoms to complete the 
interview sessions. Patients could have a severe psychiatric diagnosis, but could not be 
included if they were in an active psychotic stage at the time of inclusion or interview.  
 
The TAU interview is unstructured and non-standardized, and should cover substance use 
history/status/treatment, family/social relations, living arrangement, school/work obligations, 
medical needs and psychological needs. 
Patients were asked to report on the same 30-day period for both the TAU and ASAM 
interviews, because the interviews might not be conducted on the same day. All ASAM 
assessors had at least 3 years of clinical experience and could not participate in TAU intake 
interviews during the study. They were trained in a 32-hour course over four days in the 
understanding and use of the ASAM Criteria Software. The course included extensive training 
in ASI interviewing, since this is one of the major instruments included in the ASAM 
Software. After the course they watched 10 training videos to enhance their interviewing 
skills and facilitate familiarity with the use of the software. To maintain double-blinding, 
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patients, ASAM-assessors, TAU assessors and care providers were kept unaware of the 
ASAM-recommended LOC, so all actual placements were naturalistic, according to the TAU 
clinical recommendation.  
 
Measurement 
Data included patients’ LOC placements from TAU assessments, scores from the ASAM 
Software on the seven ASI composite subscales, duration of ASAM administration time, and 
final ASAM LOC recommendation.  
 
ASAM Criteria Software Interview 
The tool assesses patients along six dimensions of need: 1) Intoxication and Withdrawal, 2) 
Biomedical Complications and Conditions, 3) Emotional/Behavioural Complications and 
Conditions, 4) Treatment Readiness, 5) Potential for Continued Use or Relapse, and 6) 
Environmental Conditions. Within these dimensions, questions address the history of prior 
treatment, substance use duration, frequency and recency, severity of addiction, substance use 
disorder diagnosis, withdrawal symptoms, relapse potential, psychiatric symptoms, 
motivation for treatment and family/social/environmental factors. The Software incorporates 
previously validated tools such as the European version of the ASI [Lauritzen & Ravndal, 
2004]. A more detailed explanation of the assessment requirements, dimensions and LOC is 
described by Mee-Lee and colleagues [2001]. The software constructs an algorithm-based 
recommendation and a report describing the patient’s needs on the different dimensions, and a 
final level of care recommendation. There are four main LOC in ASAM, which can be 
summarized as: Level I: Outpatient treatment (LI), Level II: Intensive Outpatient (LII), Level 
III: Inpatient/residential (LIII), and Level IV: Hospitalization (LIV). A patient might receive 
no LOC recommendation either because his/her needs are not severe enough to justify a LOC 
Article II: Predictive and convergent validity 
128 
 
or because the patient’s constellations of problems might not mathematically resolve to any 
clear LOC in the ASAM decision logic. In such cases, the ASAM Criteria Software calls for 
the intake counselor to select the least intensive and restrictive LOC that will minimally meet 
the patient’s needs in all dimensions. While this is the instruction given for clinical use of the 
ASAM Criteria, because of the blinded nature of these placement recommendations, non-
resolving cases could not be used in some of the study’s data analyses. 
The diagnostic terminology is consistent with the DSM-IV (American Psychiatric 
Associations Diagnostic and Statistical Manual of Mental Disorders, 2000) (updated to DSM-
5 as of October 2013 in the web-enabled application). 
 
The European Addiction Severity Index (EuropASI) 
The ASI CS calculations were developed to evaluate the severity of addiction-related 
problems in terms of lifetime as well as recent use (past 30 days) on the following 
dimensions: medical status, employment and support status, drug and alcohol use, legal status, 
family/social relationships and psychiatric status (McLellan, Luborsky, Woody & O`Brien, 
1980; McLellan et al., 1992; McGahan, Giffith, Parente & McLellan, 1986). The ASI in the 
Norwegian ASAM Software is the European version; its reliability and validity is well 
documented (Hodgins & El-Guebaly, 1992; Leonard, Mulvey, Gastfriend & Shwartz, 2000; 
Lauritzen & Ravndal, 2004). 
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Recommendation by the ASAM Criteria 
 
Two LOC were available in this region for study: LI Outpatient treatment and LIII Inpatient 
treatment. LII Intensive outpatient services were not available in this region at the beginning 
of the study. In the outpatient setting, patients receive individual therapy at least once a week, 
for at least 10-12 sessions, but the majority have more than one session each week, e.g., with 
counsellor, psychologist, psychiatric or medical service provider. In the inpatient/residential 
setting, treatment is offered from three months to 1.5 years, depending on the patient’s needs, 
and a variety of therapies are offered. Because all patients who required detoxification 
received this prior to the study in LIV Hospital Care, the final recommendations by the 
ASAM Software for patients recruited to this study included: LI Outpatient Care, LII 
Intensive Outpatient Treatment (i.e., day treatment or partial hospital), and LIII 
Inpatient/Residential Rehabilitation. 
 
Statistical analysis 
The analysis of discrepancy between LOC assignment from TAU and ASAM algorithm based 
recommendation utilized a Crosstab with Pearson Chi-square analysis. Determination of 
convergent validity used the BL ASI CSs differences between the three LOC, followed by a 
planned contrast test to determine the significance of clinical differences between pairs of 
LOC. Determination of the predictive validity of matching vs. mis-matching employed a 
paired sample t-test on the ASI CSs mean changes from BL to F/U. Results from the 
match/mis-match conditions have previously been analysed on this sample (Stallvik et al., 
2014); this report separates the analyses by LOC and explores discrepant cases in terms of 
both match/mis-match condition and LOC assignment. Analyses were performed with the 
statistical analyze package PAWS18.
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RESULTS 
ASAM vs. TAU recommendation 
The sample consisted of 57.5 % (150 of 261) matched to the ASAM-recommended LOC by 
TAU. The mis-matched group included 19.5 % (51 of 261) undermatched and 23 % (60 of 
261) overmatched patients.  
Table1 shows the Crosstabulation distribution of ASAM-recommended LOC vs. the actual 
LOC the patients received. 
 
 
Table 1: Crosstabulation table of LOC placement by TAU and ASAM Software 
 
 LOC Placement by TAU 
(N; %) 
ASAM Criteria LOC Recommendation Outpatient Level I 
Inpatient 
Level III Total 
Recommended for: No Treatment 
 
9 
22% 
32 
78% 41 
Recommended for: LI Outpatient 
 
6 
60% 
4 
40% 10 
Recommended for: LII Intensive 
Outpatient 
 
11 
40% 
15 
60% 26 
Recommended for: LIII 
Inpatient/Residential 
 
40 
21.7% 
144 
78.3% 184 
Total 66 195 261 
 
Shaded cells = Matched patients; unshaded cells = mis-matched patients. 
No Treatment: This recommendation could arise if the patient’s data showed sub-clinical severity or were 
insufficient for the algorithm to resolve a recommendation. 
 
Of the 261 patients there were 41 who did not receive a LOC recommendation by ASAM 
(i.e., data showed sub-clinical severity or were insufficient). These patients were excluded 
from the Chi-square and ANOVA analyses. The final sample size for the analyses was 220. 
Chi-square analysis revealed overall significant differences for the LOC placement by TAU 
vs. ASAM recommendations (Ȥ²=11.363, p=.003). When the ASAM algorithm recommended 
LI, 40% (4 of 10) patients were overmatched to LIII treatment by TAU. For the ASAM 
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residential LIII recommendations, clinicians undermatched 21.7% (40 of 184) to LI. Given 
the unavailability of LII in this region, all of the 26 patients recommended by ASAM to this 
LOC were necessarily mis-matched, with 58% (15 of 26) more being sent overmatched to 
LIII than undermatched to LI. The total number of patients who were mis-matched was 111 
(42.5% of 261). Figure 1 display the TAU treatment assignment for the whole sample and the 
ASAM recommendations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Article II: Predictive and convergent validity 
132 
 
Figure 1 Procedure study design 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BASELINE SAMPLE (BL) (N=261) 
 
 
TAU 
Treatment assigned 
Treatment-as-usual (TAU) 
Interview 
N=261 
ASAM Criteria Interview 
 
N=261 
LI: Outpatient 
N=58 
LIII: 
Inpatient/residential 
N= 203
ASAM Treatment 
recommendation 
N=220 
LIII: 
Inpatient/ 
residential 
N=184 
 
LII: 
Intensive 
Outpatient 
N=26 
 
LI:  
Outpatient 
 
N=10 
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Convergent validity 
The analysis of convergent validity, using mean ASI CSs at BL, is displayed in Figure 2. The 
group that was ASAM recommended to receive the most intensive LOC, LIII 
Inpatient/Residential, had a consistent pattern of higher observed mean BL scores than the 
outpatient group (LI+LII) on all seven ASI CSs.  
 
 
Figure 2: Mean baseline clinical differences, ANOVA on mean severity differences 
between Outpatient and Residential LOC 
 
 
 
 
    † p<0.10; * p<0.05; ** p<0.01;  
      *** p<0.001 
 
 
 In a GLM univariate analysis with contrast analyses applied there were significantly higher 
severity means at the most intensive LOC on ASI Psychological CSs (p<.001) and ASI Drug 
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CSs (p<.05). We also saw a trend for higher severity on ASI Legal among the LIII compared 
to the group recommended for outpatient care. 
 
Predictive validity with three-month F/U outcomes  
Figure 3 displays the different match/mismatch conditions and their mean severity change on 
ASI CSs at F/U.  
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Figure 3: Interaction of match/mismatch conditions and intensity of LOC with paired 
sample t-test on ASI CS mean score changes from baseline to follow-up 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BL Undermatched (n=51) 
 
 
 
Follow Up (F/U) sample (n = 23) 
 
 
ASAM Criteria Recommended: 
 
x LII Intensive Outpatient (n=11) 
- Significant decrease for: 
ASI Drug (p=.016) 
 
x LIII Inpatient (n=40) 
- Significant decrease 
ASI Drug (p=.004) 
 
 
BL Matched (n=150) 
 
 
 
F/U sample (n=86) 
 
 
ASAM Criteria Recommended: 
 
x LI Outpatient (n=6) 
- One patient at F/U: thus  
t could not be computed 
 
x LIII Inpatient (n=144) 
- significant decreases for: 
ASI Medical (p<.001) 
ASI Alcohol (p<.001) 
ASI Drug (p<.001) 
ASI Legal (p<.001) 
ASI Family (p<.001) 
                 ASI Psychological (p<.001) 
BL Overmatched (n=60) 
 
 
 
F/U sample (n=44) 
 
 
ASAM Criteria Recommended: 
 
x No treatment recommendation (n=41) 
- not analyzed  
(no recommendations made) 
x LI Outpatient (n=4) 
- significant decrease for  
ASI Psychological (p=.014) 
x LII Intensive Outpatient (n=15) 
- significant decrease for 
ASI Drug (p= .034) 
ASI Psychological (p=.004) 
 
 
 
BASELINE SAMPLE (BL) (N=261) 
 
Recommended to a level of care by  
American Society of Addiction Medicine Criteria  
(N=220) 
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Undermatched: Recommended for LII/Received LI 
Of the 51 patients who were classified as undermatched, i.e., receiving a lower LOC than 
recommended by ASAM, 11 were recommended for Level II. Most ASI CSs for this 
subgroup decreased (improved) from BL to F/U, but none of the changes were significant 
except for the ASI Drug CSs (t= 4.009, p= .016); meanwhile, the ASI Employment CSs 
actually increased (worsened). 
 
Undermatched: Recommended for LIII/Received LI 
Clinicians placed 40 patients in LI Outpatient care whom ASAM had recommended for LIII. 
These patients showed mean decreases on most ASI CSs, although none were significantly 
improved except for the ASI Drug CSs (t=3.377p=.004); meanwhile, the ASI Employment 
CSs worsened in this group as well.  
 
Overmatched: LI Outpatient Recommended/Received LIII 
ASAM recommended LI Outpatient treatment for four patients who were overmatched, 
receiving LIII. These patients had non-significant decreases in mean ASI Medical, Alcohol, 
Drug, Family, and Psychological CSs. Only the ASI Psychological CS was significantly 
changed (t=8.273, p=.014).  
 
Overmatched: LII Intensive Outpatient Recommended/Received LIII 
ASAM recommended 15 patients for LII intensive outpatient care, who were placed by TAU 
in LIII inpatient. At F/U, 12 overmatched patients remained in the study; these had non-
significant decreases in all mean ASI CSs values. A significant change was found for ASI 
Drug (t=2.417, p=.034) and ASI Psychological CSs (t=3.664, p=.004). 
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Matched: Recommended LI/Received LI 
As only one patient remained at F/U, this category was not analyzed. 
 
Matched: Recommended LIII/Received LIII 
The matched group had significantly better outcomes after three months than both the 
undermatched and the overmatched groups (Stallvik et al., 2014). The matched group had 
significant reductions in severity in 6 out of 7 ASI CS areas; and a slight increase on ASI 
Employment CSs which was not significant.  
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DISCUSSION 
These analyses examined convergent validity for the ASAM Criteria Software and further 
detailed its predictive validity in terms of three-month F/U outcomes for patients whose 
placements were matched according to the ASAM Criteria vs. those whose TAU placements 
consisted of lower or higher intensity than ASAM recommended. The sample consisted of 
150 patients matched to the recommended LOC based on the ASAM Software algorithm, 51 
undermatched and 60 overmatched patients.  
 
The greatest discrepancy between TAU and ASAM was with LII Intensive Outpatient Care. 
This was caused by the unavailability of LII at the time in this region. In contrast, with the 
availability and guaranteed coverage in Norway for LIII, this Inpatient category yielded 
agreement in 78% of the cases. The ASAM Software recommended a more intensive LOC 
than TAU in 20% of cases. These results are similar to previous research (Staines et al., 2003) 
and the overall study provided a sufficient sample size of mismatched cases to yield 
meaningful results. An important finding of this study, however, is that discrepancies between 
TAU and the ASAM Criteria recommendation occur about half the time, and similarly in 
three different studies: 43% in the present Norwegian cohort, 58% in a New York City study 
(Staines et al., 2003) and 53% in a U.S. Veterans Administration Medical Center (Sharon et 
al., 2003). Such high rates of mis-matching implies substantial cost and patient restrictiveness 
penalties to societies – despite the common use of conventional managed care techniques in 
the latter two environments. 
 
Convergent validity  
Mean severity scores for patients who were ASAM-recommended to the more intensive LIII 
were higher on all ASI CSs and significantly so on ASI Drug and Psychological CSs vs. 
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patients recommended to less intensive LOC. This is in line with a previous study on the 
ASAM Criteria’s convergent validity (Sharon et al., 2003). Patients with more severe 
substance abuse, less social support, or co-occurring psychological disorders benefit more 
from inpatient vs. outpatient treatment (Magura et al., 2003; Bartak et al., 2011), justifying a 
LIII recommendation. Opposite findings were found however, in cocaine users matched to LII 
day treatment vs. those overmatched to LIII inpatient/residential treatment , although that 
study used only a partial implementation of the ASAM Criteria, First Edition (McKay & 
McLellan, 1992), which may have limited the effectiveness of its algorithm. With the present 
study’s use of the newer ASAM Criteria, 2nd Edition-Revised version and the comprehensive 
computerized implementation, the more severe means on seven out of seven dimensions, and 
significant change on ASI Drug and Psychological CSs demonstrate consistency in the 
ASAM Criteria Software’s ability to make clinical distinctions. Furthermore, it makes clinical 
sense that the ASI Psychological and Drug CSs might both show significant baseline 
differences between different LOC, based on their association in prior literature (Lehman, 
Myers, Thompson & Corty, 1993), the impact of psychological problem loading on related 
dimensions, including family and social supports (Kashner, Rader, Rodell, Beck, Rodell & 
Muller, 1991), and their relationships with legal problems (DSM-IV, 2000), which are also in 
evidence in the higher severity ASI Legal CSs.  
 
Outcomes at F/U for the different match/mis-match LOC conditions 
The undermatched group had worse 90-day outcome than the matched group, which supports 
predictive validity for the ASAM Criteria. Naturalistic undermatching may be due to patients’ 
own preferences for outpatient treatment due to work or family responsibilities, or practical 
issues such as geography or convenience. Such reasons, however, warrant more educational 
and motivational effort by clinicians in the course of assessment, since the data indicate that 
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patients would achieve better outcomes if they accept the ASAM-recommended placements. 
Alternatively, undermatching may occur due to lack of access to certain LOC, as was the case 
with many LII placements – and in this case, the ASAM Software serves as a needs 
assessment tool, precisely revealing the quantitative shortage of treatment slots in a 
geographic region. Given the adverse outcomes of such mis-matching, public entities would 
be wise to respond by improving access to care, as is now the case with provision of LII in 
this region of Norway. 
 
The overmatched group did not appear to benefit from more intensive placement by TAU, 
thus also supporting the validity of the ASAM Criteria. Although overmatched patients in LIII 
(a controlled environment) might be expected to benefit from elimination of access to 
substances and presumably fewer craving triggers, this is less effective and overly costly – 
both in terms of unnecessary restrictiveness for the patient, and inefficient service provision 
for the treatment system. Overall, these results shed a light on the crucial need for thorough 
assessments before matching patients’ needs to appropriate services.  
 
Limitations  
A relevant methodological consideration is that differences between the ASAM Software-
obtained treatment recommendation and clinically derived LOC can be a result of the 
numbers of categories available. If the clinicians had the full continuum of four LOC 
available in the community as the ASAM Criteria recommend, then discrepancies could have 
been fewer than those seen here. The naturalistic approach to the design may have biased 
against validity findings, as the prior report on this study found that the matched group at BL 
differed from the mis-matched groups with younger age, and higher ASI Drug, Legal, 
Employment and Psychological scores (Stallvik et al., 2014). These differences might have 
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reduced the extent to which matching could demonstrate a clinical outcome advantage over 
mis-matching; nevertheless, predictive validity was supported.  
 
In the measurement of convergent validity the ASI CSs were used, and ASI questions supply 
approximately 50% of the ASAM assessment’s data needs. However the ASI CSs calculations 
are actuarial and these scores are not used in the ASAM LOC determination, which employs 
considerably different hierarchical decision logic. Given these differences in calculation, the 
danger of overlapping is minimal. Therefore, the progressively more severe means on seven 
out of seven ASI CSs and meaningful clinical distinctions between the LOC lend support to 
the convergent validity of the ASAM Criteria. These findings need to be further investigated 
with larger samples and with the full continuum of ASAM LOC, because this study lacked 
LII Intensive outpatient treatment and also included only a small sample in LI Outpatient. 
LOC should also be confirmed as actually delivering the services specified by the ASAM 
Criteria – and a certification procedure has been published to aid this task (McGovern, Xie, 
Acquilano, Segal & Drake, 2007).  
 
Conclusion 
The ability of the ASAM Criteria to clinically distinguish between the different LOC as 
shown by these data lends support for the software’s convergent validity. The differential 
outcomes for the matched vs. mis-matched groups demonstrate predictive validity for the 
ASAM Criteria Software. These outcomes suggest that programs should avoid both under- 
and over-matching patients. Future studies, both national and international, should include all 
LOC specified in the ASAM Criteria, properly characterized, with larger samples. The 
convergent and predictive validity demonstrated by these results are promising for the 
widespread release of the ASAM Criteria Software that is currently underway. 
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ABSTRACT 
Objective: The complexity of substance use and psychiatric disorders demands thorough 
assessment of patients for integrated services. We tested the convergent validity of the software 
version of the American Society of Addiction Medicine (ASAM) second edition-revised criteria 
for patient placement by examining the software’s ability to discriminate based on a variety of 
demographic and clinical factors. Methods: This prospective naturalistic multi-site study  
examined the software’s assignment of patients to three types of treatment (Addiction Only 
Services, Dual Diagnosis Capable, and Dual Diagnosis Enhanced), and whether these 
assignments indicated an ability to discriminate between patients with and without dual diagnosis 
based on clinical characteristics and severity. Ten addiction treatment clinics spanning three 
counties participated, and both patients and ASAM assessors were kept blind to the ASAM 
recommendation. Patients were assigned to their respective treatment options based on routine 
assessment by clinicians at intake, which they had in addition to the ASAM interview. Three 
months after treatment initiation a follow-up interview with ASAM was conducted. Results: 
There were 261 patients in the study, 96 (36.7%) were assigned to Addiction Only Services, 42 
(16.1%) to Dual Diagnosis Capable, and 123 (47.1%) to Dual Diagnosis Enhanced. Patients 
assigned to the two Dual Diagnosis groups were significantly more likely to be younger and have 
fewer years of work than other patients. There were significant differences in history of inpatient 
and outpatient psychiatric treatment across groups. For example, a larger percentage of those in 
Addiction Only Services had never been in inpatient treatment, while more of those in the two 
Dual Diagnosis groups had three or more inpatient stays. Despite similar alcohol and drug 
severity scores, patients recommended by the Software for Dual Diagnosis Enhanced programs 
showed a gradient of significantly higher psychiatric (p<.001), legal (p<.04) and family (p<.001) 
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Addiction Severity Index composite scores at baseline than patients in Dual Diagnosis Capable 
and Addiction Only Services. Conclusions: Results show a high prevalence of co-occurring 
program recommendations with statistically significant and clinically meaningful differences 
between patient groups. The convergent validity of the revised version of ASAM Criteria 
Software is supported by these results.  
Keywords:  ASAM Criteria, dual diagnosis program, prevalence, Addiction Severity Index, 
characteristics, convergent validity, co-occurring disorders, severity composite scores 
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INTRODUCTION 
There is a high prevalence of co-occurring substance use and psychiatric disorders (i.e., dual 
diagnosis) in both Norwegian and international studies (Melberg Lauritzen & Ravndal, 2003; 
Ravndal, Vaglum & Lauritzen, 2005; Bakken, Landheim & Vaglum, 2005; Cole & Sacks, 2008; 
Schulte, Meier, Stirling & Berry, 2008; Helseth, et al., 2013). The numbers vary, but national 
studies have found prevalence rates of 32 - 65% (Bakken et al., 2005), while international studies 
have found lower but increasing numbers; 20% in 2004 (Grant et al., 2004) and 46% in 2008 
(Schulte et al., 2008). Patients with dual diagnosis have poorer prognosis, legal difficulties and 
unemployment (Dausey & Desai, 2003), and higher prevalence of suicide attempts (Darke, Ross, 
Lynskey & Teesson, 2004; Bakken & Vaglum, 2007).  
Because of the problems associated with dual diagnosis, it is critical to identify the presence of 
co-occurring disorders at intake and develop an appropriate treatment plan. Lack of early 
identification and proper treatment can lead to less benefit and worse treatment results, like high 
attrition, low treatment attendance, and worse outcomes (Magura et al., 2003; Hides, Dawe, 
Young & Kavanagh, 2007; Schulte, Meier, Stirling & Berry, 2010; Angarita, Reif, Pirard, Lee, 
Sharon & Gastfriend, 2007). In addition to early detection and appropriate planning, services 
delivered via integrated treatment programs seem to be more effective than those delivered 
sequentially (Brunette, Mueser & Drake, 2004). 
The Patient Placement Criteria of the American Society of Addiction Medicine (ASAM; Mee-
Lee, Shulman, Fishman, Gastfriend & Griffith, 2001) is one of the most elaborate sets of 
professionally-developed guidelines for matching patients with substance use disorders to 
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optimal levels of care (Hoffman, Halikas, Mee-Lee & Weedman, 1991). The validity of the 
ASAM Criteria first edition has been supported by several studies (CSAT, 1995; Baker & 
Gastfriend, 2003; Sharon et al., 2003; Staines, Kosanke, Magura, Bali, Foote & Deluca, 2003; 
Magura et al., 2003). The revised version of the ASAM Criteria introduced taxonomy of 
addiction treatment programs based on their capacity to provide services to people with dual 
diagnosis (Mee-Lee et al., (2001). The categories were defined as Addiction Only Services, Dual 
Diagnosis Capable, and Dual Diagnosis Enhanced. Studies have shown that patients with a high 
severity of co-occurring substance use and psychiatric problems who were placed in high 
service-intensity programs had better treatment outcomes than patients with high co-occurring 
severity treated in low-intensity programs, showing that matching in terms of intensity has 
improved outcomes (Chen, Barnett, Sempel & Timko, 2006). 
Based upon the fact that many patients with substance use disorders also have a co-occurring 
psychiatric disorder, researchers have proposed that all addiction treatment programs should at 
least be Dual Diagnosis Capable (Minkoff, Zweben, Rosenthal & Ries, 2003). That is, all 
addiction treatment programs should be able to support patients with dual diagnosis who have 
stable and less severe psychiatric symptoms. McGovern and colleagues (2007) studied the 
ASAM taxonomy for dual diagnosis categories and found that one-fourth of the programs 
classified themselves as Addiction Only Services, two-thirds (65%) of the programs reported 
being in the Dual Diagnosis Capable category, and a few (10%) programs classified themselves 
as Dual Diagnosis Enhanced programs. Results support the taxonomy of the ASAM 
classification system by showing that Dual Diagnosis Enhanced programs reported treating 
patients with significantly greater psychiatric severity than Dual Diagnosis Capable and 
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Addiction Only Services respectively. However, more research with the revised ASAM 
taxonomy is needed to test whether these different level of care recommendations make 
significant and meaningful clinical distinctions. 
A computerized software program has been developed to implement the ASAM Criteria Second 
Edition-revised version with new levels, sublevels, and upgraded decisions rules. This software 
version was tested in a validation study in Norway and showed support for the ASAM Criteria`s 
ability to predict outcomes. Optimally matched patients had better outcomes after three months 
than mismatched patients (Stallvik & Gastfriend 2014). In addition to the predictive validity 
testing, the Criteria have also shown convergent validity in a previous study on the main levels 
of care, where the patients with the highest severity levels also received higher level of care 
recommendations by ASAM Criteria (Sharon et al., 2003). With this present article we further 
extend the work by Sharon and colleagues by exploring whether the ASAM Criteria taxonomy 
for co-occurring disorders is able to identify those in need of dual diagnosis program 
recommendations and whether there are significant and meaningful clinical differences between 
the different groups that support such recommendations. In other words, if two patients have 
identical alcohol and drug severity, but one of them has more severe psychiatric needs, the 
ASAM Criteria Software must be able to discriminate these needs and recommend dual 
diagnosis service enhancements.  
Specifically, this study investigated: 1) the prevalence of dual diagnosis program 
recommendations (Dual Diagnosis Capable or Dual Diagnosis Enhanced) for patients seeking 
substance use disorder treatment; 2) the baseline clinical characteristics of patients who were 
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assigned to Addiction Only Services, Dual Diagnosis Capable or Dual Diagnosis Enhanced care; 
and 3) treatment outcomes at three-month follow-up among patients in all three groups. 
Outcomes included the following variables: treatment initiation, treatment retention, and severity 
scores on the Addiction Severity Index (ASI). Finally, the ASAM Criteria recommendations for 
co-occurring disorders were compared with ASI severity scores, the most commonly used 
addiction severity measure, to test convergent validity.  Specifically, the ASAM Criteria should 
be able to discriminate correctly between patients with similar alcohol and drug severity but who 
have different severity in psychiatric and related areas and therefore different needs for 
treatment.  
METHODS 
Study Design and Participants 
This naturalistic multi-site study was conducted at 10 different assessment/treatment clinics in 
the middle region of Norway covering three counties, with both rural and suburban areas 
included. These clinics offer a variety of services in both outpatient and inpatient settings. No 
formal categorization of dual diagnosis capability is reported by the clinics, but most appear to 
provide an intermediate set of services similar to those of a Dual Diagnosis Capable program. All 
services have interdisciplinary treatment services, staff, and close referral to more intense 
psychiatric care when needed.  
Patients were recruited during February 2010 – July 2012. Following a complete discussion of 
the study by assessors at the clinic, patients provided written informed consent. The study was 
Article III: Convergent validity co-occurring disorders 
155 
approved by the Norwegian Regional Ethics Committee (NREK) and conducted in accordance 
with the Declaration of Helsinki. The patients had to be at least 18 years of age, speak and 
understand the Norwegian language, and be stable enough in regard to addiction and/or 
psychiatric symptoms to complete the interview sessions. Patients were excluded based on 
psychiatric symptoms only if their symptoms were so severe that they were unable to participate 
in the interview session. All participants had substance dependence or abuse disorders meeting 
International Classification Diagnostic, version 10 (ICD-10) Criteria (WHO, 1993).  
All patients received the agency’s routine assessment at intake and an ASAM baseline interview. 
Interviews took place in routine offices and patients were contacted by the ASAM assessors 
again after three months for a follow-up interview. The ASAM assessors participated in a four-
day training on use of the revised ASAM Criteria Software that included extensive training in the 
Addiction Severity Index interviewing, since this is one of the major instruments included in 
ASAM Software. After the course they executed 10 training videos to enhance their interviewing 
skills and facilitate familiarity with the use of the software. Patients and assessors were blinded 
to the ASAM recommendation, and patients were assigned to the level of care recommended by 
the routine intake assessment. ASAM assessors registered whether patients entered their assigned 
treatment, and if they were still in treatment at the time of the follow-up interview. 
The ASAM Criteria Software Interview 
The ASAM Criteria have undergone several studies and are used by a majority of US states (Mee 
Lee et al., 2001).  Inter-rater reliability (intra-class correlation coefficient) with the first edition 
of the software was 0.77 (Baker & Gastfriend, 2003). The revised version (ASAM Patient 
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Placement Criteria –Second Edition- Revised) assesses prior treatment, substance use duration, 
frequency and recency, severity of addiction, substance use disorder diagnosis, withdrawal 
symptoms, relapse potential, psychiatric symptoms, motivation for treatment and environmental 
factors. The scores on these dimensions are matched to appropriate levels of care. Six main 
levels of care can be recommended, and the three levels discussed here are included among 
them. The diagnostic terminology used in this software version was consistent with the DSM-IV 
(American Psychiatric Associations Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition, 2000). Three types of programs within the recommended levels of care reflect 
their ability to address co-occurring substance and mental disorders. These are Addiction Only 
Services, Dual Diagnosis Capable and Dual Diagnosis Enhanced. 
Addiction Only Services are appropriate for patients without a psychiatric disorder, and those 
with a psychiatric disorder that is not perceived to be interfering with substance use treatment. 
This recommendation does not mean that there is no psychiatric diagnosis, but that this 
dimension is perhaps taken care of by other resources, stable, and/or not interfering with 
treatment for substance use disorders. 
Dual Diagnosis Capable programs are appropriate for patients with psychiatric disorders that 
may be more severe but are currently stable and not interfering with substance use treatment to a 
substantial degree. 
Dual Diagnosis Enhanced services are designed to treat patients who have more unstable or 
severe co-occurring mental disorders that will interfere significantly with substance use 
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treatment if left unaddressed. All staff must be cross-trained in both disorders. These programs 
have a high staff-to-patient ratio with a focus on patients’ dual diagnosis instability and 
integrated dual diagnosis staff, services and program content. 
The program recommendations are designed to match the functional needs of patients. The main 
difference between Dual Diagnosis Capable and Dual Diagnosis Enhanced is that the latter has 
more resources and staff mix, but the program content itself is fairly similar across both levels of 
care (Minkoff, 2008). Dual Diagnosis Enhanced programs can serve patients with a substance 
use disorder and active moderate to severe psychiatric symptomology or baseline psychiatric 
disability, whereas Dual Diagnosis Capable programs are only appropriate for those whose 
psychiatric symptoms are less active. For example, Dual Diagnosis Enhanced services would be 
appropriate for individuals with active PTSD symptoms with significant flashbacks, or baseline 
schizophrenia with moderate impairment, who need greater access to personnel trained in mental 
health issues and symptom reduction, smaller groups, and so on.  
In this study, outpatient (ASAM Level I) and inpatient/residential (Level III) care were available 
for participants. Personnel were interdisciplinary, often with additional formal education in 
substance use disorders and co-occurring psychiatric disorders. Both levels of care have access to 
and collaborate with community social workers to secure housing and to assist patients to attend 
more intensive treatment if needed by referral or via closely coordinated services such as acute 
medical or psychiatric care units. The services provide help or assistance with vocational 
training, and there is a focus on family and friend relationships to enhance patients’ social 
supports. In the outpatient setting, patients receive individual therapy at least once a week, but 
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the majority also have other sessions, such as with a counsellor, psychologist, psychiatrist or 
medical personnel. In the inpatient/residential setting, treatment is offered from three months to 
1.5 years depending on the patient’s needs. The therapies offered are varied, but common 
services include a set weekly treatment plan that patients follow over time, which includes 
individual sessions, group sessions, exercise, leisure activities, housing assistance and vocational 
training/school. 
Two stages of assessment are used to identify patient’s psychiatric needs when entering 
treatment. First, patients are asked directly if they have any psychiatric diagnoses. Second the 
ASAM assessors conduct a broad review of psychological symptoms and, if any are present, 
investigate symptom severity, recency and the relationship between symptoms and substance use 
or withdrawal.  
The European Addiction Severity Index 
The ASAM Criteria Norwegian translation incorporates previously validated tools such as the 
European version of the ASI (Ravndal, 2004; Hodgins & El-Guebaly, 1992, Leonhard, Mulvey, 
Gastfriend & Shwartz, 2000).  The European ASI uses subscale composite scores to 
quantitatively evaluate the severity of addiction-related problems on seven dimensions: medical, 
employment and support, drug use, alcohol use, legal issues, family history, family and social 
relationships and psychiatric status over the past 30 days (McLellan et al., 1992; McGahan et al., 
1986). The reliability and validity of the European ASI is well documented (Ravndal, 2004).  
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Statistical Analysis 
To show the prevalence of the different treatment recommendations by the ASAM software we 
used percentage distributions. Univariate ANOVA and Chi-square tests were used to analyse 
baseline group differences across the three levels of care recommendations on demographics, 
psychiatric symptoms, treatment history, treatment initiation, treatment retention, and suicide 
attempts. Any significant differences were explored using a Scheffe analysis to determine which 
of the groups differed. Paired sample t-tests were used to study changes in the ASI composite 
scores from baseline to follow-up. A planned contrast test was conducted using GLM Univariate 
analysis to determine whether patients with more severe psychiatric symptoms were in fact 
assigned to the higher level of care. Analyses were performed with the statistical analysis 
package PASW 18. 
RESULTS 
A total of 261 patients were recruited into the study. These participants were primarily male (n = 
171, 65.5%), were never married (n = 206, 72.9%), and had a mean age of 32.08 years (SD = 
10.63). Approximately half had a psychiatric diagnosis (n = 149, 57.1%), 66 (25.3%) were 
treated in an outpatient setting, and 195 (74.7%) were treated in an inpatient setting. The most 
common drugs of choice were stimulants (n = 84, 32.2%) and alcohol (n = 64, 24.5%), and about 
a third of participants had a lifetime history of a suicide attempt (n = 103, 39.5%). Of the 261 
patients who began the study, 158 (60.5%) remained in treatment at the 3-month follow-up. 
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Program Recommendations for Co-occurring Disorders 
Based on the routine intake assessment, 96 patients in the study (36.7%) received a 
recommendation to Addiction Only Services, 42 (16.1%) were matched to Dual Diagnosis 
Capable programs, and 123 (47.1%) were referred to Dual Diagnosis Enhanced programs. Of the 
96 patients assigned to Addiction Only Services 83 actually initiated treatment (86.5%), while 37 
(88.1%) of those assigned to the Dual Diagnosis Capable group and 106 (86.2%) of those 
assigned to the Dual Diagnosis Enhanced group actually initiated treatment. Treatment retention 
was also similar across groups, with 63 (65.6%), 27 (64.3%), and 68 (55.3%) patients still in 
treatment at the 3-month follow-up. 
Demographic Baseline Data and Characteristics 
The three groups’ characteristics at baseline are displayed in Table 1. 
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Table 1  
Demographic Characteristics and Group Differences at Baseline (N = 261) 
Characteristic 
AOS 
n=96 
DDC 
n=42 
DDE 
n=123 
ANOVA/Chi-
square, p-value 
M (SD) M (SD) M (SD) 
Age (years)  33.46 (11.18) 36.26 (11.61) 29.63 (9.23) F = 7.67, p < .001 
Education (years) 10.63 (1.87) 10.55 (1.61) 10.63 (1.98) F = .034, p = .966 
Work (years) 7.09 (8.35) 9.94 (9.61) 4.49 (5.58) F = 6.77, p < .001 
n (%) n (%) n (%) 
Gender Ȥ² = 5.96, p = .051 
Males  63(66) 21 (50) 87 (71) 
Females  33 (34) 21 (50) 36 (29) 
Marital Status R1 = 10.10, p=.092 
Never married  72 (75) 28(67) 106 (86) 
Married  10 (10) 9(21) 5 (4) 
Divorced/separated  14 (15) 5(12) 12 (10) 
Living arrangement past 3 yrs Ȥ² = 20.52, p = .115 
Family, partner, friends  49 (51) 19(45) 60 (49) 
Alone  28 (29) 20(48) 44 (36) 
No stable arrangement 19 (20) 3(7) 18 (15) 
Note.  AOS = Addiction Only Services; DDC = Dual Diagnosis Capable; DDE = Dual Diagnosis 
Enhanced. 
1Fisher Exact Test 
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The three groups were significantly different in age and work history. A Scheffe analysis in the 
Univariate ANOVA revealed a significantly lower age in the Dual Diagnosis Enhanced group 
compared to Dual Diagnosis Capable (p=.002) and Addiction Only Services group (p=.027). 
With regard to work, the Scheffe revealed that the Dual Diagnosis Enhanced recommended 
patients had significantly fewer years of work in their lifetime than Dual Diagnosis Capable 
(p=.002) , but not the Addiction Only Services (p=.194) patients. No other significant 
demographic differences were found, although there was a trend toward gender differences 
across groups (p=.051). The percentage of males was 66% in the Addiction Only Services group, 
50% in the Dual Diagnosis Capable group, and 70% in the Dual Diagnosis Enhanced group. 
Clinical History and Characteristics 
Table 2 shows clinical characteristics across the three groups. Surprisingly, while the percentage 
of patients reporting a psychiatric diagnosis was greater in the Dual Diagnosis Capable and Dual 
Diagnosis Enhanced groups compared to the Addiction Only Services group (62%, 62%, and 
49%, respectively), these differences were not statistically significant.  
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Table 2: Clinical History and Group Differences at Baseline (N = 261) 
Characteristic 
AOS 
n=96 
DDC 
n=42 
DDE 
n=123 Chi-square, p-value 
n (%) n (%) n (%) 
Has a psychiatric diagnosis 47 (49) 26 (62) 76 (62) Ȥ²=4.097, p= .129 
Symptoms experienced1 
Anxiety 47 (49) 28 (67) 70 (57) Ȥ²= 3.884, p=.143 
Depression 49 (51) 19 (45) 63 (51) Ȥ²= .492, p=.782 
Bipolar 5   (5) 6  ( 14) 13 (11) Ȥ²= 2.558, p=.278 
Personality disorder 27 (28) 13 (31) 47 (38) Ȥ²= 2.596, p=.273 
Psychosis 2   (2) 4   (10) 21 (17) Ȥ²= 13.099, p=.001 
PTSD 5   (5) 11  (26) 22 (18) Ȥ²= 12.410, p=.002 
ADHD 20 (21) 5   (12) 25 (20) Ȥ²= 1.709, p=.426 
Eating disorder 3   (3) 3   (7) 12 (10) Ȥ²= 3.625, p=.163 
History of inpatient treatment Ȥ²= 13.942, p=.007 
0 62 (65) 22 (52) 58 (47) 
1-2 19 (26) 7   (17) 38 (31) 
3 or more 9    (9) 13 (31) 27 (22) 
History of outpatient treatment Ȥ² 13.754, p=.008 
0 34 (35) 18 (43) 30 (24) 
1-2 57 (59) 19 (47) 71 (58) 
3 or more 5 (5) 4 (10) 23 (19) 
Drug of choice 
Stimulants  27 (28) 13 (31) 44 (36) Ȥ² 1.480, p=.477 
Alcohol 24 (25) 14 (33) 26 (21) Ȥ² 1.751, p=.417 
Opiates 18 (19) 8 (19) 26 (21) Ȥ² .083, p=.959 
Initiated assigned treatment 83 (87) 37 (88) 106 (86) Ȥ² = .101, p = .971 
Retention after 3 months 63 (66) 27 (64) 68 (55) Ȥ² = 2.71, p = .258 
Psychiatric disability pension  13 (14) 5 (12) 17 (14) Ȥ² = .119, p = .942 
Suicidal thoughts (lifetime) 
Suicidal thoughts (30 days) 
64(67) 
15 (16) 
23 (55) 
5 (12) 
80 (65) 
23 (19) 
Ȥ² = 1.91, p = .385, 
Ȥ² = 1.04, p = .596 
Suicidal plan (lifetime) 
Suicidal plan (30 days) 
39(41) 
7 (7) 
14 (33) 
5 (12) 
59 (48) 
19 (15) 
Ȥ² = 3.06, p = .216, 
Ȥ² = 2.87, p = .239 
Suicide attempt (lifetime) 30 (31) 19 (45) 54 (44) Ȥ² = 4.31, p = .116 
Treatment setting 
Outpatient 
Inpatient 
32 (33) 
64 (67) 
8 (19) 
34 (81) 
26 (21) 
97 (79) 
Ȥ² = 5.276, p = .072 
Note.  AOS = Addiction Only Services; DDC = Dual Diagnosis Capable; DDE = Dual Diagnosis 
Enhanced; PTSD = posttraumatic stress disorder; ADHD = attention deficit hyperactivity disorder. 
1Symptoms are reported instead of diagnoses because the software does not generate clinical 
diagnoses. 
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There were, however, significant differences across groups on history of inpatient and outpatient 
treatment. A significantly higher percentage of patients in the Addiction Only Services group 
(65%) never had inpatient treatment, as compared to those in the Dual Diagnosis Capable (52%) 
and Dual Diagnosis Enhanced groups (47%), while a larger percentage of those in the Dual 
Diagnosis Capable (31%) and Dual Diagnosis Enhanced (22%) groups had three or more 
psychiatric inpatient stays in contrast to only 9% of the Addiction Only Services group. Similar 
results were found for prior treatment in psychiatric outpatient settings. More patients in the Dual 
Diagnosis Enhanced group had three or more outpatient treatment episodes (19%), compared to 
either of the other two groups (10% in the Dual Diagnosis Capable group and 5% in the 
Addiction Only Services group).  There were no other significant differences across groups on 
clinical history  
Psychiatric Symptomatology Reported by Clinicians 
Table 2 lists the proportion of patients in each group who reported a history of experiencing 
particular psychiatric symptoms during the ASAM assessment. Symptoms are reported instead of 
diagnoses because patients may experience symptoms in multiple categories and the Software 
does not attempt to generate clinical diagnoses per se. Only two types of psychiatric symptoms 
differed across groups.  Chi square analysis shows a larger percentage of patients in both Dual 
Diagnosis recommended groups that experienced symptoms in the psychosis (p <.001) and 
PTSD categories (p<.02, than reported in the Addiction Services Only group. There were no 
other significant differences on symptom measures or suicide measures. 
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Convergent Validity Using Baseline ASI Composite Scores 
To analyze the convergent validity of the ASAM Criteria, we examined the three groups using 
their baseline Addiction Severity Index subscale composite scores compared with their assigned 
treatment type. GLM univariate analysis on baseline scores revealed significant differences in 
three-way comparisons on ASI subscale composite scores for Legal, F(2,258) = 3.16, p=.044; 
Family, F(2,258) = 8.49, p<.001; and Psychological, F(2,258) = 13.10, p<.001.  
A planned post hoc Scheffe test was applied on differences between the groups and no 
significant differences were found between the Addiction Only Services group and the Dual 
Diagnosis Capable group. Addiction Only Services group compared to Dual Diagnosis Enhanced 
group did show significantly lower severity on Psychological (p<.001) and Family (p<.05), and 
the Dual Diagnosis group compared to the Dual Diagnosis Enhanced was significantly lower in 
severity on Family (p<.001) and Psychological (p<.05).  
Differences in Severity Scores at Three-month Follow-up  
Paired sample t-tests shown in Table 3comparing each groups’ follow-up ASI CSs data with 
their own baseline scores showed that all three groups improved significantly on the Alcohol and 
Drug subscales. 
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Table 3  
Paired Sample t-test on Change in Addiction Severity Index Subscale Composite Scores from Baseline to 
Follow-up  
ASI  
Subscale 
AOS 
n=96 
Paired  
t-test 
DDC 
n=42 
Paired  
t-test 
DDE 
n=123 
Paired t-test 
Baseli
ne 
Follow
-up 
t (df), p-
value 
Baseline Follow-
up 
t (df), p-value Baseli
ne 
Follow-
up 
t (df), p-value 
Medical .20 
(±.26) 
.18 
(±.26) 
1.103 
(58),.275 
.26 
(±.30)  
.15 
(±.19) 
1.935(26),.064 .27 
(±.31) 
.19 
(±.24) 
3.145(66), 002 
Employment .85 
(±.22)  
.88 
(±.22) 
-.554 (58), 
.582 
.84 
(±.25)  
.89 
(±.18) 
-1.314(26), 
.200 
.87 
(±.21)  
.90 
(±.20) 
-1.082(66), 
.283 
Alcohol .09 
(±.15) 
.04 
(±.10) 
2.633 
(58),.011 
.11 
(±.15) 
.05 
(±.15) 
2.098(26),.046 .08 
(±.14) 
.03 
(±.08) 
2.233(66).029 
Drug .20 
(±.12) 
.10 
(±.07) 
5.837 
(58),.000 
.24 
(±.13) 
.12 
(±.07) 
4.776(26),.000 .22 
(±.11) 
.13 
(±.08) 
7.847(66).000 
Legal .08 
(±.16) 
.05 
(±.12) 
2.294 
(58),.025 
.05 
(±.14)  
.05 
(±.14) 
.617(26),.543 .12 
(±.18) 
.08 
(±.15) 
3.325(66),.001 
Family .17 
(±.17) 
.11 
(±.15) 
3.595 
(58),.001 
.13 
(±.14)  
.12 
(±.15) 
1.103(26),.280 .24 
(±.19) 
.13 
(±.16) 
5.061(66),.000 
Psychological .20 
(±.15) 
.16 
(±.13) 
2.403 
(58),.020 
.23 
(±.15)  
.22 
(±.16) 
1.205(26),.239 .32 
(±.18) 
.22 
(±.16) 
3.526(66),.001 
Note. AOS = Addiction Only Services; DDC = Dual Diagnosis Capable; DDE = Dual Diagnosis Enhanced. 
There was also a general pattern of improvement across most subscales in the Addiction Only 
Services and Dual Diagnosis Enhanced groups. Significant improvements were made by patients 
in these two groups on the Alcohol, Drug, Legal, Family, and Psychological subscales, and those 
in the Dual Diagnosis Enhanced group also improved on the Medical subscale. 
DISCUSSION 
This study investigated the Second Edition revised version of the ASAM Criteria taxonomy for 
patients with substance use disorders and co-occurring psychiatric disorders.  A total of 37% of 
patients received ASAM recommendations for Addiction Only Services, 16% for Dual Diagnosis 
Capable, and 47% for Dual Diagnosis Enhanced programs. This provides support for the 
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recommendations by the ASAM Software in this Norwegian sample. A total of 63% of patients 
were identified as needing dual diagnosis care, which is in line with prior research showing 
prevalence rates of co-occurring substance use and psychiatric disorder in the range of 32% to 
65% (Bakken et al., 2005).  
Baseline characteristics revealed significantly lower age and less work experience among Dual 
Diagnosis Enhanced patients compared to the Addiction Only Services and Dual Diagnosis 
Capable groups, as well as a trend toward a gender difference in the Dual Diagnosis Enhanced 
group, with more males compared to the two other groups. This finding is similar to another, 
which found that patients with co-occurring disorders were more likely to be males with younger 
age and less education (Kavanagh, Waghorn, Jenner et al., 2004). 
Although the percentage of patients who reported having a psychiatric diagnosis was higher in 
the two groups receiving Dual Diagnosis service recommendations than in the Addiction Only 
Services group, the differences were not statistically significant. However, there were significant 
differences on history of inpatient and outpatient psychiatric treatment, indicating that the Dual 
Diagnosis Capable and Dual Diagnosis Enhanced groups, compared to the Addiction Only 
Services group, had higher levels of symptom severity and functional impairment. Similar 
differences were seen in patterns of psychiatric symptoms. While the ASAM Criteria are not 
designed to determine psychiatric diagnoses, they do assess patterns of symptoms that occur in 
several common psychiatric disorders. Patients in both Dual Diagnosis groups showed 
significantly higher symptoms of psychosis and PTSD than those in the Addiction Only Services 
group. All of these findings regarding various psychiatric measures are consistent with the 
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ASAM recommendations, and with our expectation that differences like this would be seen if the 
taxonomy of the ASAM Criteria had the ability to appropriately discriminate between patients. 
  Unlike previous research among patients with dual diagnosis (Angarita et al., 2007), we found 
no significant differences between groups on initiation of assigned treatment. This may be 
explained by a general increase in coordination between the clinics in this region as part of an 
overall effort to improve rates of treatment initiation. With regard to suicidality, prior research 
has found a higher proportion of suicide attempts among patients with co-occurring disorders 
(Darke et al., 2004; Bakken & Vaglum, 2007). While our data did not show statistically 
significant differences in suicidality, the patterns were in the expected direction. Patients in Dual 
Diagnosis Capable and Dual Diagnosis Enhanced groups showed higher rates of suicide attempts 
than those in Addiction Only Services, and there was a gradient from Addiction Only Services, 
to  Dual Diagnosis Capable, to Dual Diagnosis Enhanced of increasing frequency of patients 
reporting suicide plans in the past 30 days. 
Both groups of patients who were ASAM-recommended for co-occurring services (Dual 
Diagnosis Capable and Dual Diagnosis Enhanced) had roughly 4:1 ratios of patients who were 
assigned to inpatient versus outpatient treatment services, while the ratio among the Addiction 
Only Services group was 2:1. Although these differences were not statistically significant, the 
trend is consistent with the ASAM Criteria’s intent to place individuals with more severe needs 
in more intensive treatment services. Prior research has shown better outcomes with this type of 
intensity and service integration matching to treat both disorders (Sharon et al., 2003; Magura et 
al., 2003; Brunette et al., 2004). Patients with more severe substance abuse, less social support, 
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or comorbid psychological disorders benefited more from initiating care with inpatient as 
opposed to outpatient treatment (Magura et al., 2003; Bartak et al., 2011). 
There were no significant group differences on show for assigned treatment at follow-up. In 
previous research involving patients with dual diagnosis, only analyses designed to examine 
specific levels of match versus mis-match proved valid for demonstrating predictive validity 
(Angarita et al., 2007). The current study was not designed to test for follow-up differences and 
had three structural artifacts that would foster regression to the mean and undermine a predictive 
finding regarding co-occurring disorders: first, groups were not assigned to differing levels of co-
occurring services; second, the Norwegian system provides a strong level of co-occurring 
services coordination for all programs in this region; and third, the higher ratio of routinely-
assigned placements of co-occurring patients into Level III residential care meant that patients 
tended to get matched to what they needed – which would tend to promote good outcomes for 
all.  
Convergent validity was supported by statistically significant differences across the three groups 
on several ASI subscale composite scores at baseline. The Dual Diagnosis Enhanced group had 
significantly higher severity scores than Dual Diagnosis Capable and Addiction Only Services on 
the Legal, Family, and Psychological subscales. This is in line with previous research with the 
earlier edition of the ASAM Criteria Software (Sharon et al., 2003) and with the present study’s 
use of the newer ASAM Criteria, 2nd Edition-Revised and the comprehensive computerized 
implementation, the significant more severe means on three of the dimensions demonstrate some 
consistency in the ASAM Criteria Software’s ability to make clinical distinctions among patients 
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with need for Dual Diagnosis programs. Furthermore, it makes clinical sense that there were 
significant baseline differences on the Psychological subscale scores between the three level of 
care groups, based on their association in prior literature (Lehman, Myers, Thompson & Corty, 
1993), their relationships with legal problems (APA, 2000), the impact of family and social 
supports (Kashner, Rader, Rodell, Beck, Rodell & Muller, 1991).   
Addiction Severity Index Composite Subscale scores at follow-up show that there are 
significantly more clinical improvements among the Addiction Only Services and Dual 
Diagnosis Enhanced group than for the Dual Diagnosis Capable group.  One explanation might 
be that the Dual Diagnosis Capable group included older patients and more females than the both 
the other groups. This group also has a higher percentage reporting alcohol as main drug of 
choice, which could affect treatment outcome. Older patients might be more engaged in their 
treatment planning and decisions,  but might also have more chronic disorders, more cognitive 
deficits from alcohol abuse that are more resistant to treatment. The Dual Diagnosis Capable 
group had significant more stays in psychiatric inpatient setting when counting three or more 
stays, suggesting higher instabilities and psychiatric severity prior to this treatment and that 
supports the chronicity notion and might be contributing to less improvements in this group at 
follow-up.  Females, which are equally represented as the men in the Dual Diagnosis Capable 
have been found to have worse treatment outcome if they has additional disorders (Cohen et al., 
2010.) Findings in their study suggest that a sub-group of women with co-occurring PTSD and 
substance use disorder who endorsed eating disorder symptoms responded differently to group 
treatment. There might be a chance that their cluster of disorder makes it more difficult to adjust 
treatment to fit their needs, and that there are a need for more specialized individualized program 
for patients experiencing a cluster of disorder that’s affecting each other. It might also be caused 
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by patients being in such a stabile state that their severity gets underestimated both by 
themselves and the assessment personnel. Issues regarding self-report measures on psychiatric 
symptoms from patients have been brought up, and Cole and colleagues (2008) found that 
patients are more likely to underestimate their psychiatric suffering thus creating a lower 
prevalence number than what the reality is. That can lead to less attention and treatment for co-
occurring psychiatric disorders among this group and might explain the lack of significant 
reduction on dimensions in the Dual Diagnosis Capable group except for Alcohol and Drug 
scores which are reduced. 
There are similar results among the Addiction Only Services and Dual Diagnosis Enhanced 
group on the Addiction Severity composite scores, both groups significantly reduced in severity 
scores on a majority of the dimensions, and had an increase in Employment score. The clinical 
improvements in both groups suggest that the services provided in this region have capability to 
deal with more acute and severe co-occurring disorders, and given the right intensity of treatment 
both groups can have successful outcomes. This is in line with prior research that shows better 
outcome with the right intensity and integration of services to treat both disorders (Sharon et al., 
2003; Magura et al., 2003; Brunette et al., 2004). Patients with more severe substance abuse, less 
social support, or co-occurring psychological disorders benefit more from inpatient vs. outpatient 
treatment (Magura et al., 2003; Bartak et al., 2011). The rise in Employment severity scores, 
although not significant,  suggests that employment needs might be a distal need and treatment 
focus compared to more proximal addiction and health priorities during the first three months. 
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Limitations and Strengths 
The use of a naturalistic design has its drawbacks in determining group differences, especially 
when group sizes differ however, naturalistic designs do reflect the naturally-occurring 
treatment-seeking population, which can also be viewed as strength. In addition, the naturalistic 
design vulnerable to uncontrolled extraneous influential variables across study cohorts. Subgroup 
analyses and between-group analyses might have been affected by small group sizes and 
differential age and gender distributions. Since this study lacked categorization of the levels of 
care and their co-occurring service capabilities, we could not determine if the results are a result 
of co-occurring needs being met. Patient self-report has been found to suffer from 
underestimation of psychological problems upon entering treatment, due to optimism in 
anticipation of treatment assignment and treatment expectancies (Rokkan & Brandtsberg-Dahl, 
2003). Another limitation is that ASAM Criteria is not a psychiatric diagnostic tool – it only 
seeks to determine the least intensive and restrictive setting of care to manage the patient’s 
clinical needs.  Therefore, an Addiction Only Service recommendation does not mean that there 
is no psychiatric diagnosis , but it cannot be used as a DSM diagnostic instrument for other 
psychiatric disorders than substance and alcohol use disorder. We can only look at symptom 
severity from patients’ response on anxiety, depression, appetite, sleep, and so on, so in a future 
study we need to include a Diagnostic instrument to compare it to ASAM and validate its 
placement to a greater extent for psychiatric assessment. However this is an assessment tool for 
placing individuals to levels of care and there are more question in the ASAM that gathers data 
to finalize the level of care recommendations. Patients might have less severe depression and 
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anxiety symptoms than a single category of "anxiety" and "depression" gives information on, and 
their scores on the other dimension might justify the recommendation made by ASAM.  
It should also be noted that the Addiction Severity Index questions are embedded in the ASAM 
Criteria interview, and we use the ASI composite scores in the convergent validity analysis. The 
actuarial ASI composite scores are not used in the ASAM determination of level of care, 
however, as this employs a hierarchical decision rule logic. Thus, while worthy of mention, the 
danger of overlap is negligible. 
Conclusion 
If the ASAM Criteria Software is valid, it should be able to discriminate successfully between 
patients with similar alcohol, drug and medical severity but who have differing severity in 
psychiatric and related areas – and it should therefore recommend different programs for these 
types of patients. The group differences that were found in this study support the convergent 
validity of the ASAM taxonomy for co-occurring disorders and the Software’s ability to identify 
patients in need of integrated program services. The prevalence of Dual Diagnosis 
recommendations by the revised edition of ASAM Criteria Software was fairly high in this 
region of Scandinavia; hence, effective treatment matching is essential for individual recovery 
and for regional public health. The improvement in ASI severity scores at follow-up in the Dual 
Diagnosis Enhanced group suggests that these patients can benefit from treatment, in similar 
ways as those without dual disorders, as long as their needs receive appropriate care. Future 
studies should investigate this further with larger and more diverse samples like individuals with 
mandated or court-ordered treatment for substance use disorder, recruit from  mental health 
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clinics, prison programs, and aim for a full spectre of included levels of care from level I to level 
IV to control for other factors associated with less beneficial treatment results. It is also vital to 
include valid diagnostic assessment tools and clinical judgment on psychiatric diagnoses  in 
future studies of the ASAM taxonomy for co-occurring disorder and validate patients’ treatment 
outcomes using research designs including DD program categorised treatment services that are 
structured to test ASAM co-morbidity matching among these programs. 
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